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Summary 
Bleeding following cardiac surgery requiring cardiopulmonary bypass (CPB) is associated with 
increased morbidity. Identification of patients at increased risk of bleeding might allow 
intervention to prevent bleeding developing. 
In this thesis, clotting factors, anticoagulants and calibrated automated thrombin generation 
were investigated as potential methods for identifying such patients. Post-CPB FXIII, fibrinogen 
and platelet count were significantly lower in those who bleed more than 2 mL/kg/hr for two 
consecutive hours and in those who bleed in excess of 1 litre at 24 hours. ROC analysis 
demonstrated these had modest predictive value. Calibrated automated thrombography was 
unable to identify patients at risk of bleeding. 
Calibrated automated thrombography was also used to investigate the effects of haemostatic 
treatment (FFP, rFVIIa, PCC and TFPI inhibition) on thrombin generation in vitro. Blocking the 
effect of TFPI produced the greatest improvement in thrombin generation. 
The effect of CPB on platelet phospholipids was investigated using mass spectrometry. Post-
CPB the ability to externalise phosphatidylethanolamine and phosphatidylserine was impaired. 
The ability to externalise and synthesise 12-HETE-PC and 12-HETE-PE in response to both 
thrombin and collagen post-CPB was also reduced.  The effect of these phospholipids on 
thrombin generation and the ability to identify patients at risk of bleeding was then 
investigated. Thrombin generation using liposomes containing 12-HETE-PC or 12-HETE was 
lower in patients who required haemostatic treatment for post-CPB bleeding compared to 
those who did not. This suggests there are variations between individuals in the way their 
coagulation factors interact with oxidised phospholipids and that this may influence bleeding.  
Finally a cell based model of thrombin generation was developed using monocytes as a source 
of tissue factor and incorporating the observed changes in phospholipids, clotting factors and 
anticoagulants. This model provides a basis to further investigate the influence of different TF 
expressing cells on thrombin generation which may affect bleeding. 
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Chapter 1  General Introduction 
1.1 Cardiac Surgery requiring the use the cardiopulmonary bypass 
Coronary artery bypass grafting (CABG) for atherosclerosis remains the most frequent 
indication for surgery requiring the use of cardiopulmonary bypass (CPB) (1). However, the 
clinical need for  valve replacement or repair is steadily increasing and in the UK, operations 
for aortic and mitral valve disease doubled in the period 2003-2008 (1).  
 
The purpose of CPB is to allow a blood-less field and the heart to be stopped, thus providing 
the cardiac surgeon with the possibility of anastomosing arterial or venous grafts to the 
coronary arteries, bypassing any atherosclerotic stenosis and thus improving the supply of 
oxygenated blood to the myocardium. The other purpose is to allow the myocardium to be 
entered and repair or replacement of the cardiac valves to be undertaken. It can also allow for 
the replacement of the ascending thoracic aorta. A schematic diagram of a CPB circuit is shown 
in Figure 1.1. Whilst for revascularisation percutaneous coronary intervention has 
supplemented surgery and in some cases replaced it (2), and in selected cases CABG can be 
undertaken without the use of CPB (3), at present cardiopulmonary bypass remains an 
essential procedure for the majority of cardiac surgery. 
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Figure 1.1 Schematic representation of a cardiopulmonary bypass circuit. Filling of the heart is 
prevented by diverting blood flow via cannulae in the inferior and superior vena cava (blue) 
and directing this to the venous reservoir. Oxygenated blood (red) is returned to the systemic 
circulation via a cannula in the aorta, distal to the position of aortic cross-clamp. Cardioplegia 
solution (black) is mixed with oxygenated blood and perfused via the coronary arteries to 
maintain the heart in asystole (RA = right atrium; LA = left atrium). 
 
1.2 Complications of surgery requiring CPB 
Outcomes from cardiac surgery have continued to steadily improve and this has enabled 
increasingly complex surgery to be performed (1). However, as with any intervention, 
complications are experienced by some patients and these include stroke, cardiac arrhythmia, 
renal failure, myocardial infarction, sepsis and bleeding (4-6). All these complications can result 
in increased morbidity, a prolonged period of invasive ventilation and intensive (level 3) or 
high dependency (level 2) care.  
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The focus of this thesis is on the prediction of bleeding. Bleeding following surgery requiring 
cardiopulmonary bypass is associated with increased morbidity and mortality (7). It accounts 
for around 4% to 15% of red blood cells transfused in the UK and USA, and approaches 20% 
globally (7, 8). A similar pattern has been observed for platelet and plasma transfusions. A 
survey from the UK in 2012 found cardiac surgery accounted for 10% of the units of platelets 
transfused (9), whilst another study reported that cardiac surgery was responsible for 12.7% of 
the plasma transfused (10). Despite this comparatively heavy usage, 70-80% of the blood 
products transfused are given to only 12-20% of patients (7, 8). This suggests that better 
identification of patients at risk of bleeding may allow a reduction in blood product use by 
allowing preventative measures to be taken before excessive bleeding develops. 
 
Definitions of bleeding following cardiac surgery have varied between studies and have 
included: blood loss in excess of 1 litre at 24 hours (11); blood loss exceeding 200 mL/kg per 
hour (12); blood loss exceeding 2 mL/kg per hour for two or more consecutive hours (12); the 
need for haemostatic treatment (13); return to theatre for re-exploration for bleeding (1, 13). 
 
1.2.1 Morbidity associated with bleeding and red cell transfusion 
In a large retrospective study of 1,188 patients undergoing cardiac surgery, Christensen et al 
reported an incidence of excess post-operative bleeding of 6.4%. This was associated with a 
near three-fold higher 30-day mortality (odds ratio [OR] = 2.9, p < 0.001), an increased 
incidence of stroke (OR = 3.3, p = 0.0033), an unsurprising increased risk of needing to return 
to theatre for re-exploration (OR = 103.655, p = 0.0001), and an increased likelihood of 
intensive care unit stay longer than 72 hours (OR = 1.3, p < 0.0001) and mechanical ventilation  
longer than 24 hours (OR = 3.4, p = 0.0002) (12). 
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Even if major bleeding does not develop, transfusion of red cells is common, with 50-80% of 
patients in one study being reported to have received at least one unit of red cells within a day 
of surgery (14). Transfusion of blood products has in itself been associated with post-CPB 
complications. A large retrospective study of 10,425 patients reported red cell transfusion was 
an independent risk factor for early mortality after CABG, and the risk increased with 
increasing numbers of red cell units transfused (15). Renal failure has also been reported more 
frequently in those receiving red cell transfusions, although whether this is causal or an 
indicator of bleeding leading to reduced renal perfusion is uncertain (16, 17). Finally, red cell 
transfusion has also been associated with an increased risk of postoperative infection. In an 
observational study of 5,158 patients who underwent cardiac surgery, overall 48% were 
transfused at least one unit of red cells, with 63-65% of those undergoing dual CABG and valve 
replacement or surgery on the thoracic aorta requiring transfusion of a median of  3-4 units 
(18). Whilst the overall incidence of infection was only 5.8%, for each unit transfused there 
was a 23% increase in the risk of infection in the first 65 post-operative days. Platelets and 
fresh frozen plasma (FFP) appear to confer no increase in risk (19). 
 
The exact mechanism for these observations is unclear. These increased risks may in part be 
associated with the duration of blood product storage prior to transfusion (20). Storage of red 
cells leads to a variety of changes including a reduction in deformability, a reduction in 2,3-
diphosphoglycerate levels which increases the affinity of haemoglobin for oxygen, thus 
reducing oxygen delivery to the tissues, and reductions in the concentration of adenosine 
triphosphate (ATP) and nitric oxide (21-24). In addition during storage of blood products, 
elastase, histamine, soluble-HLA, soluble Fas-ligand, TGF-β1 and the pro-inflammatory 
cytokines IL-1β, IL-6 and IL-8 have all been reported to increase (25).  
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Regardless of the exact mechanism by which red cell transfusion increases morbidity, given 
that bleeding is a reason for transfusion, accurate identification of those at risk of bleeding and 
early intervention might improve patient outcomes. 
 
1.3 Current concepts of normal haemostasis 
1.3.1 Primary haemostasis 
After breach of a vessel wall, a variety of components are responsible for the initial prevention 
of bleeding. These include platelets, Von Willebrand factor, collagen and laminin.  
 
Platelets are formed from megakaryocytes through a complex system of actin and tubule 
formation. They contain alpha and delta (or dense granules), mitochondria and a tubular 
system which allows a change of shape following activation. Platelet activation serves two 
important purposes. Firstly it provides a phospholipid surface upon which procoagulant and 
anticoagulant proteins can assemble and interact. Secondly, aggregation leads to the 
development of a stable thrombus to plug the physical defect that has led to bleeding. 
Platelets are initially brought to the site of an injury by interaction between GPIbα and Von 
Willebrand factor (VWF).  
 
VWF is synthesised by endothelial cells, where it is stored in Weibel-Palade bodies and in 
megakaryocytes where it ultimately ends up in platelet α-granules. VWF is also present in the 
sub-endothelium where it is associated with collagen and laminins (26).  VWF binds to GPIbα 
on platelets via its A1 domain, a process which is influenced by shear rate, and to collagen via 
its A3 domain. Thus VWF is able to bring platelets into proximity with collagen to allow their 
activation via GPVI/FCRγ (27). Binding of collagen to the GPVI/FCRγ complex leads to activation 
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of downstream signalling pathways and release of intracellular calcium, which in turn leads to 
release of ADP and ATP from delta granules. Platelet activation also occurs through the 
interaction of laminin and the platelet surface integrin α6β1 (26). 
 
VWF also influences platelet aggregation. Its C1 domain contains a binding site for the platelet 
integrin αIIbβ3. The latter becomes activated on the platelet surface following activation via 
collagen binding. VWF and fibrinogen can both act to cross-link between αIIbβ3 on adjacent 
platelets leading to aggregation.  
 
1.3.2 Platelet Activation 
Adhesion and aggregation via integrin interaction is mediated by tyrosine kinase and G-protein 
linked pathways. Ligand binding and clustering of integrins leads to actin polymerisation and 
activation of phospholipase C (PLC). After initial activation via integrin signalling, a wide variety 
of secondary activation pathways are triggered (28, 29). Triggers include ADP released from 
dense granules which activates the platelet membrane receptors P2Y1 and P2Y12, and thrombin 
generated as part of secondary haemostasis which activates PAR1 and PAR4. Platelet 
activation can also be mediated by thromboxane A2 which is a product of arachidonic acid 
metabolism. Arachidonic acid can be generated from membrane phospholipids through the 
action of phospholipase A2 (PLA2) activated by calcium released from platelet dense granules 
(30). Arachidonic acid is then then further metabolised by cyclooxygenase-1 (COX-1) to 
prostaglandins G2 and then H2. Prostaglandins H2 then serves as the substrate for thromboxane 
synthase to produce thromboxane A2. 
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1.3.3 Secondary haemostasis 
The current theory underlying haemostasis has evolved considerably over the last 50 years. 
The original coagulation cascade model, whilst useful to assist in the identification of the 
causes of abnormalities in the commonly used coagulation tests of the prothrombin time (PT) 
and activated partial thromboplastin time (APTT), has now been superseded by the cell based 
model (31).  
 
Tissue Factor (TF) expression on cells is the first step in the initiation of coagulation. There has 
been a degree of controversy as to which cells in the blood actually express TF(32). Monocytes 
have long been recognised as being able to express TF in response to stimuli such as 
lipopolysaccharide (LPS), IL-1α and TNF-β (33, 34). In addition TF can be expressed on 
macrophages in response to CD40L, vascular smooth muscle cells in response to platelet 
derived growth factor , eosinophils in response to platelet activating factor (PAF) and 
granulocyte monocyte-colony stimulating factor (GM-CSF), endothelial cells by LPS, IL-1α and 
TNF-β, and astrocytes  (35-39). In addition, there have been reports of TF being identified in 
platelets (40, 41). However, there is an increasing body of evidence to show that platelets do 
not express TF themselves (42, 43), but instead their membranes are able to incorporate TF 
expressing microparticles derived from other cell types (44, 45).  
 
Tissue factor can be expressed in active and inactive conformations, also referred to as 
decrypted and encrypted forms. Decryption has been suggested to require the formation of 
disulphide bond between cysteine residues at position 186 and 209 and the co-expression of 
phosphatidylserine (46). The presence of phosphatidylserine (PS) alone may not be only 
determinant of tissue factor activity on the cell membrane, as lower thrombin generation has 
been reported when using tissue factor isolated from a monocyte cell line and then relipidated 
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with PS compared to tissue factor presented in intact cell membranes (47). Distinct lipid rafts 
containing cholesterol may also play a role in regulating TF activity (48). 
 
Factor VII (FVII) activation takes place via a variety of mechanisms. In vitro experiments have 
demonstrated that incubation of plasma at cold temperatures results in a significant increase 
in activated factor VII (FVIIa) (49, 50). Factors IXa, Xa, XIIa and thrombin have also been 
demonstrated to able to convert FVII to FVIIa and that the conversion of FVII to FVIIa is 
increased in the presence of TF (51-53). FVII has also been reported to undergo auto-activation 
by FVIIa (54).  
 
TF in conjunction with FVIIa proceeds to cleave factor X (FX) to Xa (FXa) and factor IX (FIX) to 
IXa (FIXa). This leads to the amplification phase where a small amount of thrombin is 
generated which is then able to activate factor XI (FXI) along with the factors VIII (FVIII) and V 
(FV). In the propagation phase, activated FVIII (FVIIIa) acts as a cofactor for FIXa which 
increases its ability to activate FX. Activated FV (FVa) acts as a cofactor to FXa to significantly 
increase the production of thrombin, which in turn cleaves fibrinogen to fibrin and allows the 
formation of a definitive clot. These reactions require the presence of a phospholipid surface 
and ionic calcium. Ionised calcium plays a key role in acting as a cofactor to allow the gla-
domain containing coagulation factors, II, VII, IX and X, to interact with phospholipid surfaces 
(55). Thrombin also activates factor XIII (FXIII). Activated FXIII (FXIIIa) catalyses the cross-linking 
between the D moieties of fibrin molecules, resulting in enhanced clot strength and a 
reduction in  susceptibility to fibrinolysis (56). 
 
An alternative pathway for activation of coagulation involves contact activation. This pathway 
has generally been thought to be of importance in vitro where, amongst others, glass, silica 
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and anionic polymers have been recognised activators. More recent studies have found that 
polyphosphates appear to be the initiator of this pathway in vivo (57). Long-chain 
polyphosphates, such as those found in Salmonella, are the most potent (58). However, 
platelet dense granules also contain short-chain polyphosphates which can also mediate 
contact activation (59), albeit less potently than long-chain polyphosphates. Contact activation 
results in proteolysis of high molecular weight kininogen and prekallikrein. These activate 
factor XII which in turn cleaves FXI. This rapidly results in the formation of the tenase complex 
consisting of FIX and its cofactor FVIII, a complex that has significantly higher affinity for FX 
compared to TF-FVII. This pathway may also be important in cardiopulmonary bypass where 
the material of the bypass circuit may initiate contact activation.  
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Figure 1.2.The current concept of coagulation begins with an initiation phase (Panel A), where 
TF-FVIIa activates FX and FIX. In the amplication phase (Panel B), FXa cleaves prothrombin (II) 
to thrombin (IIa), which cleaves FVIII to FVIIIa, FV to FVa and FXI to FXIa. This results in the 
propagation phase (Panel C) where the the tenase complex (FIXa and FVIIIa) cleaves large 
amounts of FX to FXa. This forms the prothrombinase complex with FVa which leads to the 
generation of a burst of thrombin. 
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To tightly regulate this process there are inhibitors at each stage. Tissue Factor pathway 
inhibitor (TFPI) is a key inhibitor of the initiation phase of the coagulation cascade and the 
majority is associated with the endothelium bound to glycosaminoglycans (60, 61).  It is a 
protease inhibitor which binds to FVIIa and FXa (62).  Its importance can be inferred from the 
finding that unstimulated monocytes express TFPI in excess of TF, presumably as a means of 
preventing inadvertent triggering of coagulation that might otherwise occur (63). It has three 
kunitz-type domains. The first of these binds to FVIIa while the second binds FXa. The third 
domain binds to protein S which potentiates the anti-FXa activity of TFPI. TFPI is released from 
the endothelium by heparin (64). TFPI is cleared via hepatocytes, mediated by LDL receptor 
related peptide (65), and also via the renal tract (66, 67). 
 
The amplification phase is regulated by protein C which is activated by thrombin in the 
presence of thrombomodulin. Activated protein C and its cofactor protein S inactivate factors 
Va and VIIIa by proteolysis. Antithrombin, synthesised in the liver, forms a complex with 
thrombin and to a lesser extent FXa, FIXa and FXIa. These reactions are potentiated by 
naturally occurring heparins and other glycosaminoglycans. Alpha-2-macroglobulin is an 
additional inhibitor of thrombin which forms a one-to-one covalently bound complex with it, 
preventing interaction between thrombin and its substrates by steric hindrance. 
 
1.3.4 Fibrinolysis 
Once a clot has been formed, it will ultimately need to be degraded once the underlying lesion 
has been repaired. Once fibrin is generated it binds tissue plasminogen activator, generated by 
the endothelium, which in turn cleaves plasminogen at Arg561-Val 562. The product, glu-
plasmin, then undergoes autocatalytic cleavage of its N-terminal region to form lys-plasmin, 
which has an exposed lysine binding site that enhances its ability to cleave fibrin and 
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fibrinogen. PAI-1 and PAI-2 inhibit plasminogen whilst thrombin-activatable fibrinolysis 
inhibitor (TAFI) and α2-antiplasmin regulate plasmin activity.  
 
TAFI is predominantly synthesised in megakaryocytes and the liver.  Thrombin is its primary 
activator. Thrombin in conjunction with thrombomodulin is able to activate TAFI with over a 
thousand folder greater efficiency than on its own (68). TAFI activation involves cleavage at the 
arginine residue at position 92 which allows substrates to access its active site (69). Plasmin is 
also able to activate TAFI, a process that may be physiologically important for TAFI activation 
away from the endothelium and thrombomodulin bound thrombin (70-72). TAFI regulates 
plasmin activity by cleaving C-terminal lysine residues from fibrin, thus removing the binding 
site for plasmin. This process appears to act on a threshold based mechanism, whereby 
fibrinolysis is only inhibited when TAFI reaches or exceeds a certain concentration (73). 
 
1.4 Phospholipids 
1.4.1 Role in haemostasis 
The role of phospholipids in coagulation has long been recognised as essential, indeed their 
inclusion in routine laboratory assays APTT and PT is required in order for clotting to take 
place. What has become increasingly clear is that different phospholipids have different 
functions and effects. For example, whilst phosphatidylcholine has generally been considered 
to be inert, the importance of the amount in a given membrane is demonstrated by the 
observation that below a certain amount thrombin generation may be impaired (74, 75).  
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Membrane asymmetry is important to prevent coagulation. In 1977 Zwaal et al demonstrated 
that in un-activated platelets the inner membrane was able to shorten clotting times whilst the 
external membrane in comparison did not (76). Thrombin stimulation  of platelets was shown 
in 1976 to result in exposure of phosphatidylethanolamine (PE) (77). Total PE and PC in the 
platelet membranes were shown to be reduced 20% and 9% respectively by thrombin 
stimulation with the arachidonate content of PC reducing (78), indicating hydrolysis by PLA2. 
 
Under resting conditions, the external platelet membrane is composed predominantly of the 
inert phospholipid PC. On activation of the platelet, the negatively charged phospholipids PE 
(77, 79) and phosphatidylserine (PS) (80) move to the external membrane to support 
coagulation. Phospholipid exposure on cell membranes is considered to be mediated by three 
types of transporter as shown in Figure 1.3. Flippases are aminophospholipid translocases that 
mediate the movement of PE and PS from the external membrane to the internal membrane. 
A number of membrane proteins have been described with this activity, with those in platelets 
being ATP dependent (81).  Floppase activity, where predominantly PC is moved passively to 
the external membrane thus maintaining membrane asymmetry, has been associated with the 
ABC class of transmembrane transporter proteins (82), although the precise identity of these 
transporter proteins remains uncertain. Finally scramblase activity is calcium dependent, and 
on activation of platelets allows the rapid exposure of the negatively charged phospholipids PE 
and PS on the external membrane (83). Four different proteins have been reported to have 
scramblase activity, with each appearing to function in specific situations: TMEM16F plays a 
role in platelets, XKR8 and PLSCR1 in response to apoptotic stimuli and PLSCR3 specifically in 
mitochondrial degradation (84).  The clinical importance of exposure of platelet membrane 
phospholipids is demonstrated by Scott’s Syndrome, a disorder whereby platelets are unable 
to externalise aminophospholipids (85), leading to a reduction in their ability to support 
thrombin generation. 
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Figure 1.3 There are three types of transporter considered to be involved on the movement of 
phospholipids between the external and internal membrane of cells. Flippase activity is energy 
dependent and requires ATP to maintain membrane asymmetry; floppase activity appears to 
be a passive process, whilst scramblase activity is calcium dependent. 
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The existing routinely available coagulation assays have been shown to be affected by the 
phospholipid composition of the reagents used. Changing the composition of thromboplastin 
reagents by varying the proportions of PE, PC and PS has been shown to alter the sensitivity of 
the PT for deficiencies of FII, FV, FVII and FX (86).  
 
Binding of FXa to membranes composed of PC and PS induces a conformational change in the 
protease which increases its affinity for interaction with FVa as assessed by fluorescence 
anisotropy (87). Evidence also exists suggesting that PS containing phospholipid membranes 
may alter the substrate specificity of FXa to favour the production of thrombin via its 
intermediate cleavage to meizothrombin rather than prothrombin 2 (88). 
 
1.4.2 Platelet phospholipid structure and metabolism 
Glycero-phospholipids have a characteristic structure composed of a head group, such as 
choline, serine or ethanolamine, a phosphate group, a glycerol backbone and two fatty acids. 
The glycerol backbone consists of three carbon atoms, termed sn1 to sn3. The fatty acid chains 
attach at the sn1 and sn2 positions whilst the phosphate group attaches at the sn3 position 
(89).  
 
These different sections of the structure each confer different physical properties. The head 
group is hydrophilic and charged leading to the typical orientation in a lipid bilayer of head 
groups on the outer surface and fatty acid chains orientated towards the centre.  
 
The fatty acids can either be unsaturated (one or more carbon double bonds present) or 
saturated (no carbon double bonds present). Increasing fatty acid saturation been shown to 
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influence coagulation (90). The fatty acids at the sn1 position can be attached by an acyl, or a 
vinyl-ether bond in the case of plasmalogens (91, 92), whilst those at the sn2 position are 
attached via an acyl bond only. Studies using X-band electron paramagnetic resonance (EPR) 
spectroscopy, whereby the EPR spectrum is measured of a magnetically anisotropic probe 
embedded in the lipid membrane, have shown that the fluidity of the membrane is influenced 
by the fatty acid composition, with the gel-liquid transition temperature being determined at 
least in part by the fatty acid composition (93). 
 
Plasmalogen and acyl phospholipids possess distinct physical properties. For example, the 
phase transition point for plasmalogens from gel to liquid occurs at a lower temperature 
compared to acyl phospholipids (94). In addition liposomes composed of plasmalogens fuse 
more readily than those composed of acyl forms (95). These properties would therefore 
influence membrane structure and composition which would be of relevance to coagulation 
and this is further supported by the finding that majority of PE in platelets is the plasmalogen 
form (96). In addition plasmalogens have been reported to play a role in cell signalling and 
prevention of oxidative damage, and it may be these functions which explain why decreased 
levels have been reported to associated with neurodegenerative conditions and inborn errors 
of metabolism (89).  
 
The fatty acid composition of platelet glycerophospholipids has been reported to 
predominantly consist of, in decreasing order of abundance, arachidonic acid, palmitic acid, 
stearic acid, oleic acid and linoleic acid (96). The phospholipid molecule can be cleaved or 
modified at different positions by a variety of enzymes (97). Phospholipase A1 (PLA1) and 
phospholipase A2 (PLA2) hydrolyse phospholipids at the sn1 and sn2 positions respectively. 
Phospholipase C (PLC) can cleave at the phosphate group from the glycerol back bone, whilst 
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phospholipase D (PLD) cleaves the head group from the phosphate group. This is summarised 
in Figure 1.4. 
 
 
Figure 1.4 Example structure of a typical glycerophospholipid (1- stearoyl-sn2-arachidonyl-
phosphatidylcholine). The different components of the structure are annotated, along with 
enzymatic cleavage points for phospholipase A1 (PLA1), phospholipase A2 (PLA2), phospholipase 
C (PLC) and phospholipase D (PLD). Adapted from O’Donnell et al (97). 
 
Following hydrolysis by PLA2, liberated arachidonic acid can undergo oxidation by lipoxygenase 
(LOX) followed by reduction by glutathione peroxidase to from hydroxyeicosatetraenoic acid 
(HETE). Alternatively the action of cyclooxygenase (COX) can generate prostaglandins. In 
platelets, 12-LOX is the only isoform identified and oxidises the 12th carbon atom, whereas in 
macrophages it is 15-LOX and 5-LOX in eosinophils. The oxidation occurs in three steps: 1) 
hydrogen is abstracted from the arachidonic acid molecule; 2) radical rearrangement; 3) 
oxygen is inserted onto the arachidonic acid molecule, the position depending on the LOX 
isoform (98). The hydroperoxide product is unstable and is reduced to the corresponding 
hydroxide form by glutathione peroxidase. A novel family of oxidised phospholipids, 12-HETE-
PE and 12-HETE-PC, has recently been described that are rapidly generated by 12-LOX in 
platelets after stimulation with thrombin or collagen (99). The 12-hydroxyeicosatetraenoic acid 
produced is re-esterified by fatty acyl co-A ligase to form the oxidised phospholipids. This 
process is summarised in Figure 1.5 and examples of the structures of arachidonate containing 
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PE, PS and PC species are shown in Figure 1.6. These HETE-phospholipids have been shown to 
increase thrombin generation measured by calibrated automated thrombography (99).  
 
They are likely to play an important role in vivo, as a number of recent studies have 
demonstrated that platelet 12-LOX activity can be stimulated by thrombin via PAR4, collagen 
via GPVI, and also immunoglobulin via the Fcγ Receptor IIa (100, 101). This suggests a potential 
role in secondary haemostasis. Oxidisation of fatty acids can result in differences in the polarity 
and hydrophilicity of the parent phospholipid compared to their un-oxidised forms, which may 
result in changes to the properties of the lipid membrane such as fluidity and orientation of 
other phospholipid molecules. 
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Figure 1.5 The enzymatic degradation of the phosphatidylethanolamine species 18:0a/20:4-PE.  
PLA2 cleaves 18:0a/20:4-PE into lyso-PE and arachidonic acid. 12-lipoxygenase (12-LOX) may 
then oxidise arachidonic acid to 12-hydroperxoxyeicosatetraenoic acid, an unstable product 
which is then reduced by glutathione peroxidase (GPX) to produce 12-hydroyeicosatetraenoic 
acid (12-HETE). This can then be reincorporated into lyso-PE by Fatty Acyl-CoA Ligase (FACL) to 
form 12-hydroxyeicosatetra-phophatidylethanolamine (12-HETE-PE). Adapted from O’Donnell 
et al (97). 
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Figure 1.6 Examples of the structures arachidonic acid containing species of 
phosphatidylethanolamine (18:0a/20:4-PE), phosphatidylserine (18:0a/20:4-PS) and 
phosphatidylcholine (18:0a/20:4-PC). The structure of the corresponding 12-
hydroxyeicosatetrenoate derivatives of phosphatidylethanolamine (18:0a/12-HETE-PE) and 
phosphatidylcholine (18:0a/12-HETE-PC) are shown for comparison. 
 
 
1.5 Effect of CPB on haemostasis and associations with bleeding 
Bleeding following surgery requiring the use of cardio-pulmonary bypass can have various 
causes. These include dilution and consumptive of clotting factors, anticoagulation, 
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thrombocytopenia and or platelet dysfunction (102) and surgical relating to breach of the 
vasculature. 
 
During cardiopulmonary bypass, intravascular volume needs to be maintained in order for the 
bypass machine to continue to function optimally. These fluids consist of a mixture of colloids 
and crystalloids. A greater proportion of the former tend to remain in the intravascular space 
whilst only around 20% of the latter remains. Colloids may cause impairment of coagulation 
factor function through adsorption and steric hindrance as well as dilution. Crystalloids tend 
mainly to cause dilution, however excess sodium ions may interfere with coagulation by 
increasing thrombin’s cleavage of substrate.  
 
Prothrombin fragment 1.2 has been used in the past as a marker of thrombin generation. In 
general, it has been reported to increase post-CPB, along with an increase in thrombin-
antithrombin complexes. Low levels pre-CPB have been reported to be associated with 
increasing blood loss post-CPB (103), suggesting that reduced thrombin generation is a risk 
factor for post-CPB bleeding. 
 
Kininogen levels increase during-CPB indicating cleavage of high molecular weight kininogen 
and activation of the contact pathway of coagulation (104). In general studies have reported a 
decrease in prothrombin, FV and FX, FVII and XI to be unchanged or reduced, and FVIII and IX 
to be increased or unchanged post-CPB (105, 106). The differences in the reported effect of 
CPB are likely to relate to differences in the timing of post-CPB samples. 
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Postoperative blood loss has been reported to be weakly inversely correlated with fibrinogen 
concentration measured 2 hours post-CPB (r= -0.33,p = 0.019) and FXIII activity measured pre 
and 2-hrs post (r= -0.34, p=0.0009 and r=-0.41, p=0.003, respectively), suggesting that 
defective clot strength may have been the cause of blood loss (105). Pre-operative fibrinogen 
concentration has been reported to be an independent predictor of post-CPB blood loss with a 
moderate inverse correlation (r= -0.53, p<0.0001), but in the absence of a clear cut-off level 
this was of limited clinical utility (107). Post-operative bleeding has been shown to inversely 
correlate with fibrinogen level at the end of CPB (108) and those with a level <2.0 g/L have 
been reported to be significantly more likely to require in excess of 5 red cell units transfused 
in the first 24 hours post-CPB than those with a level ≥ 2.0 g/L (p<0.0001) (109). FXIII has been 
shown to be reduced post-CPB (105). The post-operative FXIII level has been shown to have 
variable effects on bleeding. Some studies have reported no association (108), whilst others 
have reported an association between FXIII, clot strength determined by thromboelastography 
and bleeding (105, 110). 
 
CPB has also been shown to affect the concentrations of anticoagulants. Total protein C levels 
fall post cardiopulmonary bypass, but activated protein C increases (111, 112).  In addition full 
length and total TFPI have been reported to increase post-CPB (113). TFPI may play a role in 
bleeding post-CPB because heparin, the standard anticoagulant used during cardiopulmonary 
bypass, releases TFPI from the endothelium (64). 
 
1.6 Effect of CPB on platelets 
Following CPB, numerical (11, 114) and functional defects of platelets have been reported. 
Platelet aggregation is reduced in response to ADP (115-118). P-selectin, a marker of platelet 
activation, has generally been reported to be either unchanged (119) or increased (120, 121). 
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Studies measuring Annexin V binding suggest there may also be changes in the phospholipids 
expressed on the external membrane of platelets post CPB (120, 122). Annexin V binds to 
negatively charged phospholipids and therefore has been used as an indicator for the presence 
of these lipids. In addition a reduction in mean platelet volume post-CPB has been reported, 
suggesting a loss of phospholipid membrane may occur (123). 
 
1.7 Haemostatic agents for management of bleeding post-CPB 
At present there are comparatively few methods to correct haemostatic failure. These consist 
of platelet transfusions, fresh frozen plasma (FFP), cryoprecipitate, or the unlicensed use of 
recombinant factor VIIa (rFVIIa), prothrombin complex concentrate (PCC), or fibrinogen 
concentrate. Inhibition of fibrinolysis by tranexamic acid (a synthetic lysine analogue which 
reduces fibrinolysis by competing for plasmin binding to lysine residues on fibrin), and 
previously aprotinin (a broad spectrum serine protease inhibitor), is also routinely used. 
 
FFP has variable clinical efficacy and it has been reported that volumes of 30 mL/kg are needed 
to obtain a clinically relevant increase in clotting factors in critically ill patients (124). In the 
setting of cardiac surgery, a large volume load such as this may have deleterious effects on 
cardiac function. Studies where lower volumes of FFP were used to treat bleeding showed no 
difference in mortality whether FFP was given or not (125). Furthermore FFP has risks 
associated with transfusion such as transfusion related acute lung injury (126).   
 
rFVIIa has been used outside of its licensed indication to manage bleeding post-CPB, typically 
where other measures have been ineffective (127). However, no randomised controlled trials 
exist and two recent meta-analyses were unable to demonstrate a reduction in mortality but 
did find an increased incidence of thrombotic events (128, 129).  
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PCCs either contain FII, FIX and FX or FII, FVII, FIX and FX depending on the manufacturer and 
the licensing jurisdiction, along with other vitamin K dependent factors including protein C and 
S. There are also variations in the amount of heparin present depending on the manufacturer 
(130). Successful off label use of PCCs to manage excess bleeding following cardiac surgery has 
been reported in a number of small studies which were either case series or retrospective 
analyses (131-133).   As with rFVIIa, no randomised trials have been reported thus far, making 
the dose to administer and the selection or patients a matter of clinical judgement. 
 
Fibrinogen concentrate has been used in a number of small prospective studies which have 
suggested a reduction in transfusion requirements and bleeding (134-136). However larger 
studies are required to provide better data on overall efficacy and safety in the setting of CPB. 
 
Finally, inhibition of fibrinolysis has been a longstanding part of management of patients 
undergoing CPB. Tranexamic acid and aprotinin both reduce post-operative bleeding and 
transfusion requirements (137, 138). However, aprotinin was withdrawn from the market in 
2007 due to safety concerns, and although since reintroduced in Europe and Canada, its use 
has remained limited (139). 
 
1.8 Assays for monitoring haemostasis 
1.8.1 Routine laboratory coagulation assays 
Current routinely available assays of coagulation consist of the prothrombin time (PT) and 
activated partial thromboplastin time (APTT). The end point of both these assays is the earliest 
formation of fibrin, and modern automated coagulometer detect this as a change in light 
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absorbance. However, this end point is reached early in the overall process of producing a 
definitive clot; therefore these assays have limited value to assessing overall haemostatic 
function. In the setting of cardiac surgery requiring CPB there is no strong evidence to suggest 
they can predict bleeding. 
 
Their main role lies in identifying individual clotting factor deficiencies. These are FVII in the 
case of the PT; FVIII, FIX, FXI, FXII, Prekallikrein and High Molecular Weight Kininogen in the 
case of the APTT; FII, FV, FX where both are prolonged. They can also be readily used to 
monitor many of the anticoagulants. The PT is routinely used to monitor warfarin, whilst the 
APTT is particularly sensitive to unfractionated heparin, an anticoagulant used clinically in 
various settings, including cardiac surgery. Unfractionated heparin consists of molecules of 
heparin sulphate of varying size. These bind to antithrombin via aspartate residues and 
potentiate its ability to inactivate FIIa, FXa and FIXa. 
 
1.8.2 Activated Clotting Time (ACT) 
During cardiac surgery requiring CPB a rapid and simple test is required to adjust the heparin 
dose. It is of critical importance to maintain adequate anticoagulation to prevent blood 
clotting in the bypass apparatus. The activated clotting time (ACT) is used for this purpose. 
Whole blood is added to a test tube containing silica, or another contact activator, along with a 
magnetic stir bar. The device is then able to record at which point the stir bar is no longer able 
to move which provides the end point for the test. During CPB, the heparin dose is adjusted to 
maintain the ACT in excess of 400 seconds. However, the ACT will also be prolonged by 
thrombocytopenia, platelet dysfunction, coagulation factor deficiencies, defective fibrin 
polymerisation and hypothermia. It is not used to assess haemostasis or guide haemostatic 
therapy 
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1.8.3 Thromboelastographic methods 
TEG and ROTEM are methods that can be used to monitor global haemostasis, and both lend 
themselves to near patient testing. Although the precise nomenclature is different, they both 
give similar results: a reaction time during which the initial activation of haemostasis is taking 
place; a maximum speed of formation and firmness of any clot formed; an indication of the 
activity of fibrinolysis.  
 
The TEG apparatus uses a system where the cuvette rotates. The reaction cuvettes usually 
contain a substance to hasten clot formation. They can also contain hepzyme to remove the 
effects of heparin, and inhibitors of platelet aggregation to increase sensitivity to fibrin 
formation. A pin attached to a pressure transducer is inserted and as the clot forms the change 
in pressure is recorded to provide a curve, differing components of which correspond to 
different stages of clot formation and fibrinolysis. ROTEM follows similar principles to TEG, the 
main difference being that the pin rotates whilst the cuvette remains static. By using different 
substances in the cuvette, the test can be made more sensitive to the contribution of 
fibrinogen (FIBTEM) or remove the effect of heparin (HEPTEM). 
 
There have been conflicting reports of the role of TEG and ROTEM in predicting bleeding post-
CPB. Only one has found any association between pre-CPB thromboelastography parameters 
and post-CPB bleeding, and those correlations were weak (140). 
 
On arrival in the intensive care unit post-CPB the TEG parameters including maximum 
amplitude (MA), reaction time (k), and alpha-angle have been reported to identify patients 
who went on to bleed excessively or needed haemostatic treatment (141, 142). However the 
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positive predictive value was at best 62% and the studies were small, making clinical 
intervention prior to bleeding developing more difficult to judge. 
 
Using ROTEM, a number of studies have reported an association between a variety of 
parameters and post-operative blood loss when measured either at the end of CPB or on 
admission to the intensive care unit (143, 144). However, in a study of 58 patients Davidson et 
al reported that at least one ROTEM parameter was abnormal in 94% of patients who did not 
go on to bleed excessively. Overall they found the positive predictive value (PPV) of ROTEM to 
identify those who bled >200mL/hr was only 14.8%, although the negative predictive value 
(NPV) was better at 100% (145). One study has even reported that ROTEM and TEG had less 
clinical utility in predicting blood loss than standard coagulation screens with lower ROC values 
(146). 
 
Overall there is little evidence to show that thromboelastography measured pre-CPB can 
predict bleeding post-CPB. In the post-CPB setting thromboelastography can help guide 
treatment in a patient who is bleeding. However, using the results to guide preventative 
treatment prior to bleeding developing may result in a quarter to a third of patients receiving 
unnecessary intervention. 
 
1.8.4 Platelet aggregometry 
More recently, studies have investigated the use of whole blood impedance aggregometry for 
monitoring platelet dysfunction. The ADP lesion post-CPB is well described, and using reduced 
aggregation in response to stimulation by ADP has been shown to have moderate predictive 
value for post-CPB bleeding (>800 mL at 12 hours) with a sensitivity of 70%, specificity of 66%, 
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NPV of  92% and PPV of 29% (147). Using the need for transfusion as a surrogate for bleeding, 
the sensitivity was 88% and specificity 59%, whilst the PPV was 65% and NPV 85% (148). 
 
1.8.5 Calibrated Automated Thrombography (CAT) 
Thrombin generation has been assessed using various methods. Many studies have assessed 
thrombin generation by measuring thrombin-antithrombin (TAT) complexes by ELISA, 
however, this does not give any real time data on how much thrombin can be generated at a 
given time point. Early methods described to measure thrombin generation in real time were 
reliant on subsampling from a cuvette or test tube and then measuring the clotting time of 
that sample, a method that firstly given the time taken to perform such assays, limited the 
number of time points that could be measured and secondly lacked sensitivity to measure very 
small amounts of thrombin (149). 
 
 Subsequently the 1980s saw attempts to measure thrombin in real time using chromogenic 
assays. Initially these still relied on sub-sampling from a cuvette or test tube in which the 
thrombin generation reaction was taking place. A thrombin substrate was then added to the 
sub-sample and the colour change measured. This was then compared with a standard curve 
generated from solutions with a known concentration of thrombin and then the thrombin 
concentration of the test sample was calculated (150). However, these methods remained 
unsatisfactory due to their time consuming nature and potential for error.  
 
In 1993 an improved method allowing continuous measurement of thrombin generation was 
described (151). In this method the optical density of the test plasma was measured every two 
seconds and the velocity of change plotted against time. The concentration of thrombin was 
then calculated based on the formula for velocity of change in optical density at given time (vt) 
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=Kcat x [Thrombin] x [Substrate]/(Km + [Substrate]). By rearranging this formula, the 
concentration of thrombin could be calculated using the equation, [Thrombin] = vt(Km + 
[Substrate])/Kcat x [Substrate]. 
 
However, because the light absorbance increased as fibrin was formed this resulted in a 
potential for erroneous calculation of the amount of thrombin generated. It was also realised 
that it was necessary to compensate for the effect of thrombin bound to α2-macroglobulin. α2-
macroglobulin is an in vivo inhibitor of thrombin with a normal plasma concentration of 2.5 to 
4 μmol/L. In vivo when in complex with thrombin, it prevents the binding of thrombin 
substrates through steric hindrance. However, small peptides, such as chromogenic or 
fluorogenic substrates used in thrombin generation assays, are still able to access the active 
site of thrombin, thus leading to a change in colour or fluorescence (152, 153). Physiologically 
this signal would be irrelevant as in vivo thrombin would be unable to bind to its usual 
substrates. 
 
Consequently, Hemker and colleagues developed a method to account for this by using a 
calibrator substance, essentially thrombin-α2-macroglobulin, and assigning this an activity 
based on measurement of a known amount of thrombin. Their algorithm then compared 
measurements from the test well with measurements from the calibrator well and then 
subtracting the difference to calculate the actual thrombin generation in the test well at any 
given point. However, chromogenic methods remained hindered by the need to defibrinate 
the plasma, as otherwise the developing fibrin clot would impair the detection of the 
chromogenic signal. 
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In 2003, Hemker and colleagues described a method for continuous measurement of thrombin 
generation using a fluorogenic substrate (154). The benefit of this technique is that a large 
number of experiments can be performed simultaneously, coupled with reduced variability 
due to the automation of the initiation of the reaction and recording of the fluorescent signal 
and the absence of the need for subsampling. Thrombin generation can be measured in either 
platelet poor plasma (PPP) or platelet rich plasma (PRP). The reaction is triggered using a 
solution containing phospholipids and tissue factor (for PPP), or tissue factor only (PRP), which 
is then added to the test plasma before addition of the fluorogenic substrate and calcium 
chloride. 
 
The parameters generated using this technique are the lag time, peak thrombin concentration, 
time to peak thrombin concentration and endogenous thrombin potential. The latter is derived 
by integrating the first derivative of the fluorescence curve obtained and is indicative of the 
total amount of thrombin that might be generated over a given period. A typical thrombin 
generation curve is shown in Figure 1.6.  
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Figure 1.7 Example of thrombin generation curve obtained using calibrated automated 
thrombography, showing the parameters of lag time, velocity index, peak thrombin and ETP. 
The lag time is the time for the first 10 nmol/L of thrombin to be generated. The endogenous 
thrombin potential (ETP) is the area under the curve.  
 
 The Thrombinoscope software subtracts substrate conversion attributable to the α2-
macroglobulin-thrombin complex from the total leaving only conversion that can be attributed 
to thrombin alone. The fluorogenic substrate used is Z-Gly-Gly-Arg-AMC. Cleavage by thrombin 
results in release of fluorescent 7-amino-4-methylcoumarin. Different plasmas will quench 
fluorescence to varying degrees, often referred to as the inner filter effect. The initial rate of 
change in fluorescence is proportional to α2-macroglobulin-thrombin activity, whilst deviation 
from the initial velocity is dependent on the level of fluorescence. Every measured 
fluorescence level requires a conversion factor to convert the change in fluorescence into a 
thrombin concentration. Failure to compensate for the inner filter effect and α2-
macroglobulin-thrombin activity can result in inaccurate estimation of the ETP and peak 
thrombin (155). 
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There has been increasing evidence that the conditions under which CAT is performed can be 
adjusted to investigate different aspects of coagulation. Collection of blood samples into 
bottles containing corn trypsin inhibitor (CTI) prevents contact activation. This has been shown 
to increase the sensitivity of the assay to changes in the propagation and amplification phases 
of coagulation when coupled with the use of concentrations of tissue factor below 1 pmol/L 
(156, 157). Meanwhile addition of thrombomodulin increases the sensitivity of the assay to 
protein C (158). The temperature at which the assay is performed also has been shown to 
impact on the results. The relationship has been contrary to what might have been 
anticipated, with thrombin generation parameters being lower when measured at 37 oC 
compared to when measured at lower temperatures (159). This is in contrast to other studies 
where thrombin generation has been assessed using a cell based assay or measurement of 
thrombin-antithrombin complexes, which have shown a decrease with falling temperatures 
(160, 161). One possible explanation that has been suggested is that at higher temperatures 
the speed of diffusion becomes more important in determining thrombin generation, because 
the stoichiometric interaction of thrombin with its inhibitors increases more rapidly compared 
to the activity of proteases involved in coagulation (162). Recently, a number of studies have 
shown different phospholipids can alter the results of CAT, either by being present as 
microparticles, or through altering the composition of the phospholipids used in the trigger 
solution (99, 163, 164).  CAT is also sensitive to TFPI, with in vitro studies showing TFPI reduces  
thrombin generation in a concentration dependent manner (165). 
 
Clinical relevance of CAT has been demonstrated in the setting of haemophilia A where it has 
been shown to be potentially useful in tailoring treatment (166, 167), in liver disease for 
assessing haemostasis (158) and in monitoring anticoagulation (158, 168). Recently, two 
studies have reported that CAT can identify patients at risk of bleeding following CPB, even 
when samples where measured preoperatively (11, 169). This raises the possibility that 
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patients at risk of bleeding might be identified preoperatively and appropriate action taken to 
reduce that risk. This would improve patient outcome by avoiding or minimising the 
complications of bleeding and transfusion post-CPB described earlier.  
 
1.9 Mass Spectrometry to investigate platelet phospholipids 
The different head groups of phospholipids also allow for derivatisation to aid in identification. 
Recently a method has been described where PE and PS, which have a primary amine group, 
can be derivatised using a cell impermeable and cell permeable biotin reagent and then 
quantified using mass spectrometry (99). For the first time this allows a means of quantifying 
these lipids on the external cell membrane and also measuring changes in response to 
stimulation with agonists, such as thrombin and collagen in the case of platelets. Biotinylation 
works by the non-enzymatic reaction of a biotinylated linker protein with an active group on 
the molecule of interest. In the case of PE and PS, N-hydroxysuccinimidobiotin (NHS-Biotin) 
reacts spontaneously with the primary amine present on the phospholipid head group, 
resulting in the formation of a biotinylated phospholipid.  
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Figure 1.8 Mixing N-hydroxysuccinimidobiotin (NHS-Biotin) with phosphatidylserine at room 
temperature results in derivisation of the serine head-group through the addition of biotin to 
the amine group. This reaction is non-enzymatic and is favoured when the pH is above 7. 
 
Modern methods of mass spectrometry allow detailed investigation of the structure of 
molecules. One such method is tandem mass spectrometry, which combined with high 
performance liquid chromatography (HPLC) can allow the identification of lipids based on their 
mass, charge and retention time (170).  The mass spectrometer used to identify and quantify 
the phospholipids described in this thesis was a Q-trap 4000 manufactured by AB SCIEX 
(Framingham, MA, USA).  
 
The Q-trap 4000 contains three quadropoles (Q1-Q3). A quadropole consists of four paired 
rods, across which electrical currents of differing voltages can be applied. These contrasting 
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currents will cause ions that pass between the quadropoles to oscillate. The degree of 
oscillation is determined by the mass to charge ratio (m/z) of the ion with the result that the 
ions are separated based on the speed with which they pass through the quadropole. This 
separation then allows their detection. The lipid molecules undergo initial separation based on 
their molecular weight and polarity using HPLC, which leads to different retention times. They 
then enter the ionisation chamber of the Q-trap where they are bombarded by electrons 
resulting in the molecules taking on a charge. The ions then enter Q1 where, having set the 
specific m/z ratio of the ions of interest, those ions are separated. Only ions with the m/z 
selected are allowed to enter the collision chamber, Q2. In Q2 they are fragmented by being 
bombarded with an inert gas, such as nitrogen, in a process termed collision activated 
dissociation. These fragmented, or daughter ions, then pass into the third quadrupole Q3, 
where they undergo further separation based on their m/z ratio and then pass to the detection 
chamber which provides a mass spectrum for the original precursor or parent ion that 
originated from Q1. This allows each ion, and ultimately each molecule to be identified based 
on the daughter ions generated. 
 
1.10 Hypothesis and aims 
If it were possible to identify patients at increased risk of bleeding prior to undergoing CPB, it 
might be feasible to intervene to prevent bleeding developing. This would reduce blood 
product transfusion, which would improve patient outcomes and reduce the demand on the 
blood supply chain. Calibrated automated thrombin generation may be a suitable test to 
inform this strategy, and it may also provide a means of monitoring the effect of haemostatic 
treatment if this is required. In addition, new methods of measuring platelet phospholipids 
provide an opportunity to develop coagulation assays which use phospholipids which better 
reflect the situation in vivo. Based on the available evidence the following hypothesis and aims 
were generated which provided the basis for this thesis. 
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1.10.1 Hypothesis 
Thrombin generation assays are useful for identifying patients at increased risk of excess 
bleeding following CPB and can be used in clinical practice to inform blood product usage.  
 
1.10.2 Primary aim 
To evaluate whether abnormalities in thrombin generation can identify patients at increased 
risk of bleeding post-CPB. 
 
1.10.3 Secondary aims 
 To investigate whether calibrated automated thrombin generation is useful in 
identifying patients at increased risk of excess bleeding post CPB as defined by 
bleeding up to 24 hours, rate of blood loss, need for re-exploration or need for infusion 
of haemostatic products. 
 Investigate whether calibrated automated thrombin generation can be used in routine 
clinical practice as a near patient test. 
 Refine the calibrated automated thrombin generation assay to optimise its sensitivity 
to the haemostatic defect associated with CPB by varying the concentration and 
source of tissue factor, composition of phospholipids vesicles and presence or absence 
of corn trypsin inhibitor. 
 To investigate the effect of different haemostatic products to correct thrombin 
generation in vitro. 
 Investigate the effect of CPB on the externalisation of 12-HETE-PE, PE, PS and the 
synthesis of 12-HETE-PE and 12-HETE-PC in unstimulated and stimulated platelets. 
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Chapter 2 Materials and Methods 
Patients were recruited who were undergoing cardiac surgery requiring the use of CPB. 
Informed consent was obtained and the study received approval from the South West Wales 
local research ethics committee (reference 11/WA/0215). Research and Development 
approval was obtained from Cardiff and Vale University Health Board. 
 
2.1 Criteria for Study Participation 
Inclusion criteria were age 18 years or older, elective and urgent cardiac surgical procedures 
involving valve procedures, re-sternotomy, operations on the aorta or coronary artery bypass 
surgery combined with another procedure such as value replacement. Patients on warfarin 
were included after routine treatment to reverse the international normalised ratio (INR), 
along with patients with any abnormality of pre-operative coagulation tests or liver 
impairment. Exclusion criteria were routine coronary artery bypass grafting as the sole 
procedure, administration of antiplatelet agents other than aspirin within the preceding 5 
days, a platelet count below 120x109/L, haemoglobin less than 100 g/L, or emergency 
procedures. 
 
2.2 Complications Recorded 
Final follow up was at discharge from the hospital or 30 days post-surgery, whichever was 
sooner. At that time the following was recorded: 
 The length of time ventilated 
 Duration of level 3 and level 2 care 
 Time from operation until discharge 
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 Major complications of cardiac surgery: myocardial infarction (defined as an elevated 
cardiac troponin), significant haemodynamic instability (defined as use of two or more 
inotropic drugs or intra-aortic balloon pump), occurrence of atrial fibrillation lasting for 
more than 24 hours, reoperation for bleeding for any cause, prolonged ventilation 
(with or without tracheostomy defined as requirement for positive pressure 
ventilation for > 48 hours), clinically presenting cardiovascular accident, sepsis and 
renal impairment requiring renal replacement therapy  
 
2.3 Definition of bleeding 
Excess bleeding was defined as a composite of any one of the following: > 1 L in 24 hours; > 
200 mL per hour for 2 consecutive hours; > 2 mL/kg per hour for 2 consecutive hours in the 
first 6 hours post-CPB; return to theatre for reoperation due to bleeding; requirement for 
haemostatic therapy. 
 
2.4 Demographic data 
The following demographic data were recorded: age, weight, gender, anticoagulant and 
antiplatelet medication history, type of operation, duration of aortic cross-clamping, duration 
of cardiopulmonary bypass, time and dose of heparin administration, time and dose of 
protamine given, volume and time of intravenous crystalloid, colloid and blood products 
administered once pre-operative blood samples had been taken and for 24hrs after the end of 
surgery. The volume of cell salvage blood and the hourly and total output from surgical drains 
were also recorded for the first 24 hours post-operatively. A copy of the data collection 
proforma is included in Appendix 1. 
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2.5 Anaesthetic and Surgical technique 
Cardiac surgery and CPB were initiated in a standard way as per the institutional protocols of 
the University Hospital of Wales. The cardiopulmonary bypass circuits and priming fluids were 
the same in all cases. The cardiopulmonary bypass circuits were manufactured by Chalice 
Medical (Worksop, Nottinghamshire, UK) and Sorin Group Inc (Arvada, CO, USA).  Peripheral 
intravenous cannulae were inserted as was an arterial cannula, through which blood samples 
for the study were drawn (see later). Anaesthesia consisted of standard induction with 
propofol, midazolam, fentanyl and the muscle paralysing agent rocuronium, before switching 
to isoflurane for maintenance of anaesthesia. Following induction of anaesthesia a central 
venous catheter was inserted. Unfractionated heparin was used as an anticoagulant to 
maintain the activated clotting time (ACT) >400 seconds. Protamine at a dose of 1 mg per 100 
units of heparin was given after the end of the cardiopulmonary bypass prior to the removal of 
the arterial and venous cannulae. Heparin reversal was defined as the ACT returning to within 
10% of baseline. The ACT was monitored using a Helena Actalyke MINI II (Helena Laboratories, 
Beaumont, Texas, USA). 
 
2.6 Sample Collection 
Whole blood samples were taken into vacutainer bottles containing 3.2% trisodium citrate 
(Greiner Bio-One, Stonehouse, UK) at a ratio of 9 parts whole blood to 1 part 3.2% trisodium 
citrate. 
1.2mg /mL Corn Trypsin Inhibitor (CTI) was purchased from Cambridge Biosciences (Bar Hill, 
Cambridge, United Kingdom). This was diluted to a concentration of 1 mg/mL in tris-buffered 
saline (TBS) pH 7.4. TBS was composed of 20 mmol/L tris(hydroxymethyl)aminomethane and 
136 mmol/L sodium chloride dissolved in distilled water with the pH adjusted to 7.4 using 
hydrochloric acid. 
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A solution of 4% trisodium citrate was made by dissolving 4g of trisodium citrate in 100 mL 
distilled water.  Blood collection tubes were then prepared by adding 400 µL of 4% trisodium 
citrate to 100 µL 1 mg/mL CTI solution in a 5 mL screw-cap vial. Whole blood when collected 
into this tube was at a ratio of 1 part anticoagulant solution to 9 parts whole blood (i.e. 0.5 mL 
anticoagulant to 4.5 mL whole blood). 
Blood samples were taken from an arterial line before heparin administration and 30 minutes 
after reversal of heparin by protamine sulphate.   
PPP was prepared by centrifuging samples at 1570 x g for 15 minutes. The plasma was then 
removed and centrifuged a second time at 1570 x g for 15 minutes, after which the plasma 
was divided into 1 mL aliquots and frozen at -80 oC for testing later.   
Samples for Full Blood Count recording where collected into vacutainers containing EDTA (BD, 
Oxford, UK).  
 
2.7 Full Blood Count Measurement 
Full blood counts were performed on an ABX Pentra DX 120 automated analyser (Horiba 
Medical, Northampton, UK). 
 
2.8 Coagulation factor and anticoagulant assays 
2.8.1 Assays of coagulation factor II, V, VII, VIII, IX, X, fibrinogen and protein C, free 
protein S, antithrombin and heparin 
The prothrombin time (PT), activated partial thromboplastin time (APTT), Clauss fibrinogen 
and factors II, V, VII, VIII, IX, X, XI, antithrombin, protein C, free protein S and post-operative 
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anti-Xa activity were measured on an ACL 500 Top (Instrumentation Laboratory, Cheshire, UK)  
automated coagulometer using standard manufacturer protocols and reagents. 
 
For measurement of the PT, FII, FV, FVII and FX, HemosILTM RecombiPlasTin 2G was used. This 
was supplied as a vial of lyophilised powder and a vial of diluent. The diluent was allowed to 
equilibrate to room temperature for 15 minutes before adding the contents to a vial of 
lyophilised reagent. This was then left to stand for 30 minutes at room temperature, swirling 
occasionally, before use. Lyophilised factor II, V, VII and X deficient plasmas, calibration 
plasma, normal control and Special Test Control Level 2 plasmas were reconstituted with 
distilled water and allowed to stand for 30 minutes at room temperature, swirling occasionally, 
before use. 
 
For measurement of the APTT, FVIII, FIX and FXI, HemosILTM CaCl2 (0.02 mol/L) and HemosILTM 
SynthASil APTT reagents were used. A vial of reagent was allowed to equilibrate to room 
temperature for 15 minutes before use. Lyophilised factor VIII, IX and XI deficient plasmas, 
calibration plasma, normal control and Special Test Control Level 2 plasmas were reconstituted 
with distilled water and allowed to stand for 30 minutes at room temperature, swirling 
occasionally, before use. 
 
Fibrinogen was measured using the Clauss method. A vial of lyophilised QFA thrombin reagent 
was reconstituted with distilled water and allowed to stand for 30 minutes at room 
temperature, swirling occasionally, before use. Lyophilised calibration plasma, normal control 
and Special Test Control Level 2 plasmas were reconstituted with distilled water and allowed 
to stand for 30 minutes at room temperature, swirling occasionally, before use. 
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Antithrombin was measured using a kit supplied by IL consisting of vials of FXa reagent 
(containing bovine Xa and heparin) and Chromogenic Xa substrate (N-α-Z-D-Arg-Gly-Arg-
pNA2HCl). Each vial was swirled gently prior to use to ensure mixing of the contents. Heparin 
was measured by anti-Xa activity using the similar Liquid Heparin kit, the difference being that 
the FXa reagent did not contain heparin. 
 
Free protein S was measured using a kit consisting of vials of lyophilised C4b-binding protein 
attached to latex beads, a vial of buffer to use for reconstitution of the former, and a vial of 
anti-protein S monoclonal antibody.  
 
Protein C was quantified using a kit containing a vial of concentrated diluent, a vial of 
lyophilised protein C activator (venom of Agkistrodon contortrix contortrix) and a vial of 
protein C chromogenic substrate (pyroGlu-Pro-Arg-pNA.HCL). The diluent vial was diluted 1 
part to 10 parts distilled water; the vials lyophilised reagents were reconstituted with distilled 
water and allowed to stand at room temperature for 30 minutes before use, with occasional 
gentle swirling to mix the contents. 
 
2.8.2 TFPI ELISA 
Full-length and total TFPI were measured by an ELISA technique. All chemicals were purchased 
from VWR International Ltd, unless otherwise stated. Distilled, laboratory grade water was 
used for all buffers. 
The following buffers and reagents were assembled: 
1. Hydrochloric acid 25% (v/v) 
2. 1 mol/L Sodium Hydroxide 
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3. 10% Tween 20 (w/v) 
4. Tris-buffered Saline (TBS): 25 mmol/L Tris(hydroxymethyl)-aminomethane; 150 
mmol/L sodium chloride, pH 7.4 
5. TBS -Tween 20: 25 mmol/L Tris(hydroxymethyl)-aminomethane; 150 mmol/L sodium 
chloride; 0.1% v/v Tween 20 
6. 0.5 mol/L EDTA, pH 8.0 
7. Washing buffer: TBS/0.1% Tween 20 v/v 
8. Blocking Buffer: TBS/2% (v/w) dry milk powder (BioRad Laboratories Ltd, Hemel 
Hempstead, UK) 
9. Sample and antibody dilution buffer: 20 mmol/L EDTA in TBS-T/1% (v/w)  dry milk 
powder 
10. Substrate solution: Sure Blue TMB (1-component peroxidase substrate, Co KPL) 
11. Stopping reagent: 1 mol/L Hydrochloric acid 
12. Capture antibody (total TFPI): Mouse monoclonal antibody against human TFPI kunitz 
domain-2 (Sanquin, Amsterdam, Netherlands) 
13. Capture antibody (full-length TFPI): Mouse monoclonal antibody against human TFPI C-
terminus domain (Sanquin, Amsterdam, Netherlands) 
14. Detection antibodies: 
a. Rabbit polyclonal antibody against human TFPI (American Diagnostica GmbH, 
Pfunstat, Germany) 
b. Anti-rabbit IgG peroxidase conjugate (Sigma-Alrdich, Dorset, UK) 
15. Recombinant human full-length TFPI  1 µg/mL (Baxter Innovations GmbH, Vienna, 
Austria) 
 
Method: 
Detection antibodies were diluted in TBS to a concentration of 1 µg/mL.  A 96 well plate (Nunc 
Maxisorp, eBioscience Ltd, Hatfield, UK) was coated by adding 100 µL of the detection 
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antibody to the relevant wells before covering and incubating at 4oC overnight. Then the 
contents were discarded and the plate washed 3 times using the washing buffer described 
above. 250 µL of blocking buffer to each well and the plate was covered and placed on a plate 
shaker at room temperature for 60 minutes, before discarding the contents and washing the 
plate 3 times. Citrated patient samples and the TFPI standard were thawed by placing in a 
water bath for 5 minutes, with the temperature set at 37 oC. The standard was diluted in the 
sample dilution buffer from 1:1.25 to 1:0. Patient and control samples were diluted 1:10 and 
1:20 for full-length TFPI and 1:25 and 1:50 for total TFPI using the same buffer. Diluted 
standard and patient samples were added to the plate in duplicate (100 µL per well) and 100 
µL of buffer was added to two additional wells for blank correction. The plate was then 
covered, placed on a plate shaker and incubated at room temperature for 2 hours. The 
contents of the plate were discarded and the plate washed 5 times. The first detection 
antibody was diluted 0.5 µg/mL using the dilution buffer (see 9 above) and 100 µL added to 
each well.  The plate was covered, placed on plate shaker and incubated at room temperature 
for 1 hour before discarding the contents and washing 5 times.  The second detection antibody 
was diluted to 0.2 µg/mL with the dilution buffer and 100 µL added to each well. The plate was 
once again covered, placed on a plate shaker and incubated at room temperature for 1 hour.  
The contents of the plate were discarded and the plate washed 5 times. TMB was pre-warmed 
to 37 oC and 100 µL was added to each well. The plate was then incubated at room 
temperature for 7 minutes, protected from the light. The reaction was stopped by adding 50 
µL of 1 mol/L hydrochloric acid to each well. Light absorbance at 450 nm was measured using a 
plate reader (Biotek, Winoosi, WT, USA) and data analysed using Gen 5.1 software. 
 
2.8.3 Von Willebrand Factor ELISA 
All chemicals were purchased from VWR International Ltd, unless otherwise stated. The 
following reagents were prepared: 
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1. Technoclone reference plasma reconstituted with sufficient distilled water to provide a 
VWF concentration of 100% (Technoclone, Vienna, Austria) 
2. Cryocheck abnormal 1 and 2 control plasma (Precison Biologic Inc, Dartmouth, NS, 
USA) 
3. Anti-rabbit VWF antibody (Dako, Ely, UK) 
4. Sodium carbonate buffer (16 mmol/L anhydrous sodium bicarbonate, 34 mmol/L 
sodium hydrogen carbonate, pH 9.6) 
5. Anti-VWF horse-radish peroxidase conjugate antibody (Dako, Ely, UK) 
6. 2% polyvinylpyrrolidine (PVP) in sodium carbonate buffer 
7. Phosphate buffered saline (PBS)/ 0.0005% (v/v) Tween 20,  pH 7.2 
8. PBS/0.0005% (v/v)Tween 20 with 0.1%  (v/w) Bovine Serum Albumin (BSA) 
9. Red-Stop reagent (Skybio Ltd, Wyboston, Befordshire, UK) 
Procedure for the ELISA: 
The Anti-rabbit VWF antibody was diluted 1 in 600 with sodium carbonate buffer and then 200 
µL was added per well to a 96-well Dynex Immunlon 4HBX plate (Fisher Scientific, 
Loughborough, UK). The plate was covered and incubated over night at 4oC. The contents of 
the wells were decanted and 200 µL of 2% PVP was added to each well. The plate was then 
covered and incubated for 30 minutes at room temperature. The contents were discarded and 
the plate was washed 3 times by adding 300 µL of PBS/Tween 20 to each well using a multi-
channel pipette and the aspirating with a stylet attached to a vacuum pump. The reference 
plasma was diluted 1 in 40 with PBS/Tween 20/0.1 %BSA. The control plasmas were thawed 
for 5 minutes in a water bath set to 37 oC before being diluted. Cryocheck abnormal 1 control 
plasma was diluted 1 in 40 and Cryoheck abnormal 2 control plasma 1 in 20, both using 
PBS/Tween 20/0.1 %BSA. Citrated patient plasma was thawed for 5 minutes in a water bath 
set to 37 oC , vortex-mixed and then diluted 1 in 80 with PBS/Tween 20/0.1 %BSA. Then 100 µL 
of PBS/Tween 20/0.1% BSA was added to each well on the plate. Next, 100 µL of plasma 
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(reference, control or test) was added to one well and then serial dilutions were made on the 
plate (4 for control and test plasma; 8 for reference plasma). The plate was covered and 
incubated at room temperature for 2 hours, before decanting the contents and washing 3 
times as described earlier. The anti-VWF horse-radish peroxidase conjugate antibody was 
diluted 1 in 1000 with PBS/Tween 20/0.1% BSA and 100 µL added to each well. The plate was 
again covered and incubated at room temperature for 1 hour. The contents were decanted 
and the plate washed 3 times as previously. 100 µL of TMB reagent was added to each well 
and the plate was incubated at room temperature for 7 minutes, protected from the light. The 
reaction was stopped by adding 50 µL of Red-Stop per well. Light absorbance at 650 nm was 
measured using a plate reader (Biotek, Winoosi, WT, USA) and data analysed using Gen 5.1 
software.  
 
2.8.4 Factor XIII Assay 
Measurement of FXIII activity was performed using the Technochrom FXIII assay kit, purchased 
from Technoclone, Vienna, Austria. Following the instructions provided, a vial of lyophilised 
NADPH reagent was reconstituted with 3 mL of distilled water and left for 30 minutes at room 
temperature, swirling occasionally. The contents of this vial was then added to a vial to a vial 
of lyophilised FXIII activator reagent (composed of thrombin and calcium), which was then left 
to reconstitute for 30 minutes at room temperature, swirling occasionally. Meanwhile a vial of 
FXIII inhibitor reagent (composed of a tetrapeptide to prevent fibrin polymerisation) was 
mixed with 1 mL of FXIII stabiliser solution (containing glycine ether ester and PI(1-12) which is 
cross-linked by FXIIIa via a glutamate residue, releasing ammonia) and left for 30 minutes at 
room temperature, swirling occasionally.  
To measure FXIII activity, calibration plasma (Technoclone, Vienna, Austria) was reconstituted 
to 100% FXIII activity using distilled water. Control plasma (Low Abnormal, FXIII activity as per 
product insert, Technoclone, Vienna, Austria) was also reconstituted with distilled water. Both 
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were allowed to stand at room temperature for 30 minutes with occasional agitation before 
use. Citrated patient samples were then thawed in a water bath at 37 oC for 5 minutes. On 
removal each aliquot was briefly mixed using a vortex-mixer and then used immediately.  A 
volume of 10 µL of calibration plasma, control plasma and test samples was added in duplicate 
to separate wells of a 96 well plate (flat-bottom Immulon 2Hb 96-well plate, Diagnostica-
Stago, Asnières sur Seine, France). Then 100 µL of either sample reagent or blank reagent was 
added to the respective wells. The plate was then placed in a plate reader (Biotek, Winnosi, VT, 
USA) preheated to 37 oC, programmed using Gen 5.0.1 software as follows: 
a. Incubate for 4 minutes and 50 seconds 
b. Shake for 10 seconds 
c. Measure absorbance at 340 nm at 5, 7, 9 and 11 minutes 
d. Subtract background absorbance using value for blank well 
e. Calculate mean velocity of change (V)  
A calibration factor (F) was then calculated using the following formula: 
F=Assigned FXIII calibration value/(V(calibration test wells) – V(calibration blank wells)) 
The FXIII activity of patient and control plasma was then calculated as a percentage of the 
calibration plasma using the following formula: 
Factor XIII concentration = F(V(sample test wells) – V(sample blank wells)) 
 
2.8.5 TAFI ELISA 
TAFI was measured using an Imunclone kit from Sekisui Diagnostics (West Malling, UK). The 
vials supplied, consisting of lyophilised TAFI calibrator and high and low control plasmas, were 
each reconstituted with 0.5 mL distilled water and left at room temperature for 30 minutes. 
The TAFI calibrator was then diluted 1 in 50 with distilled water. From this final solution a 
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standard curve was constructed by preparing the following dilutions using distilled water: 1 in 
1; 1 in 2; 1 in 4; 1 in 10; 1 in 20; 0 in 1. The control plasmas (high and low) were each diluted 1 
in 50 using distilled water. Frozen citrated plasma from patients was thawed in a water bath 
set at 37 oC for 5 minutes. These were then diluted 1 in 100 and 1 in 200 using distilled water. 
100 µL of samples, controls and calibrator solutions were added in duplicate to the well strips 
provided (wells were pre-coated with an anti-human-TAFI antibody). The wells were then 
covered and incubated at 37 oC for 2 hours. The contents of the wells were then discarded by 
inversion of the plate and violent tapping. The wells were then washed 5 times using the wash 
solution provided by adding 300 µL to each well using a multi-channel pipette and then 
aspirating with a stylet attached to a vacuum pump. 200 µL of anti-human TAFI horse-radish 
peroxidase antibody conjugate was then added to each well using a multi-channel pipette. The 
wells were again covered and incubated at 37 oC for 1 hour. At the end of the incubation 
period the contents were discarded and the plate washed as described earlier. 200 µL of TMB 
substrate provided was then added to each well using a multi-channel pipette. The wells were 
the covered and incubated in the dark for 5 minutes at room temperature. The reaction was 
then stopped by adding 50 µL of 0.45 mol/L sulphuric acid to each well. After a further ten 
minutes at room temperature, light absorbance at a wave length 450 nm was measured in a 
plate reader and data analysed using Gen 5.1 software (Biotek, Winoosi, WT, USA).  
 
2.9 Thrombin generation assays 
2.9.1 Calibrated automated thrombography 
Thrombin generation was measured using the method described by Hemker and colleagues 
(154). Experiments were performed by mixing 20 μL of trigger solution (tissue factor mixed 
with phospholipid vesicles) with 80 μL of plasma in a U-bottom Immulon 2Hb 96-well plate 
(Diagnostica-Stago, Asnières sur Seine, France). The plate was maintained at 37 oC using a plate 
warmer while the samples were pipetted onto the plate.  Thrombin generation was initiated 
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by adding Flu-Ca (2.5 nmol/L fluorogenic substrate Z-Gly-Gly-Arg from Bachem, UK and 0.1 
mol/L calcium chloride, 20 mol/L HEPES, 0.02 % (w/v) sodium azide, 60 g/L bovine serum 
albumin, pH 7.35) to the trigger-plasma mixture and fluorescence was measured using a 
Fluoroscan reader (Thermo Scientific, UK) run using Thrombinoscope software (Synapse BV, 
Maastricht, Netherlands). The effect of the protein C pathway was measured by performing 
thrombin generation with a commercial trigger containing thrombomodulin (Diagnostica-
Stago, Asnières sur Seine, France). Commercially available trigger solutions with 1 pmol/L TF 
(Stago PPP Low) and 5 pmol/L TF (Stago PPP) were also used. All commercial trigger reagents 
were a gift from Diagnostica-Stago (Asnières sur Seine, France). 
 
2.9.2 Preparation of trigger solutions for thrombin generation assays 
All un-oxidised phospholipids were purchased from Avanti Polar Lipids (Alabaster, Alabama, 
USA).  The following buffers were prepared: 
1. Buffer A consisting of 20 mmol/L HEPES, 140 mmol/L NaCl, pH 7.35 in distilled water.  
2. Buffer B consisting of 0.5% w/v BSA dissolved in Buffer A. 
 
2.9.2.1 Liposomes for investigation of the effect of different concentrations of tissue 
factor 
Liposomes were prepared by mixing 120 µL of 25 mg/mL DOPS, 120 µL of 25 mg/mL DOPE and 
458 µL 20 mg/mL DOPC at a ratio of 1:1:3 (mole: mole: mole) in a glass vial and then drying 
under an argon gas stream. Once dry, 4 mL buffer A was added and the mixture was vortexed 
before placing on a roller-mixer for 2 hours. The suspension was then passed 29 times through 
a mini-extruder device with membranes of 100 µm pore diameter (Avanti Polar Lipids, 
Alabaster, USA). 
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The contents of a vial of Innovin (Siemens, Germany) were reconstituted with 10 mL of distilled 
water to yield a solution assumed to have a TF concentration of 6 nmol/L, based on the 
product insert. This solution was further diluted in buffer B to give a TF concentration of 500 
pmol/L. Trigger solutions were then prepared by diluting the phospholipid suspension and 
Innovin solution in buffer B to achieve a concentration of phospholipids of 24 µmol/L and 
concentrations of TF of 3 pmol/L, 6 pmol/L, 18 pmol/L, 30 pmol/L and 60 pmol/L. The final in-
well TF concentration during the thrombin generation assay was 0.5 pmol/L, 1 pmol/L, 3 
pmol/L, 5 pmol/L and 10 pmol/L respectively. These solutions were then aliquoted and frozen 
at -80 oC for use later. The TF activity if these trigger solutions was checked using a TF ELISA 
technique, the results of which are shown in Appendix 3. 
 
2.9.2.2 Liposomes for investigation effects of 12-HETE-PE and 12-HETE-PC on 
thrombin generation 
For experiments using 12-HETE-PC and 12-HETE-PE, liposomes were constructed as 
summarised in Table 2.1 using 65 % 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine 
(SAPC), 5% 1-stearoyl-2-arachidonoyl-sn-glycero-3-phospho-L-serine (SAPS), 30% 1-stearoyl-2-
arachidonoyl-sn-glycero-3-phosphoethanolamine (SAPE), 65% SAPC, 5% SAPS, 20% SAPE and 
10% 12-HETE-PE or 55% SAPC, 5% SAPS, 30% SAPE and 10% 12-HETE-PC.  All 12-HETE-PE and 
PC was provided by Dr Yoel Garcia (Department of Chemistry and the Vanderbilt Institute of 
Chemical Biology, Vanderbilt University, Nashville, TN, U.S.A). After drying under a stream of 
nitrogen, the phospholipids were re-suspended in buffer A. Recombinant full length tissue 
factor (rTF) (Haematologic Technologies Incorporated, Essex Junction, VT, USA) was diluted in 
water to a concentration of 30 nmol/L. This was then added to the lipid suspension to give a 
concentration of 300 pmol/L and the mixture subjected to 10 cycles of freeze-thawing in liquid 
nitrogen each complete cycle lasting 1 minute. The suspension was then passed through a 
mini-extruder with 100 µm pore filters to obtain the final liposome preparation. This was then 
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diluted 1 in 5 in buffer B  to give a final concentration of 24 µmol/L phospholipids and 60 
pmol/L rTF. The final concentration of TF available to trigger thrombin generation was not 
known because not all TF would have been incorporated into the liposomes and half would be 
expected to face internally. Thrombin generation assays were then performed in the same 
manner described earlier.  
 
Table 2.1 Volumes of different phospholipids used to prepare a 0.5 mL suspension of each 
liposome. 
Lipid Stock Conc. 
(mmol/L ) 
Volume of stock 
sol. (μL) to make 
0.5 mL of 100 
μmol/L solution 
0% HETE 10% HETE-PC 10% HETE-
PE 
SAPE 1.303 46 13.8 13.8 9.2 
SAPS 1.200 50 2.5 2.5 2.5 
SAPC 1.235 48.6 31.6 26.8 31.6 
12-HETE-PE 1.276 47 0 0 1.7 
12-HETE-PC 1.238 42 0 4.2 0 
 
2.9.3 Thrombin generation assays to investigate effect of different haemostatic 
agents 
Thrombin generation assays were performed as described in section 2.9.1, using the PPP low 
trigger reagent. 
2.9.3.1 Calculation of concentrations of Anti-TFPI antibody 
Thrombin generation was measured in the presence and absence of the anti-TFPI antibody 
AF2974 (R&D Systems, Abingdon, UK) at a concentration of 100 nmol/L, this concentration 
having previously been determined to inhibit concentrations of full length TFPI up to 6 nmol/L 
(personal communication from Erwin Panholzer, Baxter Biosciences, Vienna, Austria, titration 
curve included in Appendix 2).  
 
52 
 
2.9.3.2 Calculation of concentrations of FFP 
FFP was obtained from the Welsh Blood Service. The post-operative plasma volume for each 
patient was estimated using the formula, 0.07 x weight x (1-haematocrit). The mean plasma 
volume was then calculated for the whole cohort. Mean weight was also calculated. These 
figures where then used to calculate the volume of FFP to add to each sample to be equivalent 
to 15mL/kg, 20mL/kg and 50mL/kg. This was 0.308 mL FFP, 0.411 mL FFP and 0.617mL FFP per 
mL patient plasma respectively. The activity of factors II, V, VII, VIII, IX, X, XI, antithrombin, 
protein C and S in the FFP were measured as described earlier. The results are shown in Table 
2.2. 
Table 2.2 Activity of coagulation factors and anticoagulants in FFP. 
Factor Activity 
II 92.5 iu/dL 
V 87.9 iu/dL 
VII 81.5 iu/dL 
VIII 92.2 iu/dL 
IX 110.2 iu/dL 
X 97.3 iu/dL 
XI 113.6 iu/dL 
Protein C 100 % 
Free protein S 100 % 
Antithrombin 113.9 iu/dL 
 
2.9.3.3 Calculation of concentrations of rFVIIa, PCC 
The mean weight of the overall cohort was used to calculate the amount of rFVIIa to add to 
plasma to be equivalent to doses of 45 µg/kg, 90 µg/kg and 180 µg/kg. Recombinant Factor 
VIIa was purchased from Novonordisk (NovoSeven, Novonordisk, Denmark). The final 
concentrations of rFVIIa in the spiked plasma were 0.93 µg/mL, 1.85 µg/mL and 3.7 µg/mL 
respectively. 
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The mean weight of the overall cohort was also used to calculate the amount of PCC to add to 
plasma equivalent to doses of 25 units/kg, 35 units/kg and 50 units/kg. PCC was a gift from CSL 
Behring (Beriplex, CSL Behring UK Ltd, Hayward Heath, UK). The final concentrations of PCC in 
the spiked plasma were 0.51 units/mL, 0.72 units/mL and 1.03 units/mL respectively. 
 
2.10 Analysis of platelet phospholipids by flow cytometry and mass 
spectrometry 
2.10.1 Preparation of washed platelets for phospholipid extraction and flow-
cytometry 
The following solutions were prepared: 
1. Acidified citrate dextrose (ACD) (85 mmol/L trisodium citrate, 65 mmol/L citric acid, 
100 mmol/L glucose, dissolved in distilled water and pH adjusted to 5.4) 
2. Modified Tyrode’s buffer (134 mmol/L sodium chloride, 12 mmol/L sodium 
bicarbonate, 2.9 mmol/L potassium chloride, 0.34 mmol/L disodium phosphate, 1 
mmol/L magnesium chloride, 10 mmol/L HEPES, 5 mmol/L glucose, dissolved in 
distilled water and pH adjusted to 7.4) 
 
Method: 
Venous blood was drawn into a syringe containing ACD to produce final ratio of blood 8.1%: 
ACD 1.9% (v/v). For the purposes of the experiments described, 41.9mL of whole blood was 
drawn from a central venous cannula into a 50 mL syringe containing 8.1 mL of acidified citrate 
dextrose (ACD), before administration of heparin and 30 minutes after heparin reversal. In the 
laboratory the ambient air temperature was maintained at 21 ˚C by air conditioning. The 
contents of the syringe were split equally into two 50 mL falcon tube and centrifuged at 250 x 
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g for 10 minutes with no brake. The platelet rich plasma was removed using a Pasteur pipette 
into a fresh 50 mL falcon tube, taking care not to disturb the red cell – plasma interface and 
avoiding air bubbles. The red cells and leucocytes were discarded and the platelet rich plasma 
was centrifuged at 900 x g for 10 minutes with no brake. The resulting platelet poor plasma 
was discarded leaving a pellet of platelets at the bottom of the tube. This pellet was gently re-
suspended in 2 mL of a solution of 1 part ACD to 9 parts modified Tyrode’s buffer (v/v) using a 
Pasteur pipette. The volume was made up to 10 mL by adding a further 8 mL of the diluted 
ACD solution. The tube was then centrifuged at 800 x g for 10 minutes with no brake. The 
supernatant was discarded and the platelet pellet re-suspended in 2 mL modified Tyrode’s 
buffer. A 0.1% (v/v) solution of trypan blue (Sigma-Aldrich, Dorset, UK) was prepared by 
dilution with modified Tyrode’s buffer. An aliquot of the platelet suspension was then diluted 1 
in 50 in the 0.1% Trypan blue solution; 10 µL of this suspension was then pipetted under a 
glass clover slip of an improved Neubauer Haemocytometer and the platelets were counted. A 
minimum of 100 cells were counted using the large 4 outer quadrant squares (each large outer 
square contains 16 squares and has a total area of 1 mm2). The number of platelets in the 
original suspension was calculated as follows: platelets/mL = number of cells counted x 
(Dilution factor / Number of quadrants used to count) x 104 x 2(to take account of the volume 
of the original suspension being 2 mL). Further modified Tyrode’s buffer was added to add the 
original suspension to obtain final platelet concentration of 2x108 /mL, the volume determined 
by dividing total number of platelets by the desired concentration. 
 
2.10.2 Flow cytometry on whole blood and washed platelets for CD61 and Annexin V 
All antibodies were purchased from Becton Dickinson. A 1 in 10 Dilution of the 10X Annexin V 
Buffer supplied in Annexin V kit was prepared. The following tubes were prepared: 
1. Unstained 
a. 20 μL Whole blood or PRP 
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b. 80 μL 1 in 10 dilution of Annexin V buffer 
2. CD61 PC7 
a. 10 μL CD61 PC7 
b. 20 μL Whole blood or PRP 
c. 70 μL 1 in 10 dilution of Annexin V buffer 
3. CD61 PC7 / Annexin V FITC 
a. 10 μL CD 61 PC7 
b. 20 μL Whole blood or PRP 
c. 70 μL 1 in 10 dilution of Annexin V buffer 
4. Fixed (3%  paraformaldehyde) / Annexin V (positive control)  
a. 20 μL Whole blood or PRP 
b. 80 μL Annexin V buffer 
 
The tubes were incubated for 15 minutes in the dark. Then 10 μL was transferred from tube 3 
and added to a fresh tube containing 89 μL Annexin V Buffer and 1 μL Annexin V. From tube 4, 
10 µL was transferred to a fresh tube containing 80 μL Annexin V buffer, 9 μL 30% 
paraformaldehyde and 1 μL Annexin V. All tubes were then incubated for 15 minutes.  Then 10 
μL was transferred from tubes 1 and 2 to fresh tubes. These four final tubes were then made 
up to a volume of 500 µL using modified Tyrode’s buffer. These were then run on a Beckman 
Coulter Cyan ADP Flowcytometer and the data analysed using Summit software version 4.3 
(Beckman Coulter, Fullerton, CA, USA). Platelets were first identified using forward and side 
scatter. Gating on this population then allowed identification of CD61 and Annexin V positive 
events.  Each condition was run in triplicate. 
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2.10.3 Stimulation of washed platelets prior to phospholipid extraction 
The following reagents were prepared: 
1. A solution of 20 units/mL human thrombin (Sigma-Aldrich, Dorset, UK) was prepared 
by diluting to the desired concentration using distilled water. 
2. A solution of 20 mmol/L calcium chloride by diluting a pre-prepared solution of 1 mol/L 
calcium chloride in modified Tyrode’s buffer 
3. A solution of 200µg/mL collagen (Mascia-Brunellli, Milan, Italy), using the diluent 
provided. 
4. 5mg/mL EZ-Link Sulfo-NHS-Biotin (Thermo-Fisher Scientific, Cramlington, UK) in 
modified Tyrode’s buffer 
5. 0.0366g/mL Lysine (Sigma-Aldrich, Dorset, UK) in modified Tyrode’s buffer 
6. 6.8276mg/mL EZ-Link NHS-Biotin (Thermo-Fisher Scientific, Cramlington, UK) dissolved 
in DMSO 
Table 2.3 Volumes of reagents and washed platelets used in platelet stimulation experiments. 
Condition Modified Tyrode’s 
Buffer 
Platelet Suspension Calcium 
Chloride 
Agonist 
Untreated 330 µL 1000 µL 70 µL Nil 
Thrombin 316 µL 1000 µL 70 µL 14 µL 
Collagen 260 µL 1000 µL 70 µL 70 µL 
 
Plastic Eppendorf tubes, prepared as shown in Table 2.3 were incubated in a water bath at 37 
˚C for 10 minutes. They were then removed from water bath and 140 µL was removed to fresh 
Eppendorf tubes to use for biotinylation of total phospholipids as described later.  
 
To the remaining suspension in each tube, 602 µL Sulfo-NHS-EZ linked Biotin was added and 
incubated for 10 minutes at room temperature. To bind any un-reacted biotin, 504 µL of lysine 
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solution was added to each tube and incubated for 10 minutes at room temperature. Finally 
94 µL of modified Tyrode’s buffer was added to each tube to make the volume up to 2600 µL. 
 
For biotinylation of total phospholipids, 60 µL of modified Tyrode’s solution and 20 µL of EZ-
link NHS Biotin solution were added to each tube containing 140 µL of the platelet suspension. 
The tubes were then incubated at room temperature for 10 minutes. The volume of each tube 
was then made up to 400 µL by the addition of 180 µL modified Tyrode’s buffer. 
 
2.10.4 Extraction of externalised biotinylated phospholipids 
Chloroform, methanol and HPLC grade water were purchased from Fisher Scientific 
(Loughborough, UK). Glass extraction tubes (Fisher Scientific, Loughborough, UK) were labelled 
and 9.75 mL of a mixture chloroform-methanol (1:2 v/v) was added to each tube. Next 10 µL of 
1ng/µL biotinylated 1,2-dimyristoyl-sn-glycero-3-PS (DMPS-B) and biotinylated 1,2-dimyristoyl-
sn-glycero-3-PE (DMPE-B) were added to each tube, followed by the platelet samples. The 
contents of each tube were then mixed thoroughly for 1 minute using a vortex mixer. Next 
3.25 mL of chloroform was added to each tube before mixing for a further minute. A volume of 
3.25 mL HPLC grade water was then added to each tube and the contents mixed on a vortex 
mixer for a further minute. The glass tubes were then centrifuged at 500 x g for 5 minutes in a 
refrigerated centrifuge cooled to 4˚C. The lower layer from each tube was then transferred to 
a fresh set of glass extraction tubes and the contents dried using a vacuum dryer for 30-60 
minutes. Once dry, 100 µL of methanol was added to each tube and the contents re-
suspended by vortex mixing for 1 minute. The contents of each tube was then transferred to a 
glass HPLC vial and frozen at -80 oC prior to analysis. 
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2.10.5 Phospholipid extraction for measurement of total phospholipids 
Two sets of glass extraction tubes (Fisher Scientific) were labelled with the relevant sample 
numbers. A mixture of 1 part chloroform to 2 parts methanol (v/v) was prepared and 1.5 mL 
added to the first set of tubes. Then 10 µL of 1ng/µL internal standards consisting of DMPS-B, 
DMPE-B and 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) were added to each tube 
followed by the platelet samples. The contents of each tube were then thoroughly mixed for 1 
minute using a vortex mixer. Next 0.5 mL of chloroform was added to each tube before mixing 
for a further minute, followed by 0.5 mL HPLC grade water and mixing for a final minute. The 
tubes were then centrifuged at 500 x g for 5 minutes at 4 oC using a refrigerated centrifuge. 
The lower layer from each tube was then transferred to a fresh set of glass extraction tubes 
and the contents dried using a vacuum dryer for 30-60 minutes. Once dry, 100 µL of methanol 
was added to each tube and the contents re-suspended by vortex mixing for 1 minute. The 
contents of each tube was then transferred to a HPLC vial and frozen at -80 oC prior to analysis. 
 
2.10.6 Preparation of biotinylated phospholipid standards 
Biotinylated 1,2-dimyristoyl-sn-glycero-3-PS (DMPS; 14:0/14:0-PS) and 1,2-dimyristoyl-sn-
glycero-3-PE (DMPE; 14:0/14:0-PE) were prepared by pipetting 1 mg of each lipid into separate 
glass extraction vials and then drying under a stream of nitrogen gas. Each lipid was then re-
suspended by adding 220 µl chloroform and 110 µl methanol to each vial and vortex mixing for 
1 minute. Next 6.6 mg of NHS biotin and 3.3 µl tri-ethylamine were added each vial was 
incubated for 30 minutes at room temperature. To try to remove as much unreacted biotin as 
possible, the vials were then centrifuged at 500 x g for 5 minutes and upper three quarters of 
the solution removed to a fresh glass vial using a glass Pastuer pipette. The contents of each 
vial was then dried under a nitrogen gas stream before re-suspending by adding 0.5 mL 
methanol and vortex mixing for 1 minute. The lipid preparation was then purified by using 
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reverse phase HPLC on a Discovery C18 column (25 cm x 4.6 mm, 5μm, Sigma Aldrich, Dorset, 
UK) with the following conditions: 
1. Flow rate of 1 mL/min. 
2. Gradient elution profile of 50 % mobile phase B to 100 % mobile phase B (mobile 
phase A consisted of 5 mmol/L ammonium acetate in HPLC grade water; mobile phase 
B consisted of 5 mmol/L ammonium acetate in methanol) over 15 min. The gradient 
was then held at 100% B for 20 minutes before re-equilibrating to 50% B.  
3. UV absorbance was measured at 205 nm. 
 
On identification of the peak in UV absorbance, the fraction was collected. The process was 
repeated until all the original lipid preparation had been purified. The fractions were then 
pooled in a single glass vial and dried in a stream of nitrogen gas. The glass vial in which the 
sample was to be stored was weighed, with care being taken to ensure that the vial was clean, 
dry and gloves were worn at all times when handling. The purified lipid sample was then 
pipetted into the pre-weighed glass vial and the solvent evaporated using a stream of nitrogen. 
The glass vial was then reweighed and the difference in weight used to determine the weight 
of the biotinylated lipid present. The contents of the vial were then re-suspend in methanol 
added at a volume sufficient to produce a concentration of the lipid of 100 ng/µL and then 
stored under nitrogen gas at -80 oC for use later. 
 
Biotinylated versions of the following lipids for use as internal standards were provided by Dr 
Stephen Clark and Dr Christopher Thomas: 1-stearoyl-2-oleoyl-sn-glycero-3-PS (SOPS; 
18:0a/18:1-PS), 1,2-dioleoyl-sn-glycero-3-PS (DOPS; 18:1a/18:1-PS), 1-stearoyl-2-arachidonoyl-
sn-glycero-PS (SAPS; 18:0a/20:4-PS), 1-(1Z-stearoyl)-2-arachidonoyl-sn-glycero-3-PE (SpAPE; 
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18:0p/20:4-PE), 1-stearoyl-2-arachidonoyl-sn-glycero-3-PE (SAPE; 18:0a/20:4-PE)  and 
18:0a/12-HETE-PE.  
 
2.10.7 Mass-spectrometry to identify and quantify externalised and total PE, PS, 12-
HETE-PE 
Samples were run using HPLC/MS/MS using a Shimadzu DGU 14A degasser HPLC system with 
SIL-HTc Auto-sampler and LC-10AD VP μ Binary Pump System attached to an AB Sciex 4000 Q-
Trap mass spectrometer. The methods used were those  described by Thomas and Clark et al 
(171).  
 
For the measurement of biotinylated PE, PS and 12-HETE-PE, reverse phase HPLC was 
performed using an Ascentis C18 column (5µm, 150 × 2.1 mm, Sigma Aldrich, Dorset, UK) with 
the following conditions at 22 C: 
1. Flow rate 400 µL/min. 
2. Isocratic mobile phase consisting of 20 mmol/L ammonium acetate in methanol.  
 
From each sample, 10µL was injected on to the HPLC column. The phospholipids were then 
detected using the multiple reaction monitoring (MRM) transitions listed in Table 2.4. PE 
species were monitored by formation of the sn2 carboxylate anion, whilst PS species were 
monitored by neutral loss of biotinylated serine. Biotinylated 12-HETE-PE species were 
monitored by the ion formed from the characteristic fragmentation of the oxidized sn2 lipid. 
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Table 2.4 MRM transitions used to monitor biotinylated PE, PS and 12-HETE-PE. 
Lipid Mass Biotinylated Mass m/z  
[M-H]
-
 
Biotinylated MRM 
transition 
DMPE (14:0/14:0-PE) 635 861 860 860 →227 
SpAPE (18:0p/20:4-PE) 751 977 976 976 →303 
SAPE (18:0a/20:4-PE) 767 993 992 992→303 
PpAPE (16:0p/20:4-PE) 723 949 948 948 →303 
SOPE (18:0a/18:1-PE) 745 971 970 970 →281 
OpAPE (18:1p/20:4-PE) 749 975 974 974 →303 
DMPS (14:0/14:0-PS) 679 905 904 904 →591 
SOPS (18:0a/18:1-PS) 789 1015 1014 1014→701 
DOPS (18:1a/18:1-PS) 787 1013 1012 1012 →699 
SAPS (18:0a/20:4-PS) 811 1037 1036 1036 →723 
18:0a/12-HETE-PE 783 1010 1009 1009 → 179 
18:0p/12-HETE-PE 767 994 993 993 → 179 
18:1p/12-HETE-PE 765 992 991 991 → 179 
16:0p/12-HETE-PE 739 966 965 965 → 179 
 
 
2.10.8 Mass Spectrometry for 12-HETE-PC, SAPC and PAPC 
Using the same HPLC system and mass spectrometer described earlier, reverse phase HPLC 
was performed using a  Luna C18 (3 µm,150 × 2 mm) column (Sigma-Aldrich, Dorset, USA) and 
conditions at 22  C as follows: 
Flow rate 0.2 mL/min Gradient elution profile - 50 % mobile phase A and 50% mobile phase B 
to 100 % mobile phase B (mobile phase A: methanol: acetonitrile: water, 60: 20: 20, 1 mmol/L 
ammonium acetate; mobile phase B: methanol, 1 mmol/L ammonium acetate) over 10 min 
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followed by 30 min at 100 % mobile phase B before re-equilibration to 50 % mobile phase A 
and 50% mobile phase B.  
 
From each sample, 10µL was injected on to the HPLC column and the MRM transitions listed 
on Table 2.5 were monitored in negative mode. PC species were monitored by formation of 
the sn2 carboxylate ion, with 12-HETE-PC monitored by the ion resulting from characteristic 
fragmentation of the oxidized sn2 lipid. 
 
Table 2.5 MRM transitions monitored for detection of PC and 12-HETE-PC. 
Lipid Mass m/z [M-CH3]
-
 MRM transition 
DMPC (14:0/14:0-PC) 678 663 663 →227 
SAPC (18:0/20:4-PC) 810 795 795 →303 
PpAPC (16:0/20:4-PC) 782 767 767 →303 
16:0a/12-HETE-PC 798 783 783→ 179 
18:0a/12-HETE-PC 826 811 811→179 
 
 
2.10.10 Phosphatidylcholine Lipid Standard Curve 
A solution containing the internal standard DMPC at concentration of 0.02 ng/μL was prepared 
by diluting DMPC in methanol. A solution of the analyte standards (C) was prepared by diluting 
SAPC and 16:0/12-HETE-PC together in methanol such that each had a concentration of 2 
ng/μL. Then serial dilutions of the test standard mixture (see table below) was prepared as 
outlined in Table 2.6 and then adding 100 μL of each dilution to 100 μL of the internal standard 
solution. 
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Table 2.6 Preparation of standard curve for quantification of PC and 12-HETE-PC. 
Dilution Number Procedure Concentration of 
each analyte 
standard 
Final 
Concentration 
(after adding 
internal standard) 
Amount on 
column (final) 
1 Undiluted mixture 
C 
2 ng/μL 1 ng/μL 10 ng 
2 150 μL of (1) with 
150 μL methanol 
1 ng/μL 0.5 ng/μL 5 ng 
3 60 μL of (2) with 
240 μL methanol 
0.2 ng/μL 0.1 ng/μL 1 ng 
4 150 μL of (3) with 
150 μL methanol 
0.1 ng/μL 50 pg/μL 500 pg 
5 60 μL of (4) with 
240 μL methanol 
20 pg/μL 10 pg/μL 100 pg 
6 150 μL of (5) with 
150 μL methanol 
10 pg/μL 5 pg/μL 50 pg 
7 60 μL of (6) with 
240 μL methanol 
2 pg/μL 1 pg/μL 10 pg 
8 150 μL of (7) with 
150 μL methanol 
0.5 pg/μL 0.5 pg/μL 5 pg 
9 60 μL of (8) with 
240 μL methanol 
0.2 pg/μL 0.1 pg/μL 1 pg 
 
2.10.11 Biotinylated Lipid Standard Curve 
A solution containing the internal standards DMPE-B and DMPS-B, each at a concentration of 
0.02 ng/μL, was prepared by diluting in methanol. A solution of the analyte standards (F) was 
prepared by diluting SAPS-B, SOPS-B, DOPS-B, S(p)APE-B, SAPE-B and 18:0/12-HETE-PE-B 
together in methanol such that each had a concentration of 2 ng/μL. Then serial dilutions of 
the test standard mixture were prepared, as outlined in Table 2.7, before then adding 100 μL 
of each dilution to 100 μL of the internal standard solution to produce the final concentration. 
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Table 2.7 Preparation of standard curve for quantification of biotinylated PE, PS and 12-HETE-
PE. 
Dilution Number Procedure Concentration of 
each analyte 
standard 
Final 
Concentration 
(after adding 
internal standard) 
Amount on 
column (final) 
1 Undiluted mixture 
F 
2 ng/μL 1 ng/μL 10 ng 
2 150 μL of (1) with 
150 μL methanol 
1 ng/μL 0.5 ng/μL 5 ng 
3 60 μL of (2) with 
240 μL methanol 
0.2 ng/μL 0.1 ng/μL 1 ng 
4 150 μL of (3) with 
150 μL methanol 
0.1 ng/μL 50 pg/μL 500 pg 
5 60 μL of (4) with 
240 μL methanol 
20 pg/μL 10 pg/μL 100 pg 
6 150 μL of (5) with 
150 μL methanol 
10 pg/μL 5 pg/μL 50 pg 
7 60 μL of (6) with 
240 μL methanol 
2 pg/μL 1 pg/μL 10 pg 
8 150 μL of (7) with 
150 μL methanol 
0.5 pg/μL 0.5 pg/μL 5 pg 
9 60 μL of (8) with 
240 μL methanol 
0.2 pg/μL 0.1 pg/μL 1 pg 
 
2.10.12 Quantification of phospholipids 
Each standard curve was run as described for the relevant samples (biotinylated and non-
biotinylated). The peak area for each lipid was integrated. For each analyte standard, the ratio 
of analyte standard (AS) to internal standard (IS) for ng amounts of lipid in each standard vial 
was calculated followed by the ratio for AS to IS peak area in counts per second (cps). These 
two ratios were then plotted against each other as shown in Figure 2.1, and an equation 
generated to provide the slope of the line of best fit. 
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Figure 2.1 Example of plot generated for weight ratio against peak area ratio for SAPE-B 
showing equation including line slope. The slope is circled in red. 
 
 
The amount of each lipid present in each patient sample was calculated by first integrating the 
peak area for the lipid and internal standard and then applying the following formula:   
Amount of lipid present in ng = (Lipid peak area / internal standard peak area) x (amount of 
internal standard added [in all cases 10 ng]/ slope from standard curve) 
The amount of lipid was then expressed as ng per 2x108 platelets. 
 
2.11 Monocyte Isolation for Cell-based coagulation model 
2.11.1 In vitro Modelling 
Monocytes were isolated in a Class 2 tissue culture hood from buffy coats purchased from the 
Welsh Blood Service. Sterile Phosphate Buffered Saline (PBS) suitable for cell culture was 
purchased from Life Technologies Ltd (Paisley, UK). The contents of the Buffy coat were diluted 
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at a ratio of 1 to 1 with PBS. This was then overlaid onto Lymphoprep (Alere Ltd, Stockport, UK) 
at a ratio of 2:1 in 50 mL falcon tubes. The tubes were centrifuged at 800 x g with no brake 
applied in a refrigerated centrifuge with the temperature set to 4 oC (Heraeus, Sweden) for 20 
minutes. The interface layer was then carefully removed using a sterile pipette and diluted 1 to 
1 with ice cold PBS containing 0.4% (w/v) trisodium citrate pH 7.4. The tube was then 
centrifuged at 400 x g with no brake applied, at 4 oC for 10 minutes. The supernatant was 
carefully removed and the pellet re-suspended in 45 mL of ice-cold PBS/0.4% Citrate. This 
process was repeated a further 5 times (centrifuging with the brake on) until the supernatant 
at the end of centrifuging was no longer cloudy. The pellet was then re-suspended in 2 mL 
RPMI 1640 media (Life Technologies Ltd Paisley, UK). An aliquot of the cell suspension was 
diluted 1 in 50 with a solution of 1% (v/v) trypan Blue. The number of cells present was 
counted using a modified Neubauer haemocytometer and calculated using the formula 
described in the section on preparation of washed platelets. The original suspension was then 
diluted further with RPMI fortified with 100 units/ mL penicillin and streptomycin with 2 
mmol/L glutamine to yield a cell concentration as desired (see Chapter 6).  
 
200 µL of this suspension was then placed in wells of a 96 well plate BD cell culture plate, the 
type determined by the experiment being performed (see Chapter 6). Some wells were left 
blank and some contained media only. The plate was then covered and incubated for 2 hours 
at 37 oC in a humidified cell culture incubator with carbon dioxide set to 5%. The media was 
removed and the wells were then washed with 300 µL RPMI to remove non-adherent cells. 
200 µL of media was then added to each well, either containing RPMI alone or RPMI with 
varying concentrations of LPS. The plate was then covered and incubated under the same 
conditions for a further 18 hours. At the end of incubation, the media was removed and the 
wells washed with further RPMI. 20 µL of liposomes were then added (or calibrator) to the 
wells, followed by 80 µL of pooled PPP from a minimum of 4 normal donors (blood collected 
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into sodium citrate and CTI as described in section 2.6 above). Thrombin generation was then 
measured as described earlier. 
 
2.11.2 Crystal Violet Staining for adherent cells in 96-well plate 
The contents of the wells of the 96 well plate were removed and the cells were fixed by adding 
200 µL ethanol per well. The plate was incubated at room temperature for 10 minutes. The 
ethanol was then removed and 200 µL of 0.1% (w/v) crystal violet solution was added, after 
which the plate was incubated at room temperature for 30 minutes. The crystal violet solution 
was then discarded and the plate washed 5 times with distilled water. Then 200 µL of 0.2% 
(v/v) Triton X was added to each well to lyse the cells and light absorbance was measured at 
570 nm on Biotek plate reader and analysed using Gen 5.1 software (Biotek, Winoosi, VT, 
USA).  
 
2.12 Cascade model using purified coagulation factors and anti-
coagulants 
Coagulation factors II, V, and X were purchased from Cambridge Biosciences Ltd (Cambridge, 
UK). Lyophilised factors VIII and IX were purchased from Tebu-Bio UK (Peterborough, UK). 
Lyophilised protein S and antithrombin were purchased from Enzyme Research Laboratories 
Ltd (Swansea, UK). Human full length TFPI was a gift from Dr Michael Dockal, Baxter 
Biosciences GmbH, Vienna, Austria. Lyophilised reagents were reconstituted with distilled 
water. All reagents were diluted to the desired concentration using distilled water and then 
frozen at -80 oC until further use. 
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The concentration of these coagulation factors was calculated so that the final in-well 
concentration was the same as the activity measured using the ACL500 Top. All coagulation 
and anti-coagulant factors were diluted in distilled water before adding to the respective wells 
of a 96 well plate. Thrombin generation assays were performed as described earlier. 20 µL of 
trigger solution or calibrator was added to each well, followed by 80 µL of the coagulation 
factor mix. Each condition was run in duplicate.  
 
2.13 Statistical Analysis 
Data was analysed using PASW Statistics version 18 software (SPSS Inc. Released 2009. PASW 
Statistics for Windows, Version 18.0. Chicago, MI, USA). The Mann Whitney-U test was applied 
to examine differences between unrelated variables, whilst the Wilcoxon Rank test was used 
to examine differences between related samples. Analysis of multiple related samples was 
performed using Friedman’s test. Spearman’s correlation coefficients were calculated to 
investigate the relationship between full-length TFPI and thrombin generation parameters 
Analysis of multiple related samples was performed using Friedman’s test. Comparison of 
means was performed using Student’s t-test for paired variables and ANOVA for multiple 
related variables. A receiver operator characteristic (ROC) analysis was performed where 
factors where significantly different between patients that bleed excessively and those that did 
not.  
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Chapter 3 The effect of CPB on clinical parameters, coagulation 
factors and thrombin generation and their association with 
bleeding 
 
3.1 Introduction 
Surgery requiring cardiopulmonary bypass is associated with increased morbidity and mortality 
(172, 173) and accounts for around 4% to 15% of red blood cells transfused in the UK and USA 
(174, 175). Blood products are a limited resource and may become scarcer in the future due to 
the impact of an aging population; therefore, the need to target blood products to those with 
greatest need will increase.  
 
Bleeding following cardiopulmonary bypass may be caused by dilution and consumptive of 
clotting factors, anticoagulation, thrombocytopenia and or platelet dysfunction (102) and 
surgical causes. Recent studies have reported that thrombin generation performed in both 
pre- and post-operative blood samples may identify patients at increased risk of excess 
bleeding (11, 169). This raises the possibility that intervention could be targeted at these 
patients before bleeding becomes established, thus improving patient outcome and reducing 
the use of blood products. Thrombin generation assays are potentially more useful than 
routine tests of coagulation because they integrate the effects of both pro and anticoagulant 
factors. Previous studies have shown that pro-coagulant factors  (176) and protein C levels fall 
post cardiopulmonary bypass, but activated protein C increases (111, 112).  Thrombin 
generation assays performed in the presence of thrombomodulin might therefore better 
describe global haemostasis.  Tissue Factor Pathway Inhibitor (TFPI) may also play a role in 
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bleeding because heparin, the standard anticoagulant used during cardiopulmonary bypass, 
releases TFPI from the endothelium (64).  
 
At present thrombin generation assays lack standardisation (177, 178). Some groups advocate 
the addition of corn trypsin inhibitor (CTI) to reduce contact activation and this has been 
shown to increase sensitivity to the propagation phase at low concentrations of tissue factor 
(156, 157).  The optimal concentration of tissue factor to use in the assays is also uncertain. 
Lower concentrations may be more physiologically relevant and altering the concentration 
used may change the sensitivity of the assay to detect patients at risk of excess bleeding.  
 
The composition and volume of intravenous fluids infused peri-operatively may also influence 
bleeding. Crystalloids have been shown to cause dilution of coagulation factors which may 
influence haemostasis (179). Colloids fluids are frequently used for resuscitation in the setting 
of intravascular volume depletion, especially where there was a desire to avoid total body fluid 
overload. However, colloids carry their own problems in that they have been reported to affect 
haemostasis (180). 
 
The experiments detailed in this chapter sought to identify clinical and haemostatic 
parameters that might influence postoperative bleeding and to confirm whether thrombin 
generation assays were able to identify individuals at increased risk of bleeding. In addition the 
effect of changing the conditions of thrombin generation assay was explored. 
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3.2 Results 
3.2.1 Demographic data and clinical parameters 
A total of 102 patients were recruited to this section of the study. 10 patients were excluded 
from further analysis as measurement of heparin anti-Xa activity in post-operative samples 
revealed persistent contamination (>0.3 anti-Xa units/mL) despite the ACT after protamine 
administration having been within 10% of the starting value. A further 5 patients were found 
to have received one or more units of FFP in the interval between protamine being given and 
blood samples being taken and were therefore also excluded. This left 87 patients in the 
subsequent analysis. 
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Table 3.1 Type of operation by frequency of bleeding.  
Type of 
Operation 
Total 
undergoing 
procedure 
No 
Bleeding 
> 1L > 
200mL/hr  
> 
2mL/kg/hr 
Need for 
haemostatic 
treatment 
Re-
operation 
Excess 
bleeding 
by any 
end 
point 
AVR 21 11 4 3 4 10 2 10 
AVR + 
another 
procedure 
35 21 6 5 7 14 1 14 
CABG 
(Decision not 
to proceed 
with planned 
AVR) 
1 0 1 1 1 1 1 1 
LV 
Aneurysm-
ectomy + 
CABG 
1 0 1 0 1 1 0 1 
MV Repair / 
Replacement 
alone 
5 4 1 0 0 1 0 1 
MV Repair + 
another 
procedure 
12 9 0 0 0 3 0 3 
Redo AVR 2 
 
2 
 
0 0 0 1 0 0 
Redo AVR + 
another 
procedure 
3 
 
0 2 
 
1 2 3 2 3 
Replacement 
of portion of 
ascending 
aorta +/- 
another 
procedure 
7 1 3 0 0 6 1 6 
Total 87 
(100%) 
48 
(55%) 
18 
(21%) 
10 
(11%) 
15 
(17%) 
37 
(43%) 
7 
(8%) 
39 
(45%) 
AVR= aortic valve replacement, MV= mitral valve, MVR= Mitral Valve Replacement, TA= tricuspid 
annuloplasty, LV= Left Ventricle, CABG= Coronary Artery Bypass Graft.
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Table 3.2 Clinical Parameters of patients recruited divided by end point. 
End point Whole 
Cohort 
<1L >1L <200mL/hr >200mL/hr <2ml/kg/hr 
for 2 hours 
>2ml/kg/hr 
for 2 hours 
No 
Haemostatic  
treatment  
Haemostatic 
treatment 
No  
Re-op 
 
Re-op 
Age 
(years) 
68 
28-88 
(62-76) 
69 
29-88 
(62-76) 
63 
28-81 
(58-71) 
69 
59-88 
(61-76) 
67 
28-81 
(65-75) 
68 
29-88 
(61-76) 
69 
28-81 
(67-75) 
68 
29-88 
(62-76) 
67 
28-88 
(61-76) 
69 
29-88 
(62-76) 
66 
28-71 
(46-69) 
Weight 
(kg) 
 
78 
48-134 
(67-90) 
76 
48-134 
(66-89) 
90 
60-121 
(72-97) 
78 
48-134 
(67-90) 
87 
60-99 
(71-94) 
80 
48-134 
(66-90) 
75 
60-99 
(68-90) 
75 
48-120 
(66-88) 
84 
58-134 
(69-96) 
77 
48-134 
(67-90) 
88 
74-99 
(81-94) 
Sex 
(M/F) 
60/27 46/23 14/4 25/25 8/2 50/22 10/5 31/16 29/11 55/25 5/2 
Wafarin/Heparin 
pre-op (yes/no) 
9/78 6/63 3/15 7/70 2/8 7/65 2/13 4/43 5/35 8/72 1/6 
Aspirin pre-op 
(yes/no) 
34/53 26/43 8/10 30/47 4/6 27/45 7/8 19/28 15/25 33/47 1/6 
Time on bypass 
(minutes) 
144 
64-265 
(115-178) 
139 
64-250 
(114-163) 
175* 
79-270 
(158-203) 
145 
67-270 
(115-178) 
144 
79-203 
(124-201) 
143 
64-270 
(114-167) 
156 
79-203 
(144-200) 
132 
64-230 
(113-158) 
162** 
79-270 
(133-203) 
151 
64-270 
(115-178) 
151 
79-230 
(111-
217) 
Aortic Cross-clamp 
time 
(minutes) 
112 
50-219 
(95-145) 
111 
50-217 
(91-139) 
143 
61-228 
(125-167) 
115 
50-228 
(95-143) 
104 
61-178 
(92-160) 
112 
50-228 
(91-141) 
127 
61-178 
(100-157) 
106 
50-210 
(91-131) 
131** 
61-228 
(101-176) 
123 
50-228 
(95-143) 
118 
61-199 
(82-183) 
Days ventilated 
 
<1 
<1-8 
(<1-1) 
<1 
<1-8 
(<1-1) 
1 
1-2 
(<1-1) 
<1 
<1-8 
(<1-1) 
<1 
<1-2 
(<1-1) 
<1 
<1-8 
(<1-1) 
<1 
<1-2 
(<1-1) 
<1 
<1 
<1 
1 
<1-8 
(<1-1) 
<1 
<1-8 
(<1-1) 
1 
1-6 
(2-4) 
Duration of Level 
2/3 care 
(days) 
3 
1-20 
(3-5) 
3 
1-20 
(2-5) 
4 
2-13 
(3-6) 
3 
1-20 
(2-5) 
4 
3-13 
(2-6) 
3 
1-20 
(2-5) 
4 
3-13 
(3-6) 
3 
1-10 
(3-5) 
3 
2-20 
(3-5) 
3 
1-20 
(3-5) 
8*** 
3-13 
(5-10) 
Days to discharge 
post-op  
 
12 
5-49 
(8-16) 
12 
5-49 
(8-17) 
12 
5-21 
(7-14) 
12 
5-49 
(8-16) 
13 
5-21 
(8-14) 
13 
5-21 
(8-16) 
14 
5-21 
(8-14) 
12 
5-35 
(9-15) 
12 
5-49 
(7-18) 
13 
5-49 
(8-16) 
17*** 
13-28 
(14-21) 
Complications 
(yes/no) 
27/60 19/50 8/10 20/57 7/3 18/54 9/6 10/37 17/23 20/60 7/0 
Data shown are the median and range (inter-quartile range). *Statistically significant difference between >1L and <1L (p< 0.05. **Statistically significant difference between no haemostatic treatment 
and need for haemostatic treatment (p< 0.05).  ***statistically significant difference between reoperation and no reoperation (p< 0.05).  
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Table 3.3 Intravenous fluids and blood products administerted intra- and post-operatively divided by bleeding end point. 
End point Whole 
Cohort 
<1L >1L <200mL/hr >200mL/hr <2ml/kg/hr 
for 2 hours 
>2ml/kg/hr 
for 2 hours 
No 
Haemostatic  
treatment 
Haemostatic 
treatment 
No  
Re-op 
 
Re-op 
Intraoperative 
volume crystalloid  
(mL/kg) 
13 
0-36 
(8-20) 
13 
0-32 
(8-18) 
14 
5-36 
(8-22) 
14 
0-36 
(8-20) 
 
11 
5-27 
(8-16) 
13 
0-32 
(8-20) 
14 
5-36 
(9-16) 
14 
0-32 
(8-21) 
14 
5-36 
(8-17) 
13 
0-36 
(8-20) 
11 
5-37 
(5-22) 
Intraoperative 
volume of colloid 
(mL/kg) 
13 
0-47 
(8-18) 
13 
0-47 
(8-18) 
17 
4-35 
(10-19) 
13 
0-47 
(8-17) 
17 
8-24 
(16-21) 
13 
0-47 
(8-17) 
17*** 
8-35 
(16-24) 
14 
0-47 
(7-17) 
14 
4-35 
(9-19) 
13 
0-47 
(8-18) 
17 
11-28 
(16-26) 
Post-operative 
volume crystalloid  
(mL/kg) 
13 
0-30 
(10-16) 
13 
0-28 
(11-16) 
11 
0-30 
(0-17) 
13 
0-29 
(10-16) 
13 
0-30 
(11-23) 
13 
0-28 
(10-16) 
14 
0-30 
(12-23) 
13 
0-23 
(10-15) 
13 
0-30 
(10-17) 
13 
0-30 
(10-16) 
11 
0-30 
(6-22) 
Post-operative 
volume of colloid 
(mL/kg) 
23 
0-52 
(18-29) 
23 
0-52 
(19-30) 
20* 
0-34 
(10-23) 
23 
0-52 
(19-30) 
11** 
0-34 
(4-22) 
23 
0-52 
(19-30) 
18*** 
0-34 
(9-22) 
26 
9-52 
(21-30) 
19‡ 
0-40 
(11-23) 
23 
0-52 
(17-28) 
28 
20-34 
(22-34) 
Cell Salvage 
Volume  
(mL/kg)  
9 
3-52 
(7-12) 
10 
3-52 
(7-12) 
9 
6-24 
(8-11) 
10 
3-52 
(7-12) 
9 
6-13 
(8-11) 
9 
3-52 
(7-12) 
9 
6-13 
(8-11) 
10 
3-16 
(7-12) 
9 
5-52 
(7-11) 
9 
3-52 
(7-12) 
13 
11-29 
(12-21) 
Number of red cell 
units transfused 
 
1 
0-12 
(0-3) 
1 
0-8 
(0-2) 
4* 
0-12 
(1-7) 
1 
0-12 
(0-2) 
5** 
0-9 
(3-8) 
1 
0-8 
(0-2) 
5*** 
0-12 
(3-8) 
1 
0-5 
(0-2) 
3‡ 
0-12 
(0-5) 
1 
0-12 
(0-3) 
6‡‡ 
0-8 
(6-8) 
Number of platelet 
units transfused 
0 
0-5 
(0-1) 
0 
0-5 
(0-1) 
1* 
0-4 
(1-3) 
0 
0-5 
(0-1) 
3** 
1-3 
(1-3) 
0 
0-5 
(0-1) 
 
2*** 
1-4 
(1-3) 
 
0 
0-1 
(0-0) 
1‡ 
0-5 
(1-2) 
0 
0-4 
(0-1) 
3‡‡ 
1-5 
(3-4) 
Number of FFP 
units transfused 
0 
0-12 
(0-4) 
0 
0-12 
(0-4) 
8* 
0-12 
(4-9) 
0 
0-12 
(0-4) 
9** 
4-12 
(6-11) 
0 
0-12 
(0-4) 
8*** 
4-12 
(4-10) 
0 
- 
- 
4‡ 
2-12 
(5-7) 
0 
0-12 
(0-4) 
10‡‡ 
8-12 
(10-12) 
Data shown are the median and range (inter-quartile range). *Statistically significant difference between >1L and <1L (p< 0.05). **Statistically significant difference between >200mL/hr and <200mL/hr 
(p< 0.05) . ***Statistically significant difference between >2mL/kg/hr and <2mL/kg/hr (p< 0.05). ‡ Statistically significant difference between no haemostatic treatment and haemostatic treatment (p< 
0.05). ‡‡ Statistically significant difference between no re-operation and reoperation (p< 0.05). 
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The majority of patients (90%) underwent heart valve surgery with or without an additional 
procedure. Replacement of the aortic valve, with or without another procedure, accounted for 
64% of all operations. There was no significant difference between the type of operation and 
the frequency of bleeding (Table 3.1).  Patients who bled excessively received significantly 
more red cells and platelet transfusions regardless of bleeding endpoint (p<0.01) (Table 3.3). 
Patients who received haemostatic treatment with FFP, cryoprecipitate and fibrinogen had a 
significantly longer time on bypass (162 versus 132 minutes, p=0.005) and longer aortic cross-
clamp times (131 versus 106 minutes, p=0.003) (Table 3.2).  Patients who bled in excess of 1L 
at 24 hours also spent a longer on bypass than those who did not (175 versus 139 minutes, 
p=0.04). Post-operative colloid administration was lower in those who bled compared to those 
who did not, apart from those needing to return the theatre where there was no difference 
(>1L 20mL/kg versus 23 mL/kg, p=0.02; >200mL/hr 11 versus 23, p=0.04; >2mL/kg/hr 18 versus 
23, p=0.007; need for haemostatic treatment 19 versus 26, p<0.0001). This finding is most 
likely due to these patients receiving blood products rather than colloids or crystalloids. There 
was no significant difference between those who bled and those who did not in the frequency 
of preoperative aspirin administration, other anticoagulant use, or in the residual anti-Xa 
activity in post-operative samples. 
 
3.2.2. Clotting factors, inhibitors and platelet count 
The results for this section are summarised in tables 3.4 to 3.9. Overall the median 
concentration of clotting factors was significantly lower post cardiopulmonary bypass 
compared to before. In contrast the overall median concentrations of VWF increased.  The 
anticoagulants antithrombin, protein C and S were also lower post-cardiopulmonary bypass. 
Total TFPI increased significantly while full length TFPI decreased.   
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Comparing the levels between the different end-points for bleeding, there were no significant 
differences in pre-operative samples. Post-operatively, prothrombin (49 iu/dL versus 53 iu/dL, 
p=0.028), Factor V (42 iu/dL versus 50 iu/dL, p=0.038) and X (42 iu/dL versus 47 iu/dL, 
p=0.034), Factor XIII (46% versus 59%, p=0.013), Fibrinogen (1.4 g versus 1.7g, p=0.031) and 
platelet count (101x109/L versus 110 x109/L, p=0.042)  were significantly lower in those who 
went on to bleed more than 2 mL/kg/hr for two consecutive hours in the first six hours after 
the end of surgery. ROC analysis showed these had modest value in predicting bleeding. 
 
Prothrombin (50 iu/dL versus 53 iu/dL, p=0.045), Factor XIII (46% versus 58%, p=0.012), 
Fibrinogen (1.4 g/L versus 1.7 g/L, p=0.006) and platelet count (104 x109//L versus 118 x109//L, 
p=0.048) were also lower in those who went on to bleed in excess of 1 litre at 24 hours. ROC 
analysis suggested fibrinogen had modest predictive value. 
 
For those bleeding at >200mL/hr for 2 consecutive hours, Factor XIII was significantly lower 
(45% versus 58%, p=0.048), as was Factor VII (56 iu/dL versus 70 iu/dL, p=0.039). ROC analysis 
demonstrated these had modest predictive value. 
 
There were no significant differences in post-operative clotting factors, inhibitors or platelet 
counts for those who required haemostatic treatment. The same applied to those who needed 
to return to theatre for re-operation due to bleeding. 
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Table 3.4 Concentrations of clotting factors, inhibitors and platelet count before and after CPB 
for all patients.  
End point Whole Cohort Pre-CPB Whole Cohort Post-CPB 
APTT 
(sec) 
29 
23-38 
(28-31) 
31* 
22-46 
(30-35) 
PT  
(sec) 
11 
10-16 
(10-12) 
15* 
12-22 
(14-17) 
Fibrinogen  
(g/L) 
3.2 
1.7-7.9 
(2.6-4.0) 
1.6* 
1.1-3.8 
(1.4-1.9) 
Factor II 
(iu/dL) 
95 
44-152 
(85-107) 
52* 
33-83 
(47-60) 
Factor V  
(iu/dL) 
92 
51-135 
(76-109) 
50* 
17-93 
(40-58) 
Factor VII  
(iu/dL) 
104 
48-192 
(80-118) 
68* 
25-146 
(58-80) 
Factor VIII  
(iu/dL) 
129 
75-262 
(106-157) 
92* 
49-216 
(74-117) 
Factor IX 
(iu/dL) 
133 
59-224 
(117-151) 
104* 
62-157 
(93-123) 
Factor X 
(iu/dL)  
90 
27-148 
(78-104) 
46* 
20-57 
(38-54) 
Factor XI 
(iu/dL) 
95 
42-183 
(82-109) 
60* 
35-137 
(50-72) 
Full length TFPI  
(ng/mL) 
21 
7-39 
(16-24) 
15* 
4-35 
(11-22) 
Total TFPI  
(ng/mL) 
56 
32-99 
(48-67) 
113* 
60-165 
(93-127) 
VWF  
(iu/dL) 
145 
62-322 
(113-188) 
172* 
84-367 
(136-206) 
Anti-Thrombin 
(%) 
92 
11-144 
(83-100) 
51* 
30-77 
(45-58) 
Protein S  
(%) 
84 
43-125 
(72-98) 
46* 
30-85 
(39-55) 
Protein C  
(%) 
106 
64-204 
(92-119) 
61* 
39-93 
(52-69) 
Factor XIII  
(%) 
104 
30-213 
(90-117) 
56* 
21-107 
(45-67) 
TAFI 
(%) 
101 
42-182 
(83-125) 
69* 
31-120 
(60-80) 
Platelet Count 
(x109/L) 
224 
124-670 
(188-258) 
115* 
42-258 
(98-137) 
Anti-Xa activity 
(iu/mL) 
- 0.12 
0.00-0.30 
(0.08-0.19) 
Data shown are the median and range (inter-quartile range). * indicates significantly different results 
between pre and post samples (p<0.05). 
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Table 3.5 Concentrations of clotting factors, inhibitors and platelet count before and after CPB 
comparing those who bled less or more than 1L.  
End point <1L Pre-CPB <1L Post-CPB >1L Pre-CPB >1L Post-CPB ROC area post-CPB 
 (95% CI) 
APTT 
(sec) 
30 
23-38 
(28-32) 
31 
22-46 
(30-34) 
28 
25-32 
(27-30) 
34 
27-46 
(30-37) 
- 
PT  
(sec) 
11 
10-16 
(10-12) 
15 
12-20 
(14-17) 
11 
10-14 
(11-12) 
16 
13-22 
(15-18) 
- 
Fibrinogen  
(g/L) 
3.2 
1.7-7.9 
(2.6-4) 
1.7 
1.1-3.8 
 (1.4-2) 
3 
2-4.6 
(2.4-4) 
1.4* 
1.1-2.2 
(1.3-1.7) 
0.75 
(0.6-0.9) 
Factor II 
(iu/dL) 
96 
44-152 
(82-110) 
53 
33-83 
(47-63) 
92 
60-117 
(87-100) 
50* 
39-58 
(44-53) 
0.66 
(0.5-0.83) 
Factor V  
(iu/dL) 
87 
51-135 
(74-104) 
50 
17-93 
(41-59) 
98 
60-121 
(84-112) 
46 
26-59 
(35-56) 
- 
Factor VII  
(iu/dL) 
104 
48-192 
(79-122) 
68 
33-125 
(59-80) 
99 
48-151 
(80-107) 
67 
25-146 
(56-76) 
- 
Factor VIII  
(iu/dL) 
129 
75-262 
(104-156) 
97 
49-216 
 (78-119) 
122 
79-252 
(112-169) 
74 
52-142 
(67-109) 
- 
Factor IX 
(iu/dL) 
130 
59-224 
(114-152) 
107 
65-157 
 (94-124) 
134 
94-183 
(127-148) 
100 
79-144 
(86-105) 
- 
Factor X 
(iu/dL)  
90 
27-148 
(76-104) 
47 
20-77 
(38-56) 
92 
48-114 
(84-103) 
45 
24-57 
(35-48) 
- 
Factor XI 
(iu/dL) 
95 
42-183 
(82-107) 
62 
35-137 
 (51-73) 
88 
58-183 
(76-125) 
57 
36-76 
(45-61) 
- 
Full length TFPI  
(ng/mL) 
21 
7-39 
(17-24) 
16 
4-35 
(11-22) 
20 
10-38 
(15-25) 
13 
5-33 
(11-17) 
- 
Total TFPI  
(ng/mL) 
57 
32-99 
(48-67) 
115 
60-165 
 (95-127) 
53 
36-79 
(48-61) 
100 
65-160 
(87-116) 
- 
VWF  
(iu/dL) 
135 
62-322 
(109-180) 
171 
85-367 
 (136-207) 
176 
95-268 
(144-217) 
174 
84-277 
(132-203) 
- 
Anti-Thrombin 
(%) 
93 
61-144 
(84-101) 
52 
30-77 
(47-59) 
92 
11-109 
(81-100) 
45 
35-60 
(43-56) 
- 
Protein S  
(%) 
80 
43-112 
(70-94) 
46 
30-85 
(40-56) 
94 
58-125 
(78-104) 
45 
35-63 
(38-51) 
- 
Protein C  
(%) 
106 
64-204 
(91-121) 
62 
39-93 
(54-70) 
104 
76-149 
(96-112) 
58 
42-74 
(49-65) 
- 
Factor XIII  
(%) 
105 
59-213 
(91-119) 
58 
21-107 
 (47-68) 
98 
30-131 
(73-111) 
46* 
25-67 
(43-55) 
0.66 
(0.5-0.83) 
TAFI 
(%) 
97 
42-182 
(82-121) 
70 
31-120 
 (60-80) 
105 
56-175 
(97-136) 
66 
35-117 
(61-88) 
 
Platelet Count 
(x109/L) 
226 
124-670 
(188-267) 
118 
42-258 
(101-139) 
224 
134-448 
(202-239) 
104* 
62-173 
(88-124) 
0.6 
(0.4-0.8) 
Anti-Xa activity 
(iu/mL) 
- 0.13 
0.0-0.29 
(0.08-0.19) 
- 0.12 
0.1-0.3 
(0.07-0.19) 
- 
Data shown are the median and range (inter-quartile range). * indicates significantly different results 
between post-CPB samples in those bleeding <1L or >1L (p<0.05). CI= confidence interval. 
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Table 3.6 Concentrations of clotting factors, inhibitors and platelet count before and after CPB 
comparing those who bled at a rate of more or less than 200 mL/hr. 
End point <200mL/hr  
Pre-CPB 
<200mL/hr  
Post-CPB 
>200mL/hr  
Pre-CPB 
>200mL/hr  
Post-CPB 
ROC area post-
CPB  
(95% CI) 
APTT 
(sec) 
30 
23-38 
(30-32) 
31 
22-46 
(30-35) 
28 
26-31 
(27-30) 
34 
27-46 
(30-36) 
- 
PT  
(sec) 
11 
10-16 
(10-12) 
15 
12-20 
(14-17) 
11 
10-14 
(11-12) 
17 
14-22 
(15-18) 
- 
Fibrinogen  
(g/L) 
3.2 
1.7-7.9 
(2.6-4) 
1.7 
1.1-3.8 
(1.4-2) 
3 
2-4.6 
(2.6-4) 
1.4 
1.2-2.2 
(1.3-1.7) 
- 
Factor II 
(iu/dL) 
96 
44-152 
(83-109) 
53 
33-83 
(47-61) 
90 
60-107 
(85-100) 
50 
39-57 
(43-52) 
- 
Factor V  
(iu/dL) 
87 
51-135 
(76-105) 
50 
17-93 
(40-58) 
101 
60-117 
(93-112) 
46 
26-59 
(32-56) 
- 
Factor VII  
(iu/dL) 
104 
48-192 
(79-120) 
70 
33-146 
(60-81) 
102 
48-120 
(80-110) 
56* 
25-82 
(47-67) 
0.71 
(0.53-0.89) 
Factor VIII  
(iu/dL) 
128 
75-162 
(101-157) 
94 
49-216 
(77-119) 
144 
106-208 
(114-157) 
73 
52-135 
(70-109) 
- 
Factor IX 
(iu/dL) 
133 
59-224 
(115-152) 
106 
65-157 
(94-124) 
128 
98-183 
(121-146) 
100 
79-144 
(84-104) 
- 
Factor X 
(iu/dL)  
92 
27-148 
(77-104) 
47 
20-77 
(38-56) 
85 
52-113 
(81-97) 
41 
29-50 
(32-47) 
- 
Factor XI 
(iu/dL) 
95 
42-183 
(82-108) 
60 
35-137 
(50-72) 
88 
63-132 
(85-125) 
60 
37-76 
(54-61) 
- 
Full length TFPI  
(ng/mL) 
20 
7-32 
(16-24) 
15 
4-35 
(11-22) 
24 
10-32 
(20-26) 
17 
9-33 
(11-18) 
- 
Total TFPI  
(ng/mL) 
56 
32-99 
(48-67) 
114 
60-165 
(94-127) 
51 
36-79 
(48-61) 
103 
65-153 
(82-129) 
- 
VWF  
(iu/dL) 
143 
62-352 
(109-181) 
171 
85-367 
(134-205) 
188 
113-260 
(144-227) 
174 
84-277 
(145-217) 
- 
Anti-Thrombin 
(%) 
93 
61-144 
(84-101) 
51 
30-77 
(81-95) 
88 
11-103 
(45-59) 
45 
35-57 
(43-52) 
- 
Protein S  
(%) 
82 
43-112 
(71-95) 
46 
30-85 
(40-56) 
94 
58-125 
(74-104) 
44 
35-55 
(38-50) 
- 
Protein C  
(%) 
106 
64-204 
(92-121) 
62 
39-93 
(54-70) 
96 
76-149 
(94-108) 
55 
42-71 
(46-62) 
- 
Factor XIII  
(%) 
105 
59-213 
(90-118) 
58 
21-107 
(45-68) 
89 
30-131 
(72-98) 
45* 
25-64 
(40-55) 
0.70 
(0.54-0.87) 
TAFI 
(%) 
100 
42-182 
(83-124) 
70 
31-120 
(60-80) 
105 
56-159 
(94-135) 
64 
35-117 
(61-88) 
- 
Platelet Count 
(x109/L) 
223 
124-670 
(188-265) 
117 
42-258 
(98-138) 
227 
134-254 
(214-239) 
110 
80-173 
(90-129) 
- 
Anti-Xa activity 
(iu/mL) 
- 0.13 
0-0.3 
(0.08-0.19) 
- 0.11 
0.1-0.26 
(0.07-0.19) 
- 
Data shown are the median and range (inter-quartile range). * indicates significantly different results 
between post-CPB samples in those bleeding <200 mL/hr or >200 mL/hr(p<0.05). CI= confidence 
interval. 
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Table 3.7 Concentrations of clotting factors, inhibitors and platelet count before and after CPB 
in those who bled more or less than 2 mL/kg/hr for 2 consecutive hours. 
End point <2mL/kg/hr for 2 
hours Pre-CPB 
<2mL/kg/hr for 2 hours 
Post-CPB 
>2mL/kg/hr for 2 
hours Pre-CPB 
>2mL/kg/hr for 2 hours 
Post-CPB 
ROC area 
post-CPB  
(95% CI) 
APTT 
(sec) 
30 
23-38 
(28-32) 
31 
22-46 
(30-34) 
38 
26-32 
(27-30) 
34 
27-46 
(31-37) 
- 
PT  
(sec) 
11 
10-16 
(10-12) 
15 
12-20 
(14-17) 
11 
10-14 
(10-12) 
16 
13-22 
(15-18) 
- 
Fibrinogen  
(g/L) 
3.2 
1.7-7.9 
(2.6-3.8) 
1.7 
1.1-3.8 
(1.4-2) 
3.3 
2-4.6 
(2.6-4.2) 
1.4* 
1.2-2.2 
(1.3-1.7) 
0.68 
(0.53-0.83) 
Factor II 
(iu/dL) 
95 
44-152 
(82-120) 
53 
33-83 
(48-62) 
98 
60-137 
(87-107) 
49* 
39-60 
(43-52) 
0.68 
(0.55-0.81) 
Factor V  
(iu/dL) 
87 
51-135 
(75-104) 
50 
17-93 
(41-58) 
100 
60-121 
(84-113) 
42 
26-59 
(32-52) 
0.68 
(0.53-0.83) 
Factor VII  
(iu/dL) 
102 
48-192 
(78-117) 
70 
33-146 
(60-80) 
106 
48-151 
(88-120) 
63 
25-97 
(54-75) 
- 
Factor VIII  
(iu/dL) 
126 
75-262 
(101-154) 
98 
49-216 
(79-121) 
153 
79-252 
(114-173) 
73 
52-135 
(67-95) 
- 
Factor IX 
(iu/dL) 
133 
59-224 
(115-150) 
107 
65-157 
(95-124) 
134 
94-183 
(121-154) 
100 
79-144 
(84-104) 
- 
Factor X 
(iu/dL)  
90 
27-148 
(76-104) 
47 
20-77 
(39-57) 
94 
52-113 
(84-104) 
42* 
29-50 
(35-47) 
0.68 
(0.55-0.80) 
Factor XI 
(iu/dL) 
94 
42-183 
(82-102) 
60 
35-137 
(51-72) 
107 
58-183 
(85-127) 
59 
36-76 
(42-65) 
- 
Full length 
TFPI  
(ng/mL) 
20 
7-39 
(17-24) 
15 
4-35 
(11-22) 
23 
10-38 
(16-27) 
17 
9-33 
(11-22) 
- 
Total TFPI  
(ng/mL) 
56 
32-99 
(48-67) 
115 
60-165 
(95-128) 
55 
36-79 
(48-67) 
102 
65-153 
(87-112) 
- 
VWF  
(iu/dL) 
136 
62-322 
(109-180) 
174 
85-367 
(137-207) 
182 
95-268 
(144-227) 
154 
84-277 
(128-198) 
- 
Anti-
Thrombin 
(%) 
93 
61-144 
(83-101) 
52 
30-77 
(47-59) 
92 
11-112 
(84-100) 
45 
35-57 
(41-52) 
- 
Protein S  
(%) 
83 
43-112 
(72-95) 
47 
30-85 
(41-56) 
91 
58-125 
(74-104) 
42 
31-55 
(37-48) 
- 
Protein C  
(%) 
106 
64-204 
(91-120) 
62 
39-93 
(54-70) 
105 
76-149 
(95-112 
55 
42-71 
(46-62) 
- 
Factor XIII  
(%) 
104 
59-154 
(90-118) 
59 
21-107 
(46-68) 
98 
30-131 
(73-114) 
46* 
25-64 
(42-55) 
0.71 
(0.59-0.84) 
TAFI 
(%) 
99 
42- 182 
(82-121) 
70 
31-120 
(60-79) 
105 
56-175 
(89-137) 
65 
35-117 
(59-88) 
 
Platelet 
Count 
(x109/L) 
222 
124-670 
(188-265) 
119 
42-258 
(101-138) 
230 
134-448 
(207-240) 
101* 
62-173 
(86-129) 
0.66 
(0.50-0.83) 
Anti-Xa 
activity 
(iu/mL) 
- 0.13 
0-0.3 
(00.85-0.19) 
- 0.1 
0.1-0.26 
(0.07-0.135) 
- 
Data shown are the median and range (inter-quartile range). * indicates significantly different results 
between post-CPB samples in those bleeding <2mL/kg/hr or >2 mL/kg/hr (p<0.05). CI= confidence 
interval. 
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Table 3.8 Concentrations of clotting factors, inhibitors and platelet count before and after CPB 
in those who did and did not require haemostatic treatment. 
End point No Haemostatic 
Treatment Pre-CPB 
No Haemostatic 
Treatment Post-CPB 
Haemostatic Treatment 
Pre-CPB 
Haemostatic Treatment 
Post-CPB 
APTT 
(sec) 
29 
26-38 
(28-31) 
31 
22-46 
(30-34) 
30 
23-38 
(27-32) 
32 
24-46 
(30-36) 
PT  
(sec) 
11 
10-15 
(10-12) 
15 
12-20 
(14-17) 
11 
10-16 
(10-12) 
15 
12-22 
(14-17) 
Fibrinogen  
(g/L) 
3.4 
1.7-7.9 
(2.6-4) 
1.7 
1.2-3.8  
(1.5-2) 
3 
2-5.9 
(2.6-4) 
1.5 
1.1-3.3  
(1.3-1.9) 
Factor II 
(iu/dL) 
95 
44-142 
(81-108) 
52 
33-83 
(47-61) 
98 
49-152 
(87-104) 
53 
37-78 
(47-60) 
Factor V  
(iu/dL) 
87 
55-135 
(72-107) 
50 
29-93 
(42-61) 
94 
51-121 
(83-109) 
47 
17-64 
(37-56) 
Factor VII  
(iu/dL) 
104 
57-166 
(78-122) 
66 
33-123 
(58-78) 
101 
48-192 
(82-115) 
71 
25-146 
(59-80) 
Factor VIII  
(iu/dL) 
129 
75-262 
(106-154) 
98 
49-216 
(79-121) 
126 
75-260  
(106-169) 
85 
52-169 
(70-113) 
Factor IX 
(iu/dL) 
134 
87-224 
(115-157) 
107 
69-157 
(95-125) 
130 
59-183 
 (118-146) 
103 
65-144 
(86-121) 
Factor X 
(iu/dL)  
87 
27-145 
(76-106) 
46 
20-67 
(38-55) 
96 
51-148 
(83-103) 
46 
30-77 
(38-53) 
Factor XI 
(iu/dL) 
96 
55-181 
(82-108) 
60 
35-101 
(52-73) 
93 
42-183 
(82-109) 
59 
36-137 
(49-72) 
Full length 
TFPI  
(ng/mL) 
21 
7-39 
(16-25) 
15 
4-35 
(11-22) 
20 
10-38 
(17-24) 
16 
8-33 
(12-21) 
Total TFPI  
(ng/mL) 
57 
32-99 
(47-69) 
115 
62-155 
(94-136) 
55 
36-84 
(48-66) 
104 
60-165 
(89-125) 
VWF  
(iu/dL) 
144 
62-274  
(105-181) 
172 
85-367 
(140-204) 
149 
73-322 
(117-188) 
169 
84-289 
(132-208) 
Anti-
Thrombin 
(%) 
93 
69-117 
(82-102) 
51 
30-75 
(47-57) 
92 
11-144 
(84-99) 
50 
34-77 
(45-58) 
Protein S  
(%) 
80 
43-112 
(69-96) 
46 
30-85 
(39-55) 
88 
58-125 
(74-99) 
46 
31-71 
(40-55) 
Protein C  
(%) 
107 
64-164 
(91-120) 
61 
39-87 
(52-71) 
104 
76-204 
(95-112) 
61 
42-93 
(54-67) 
Factor XIII  
(%) 
104 
59-198 
(90-116) 
58 
21-107 
(47-67) 
103 
30-213 
(89-117) 
52 
25-85 
(43-64) 
TAFI 
(%) 
99 
61-182 
(85-125) 
69 
39-120 
(52-79) 
103 
42-175 
(83-123) 
71 
31-117 
(59-88) 
Platelet 
Count 
(x109/L) 
228 
124-393 
(184-265) 
119 
42-227 
(99-142) 
223 
134-670 
(189-247) 
113 
62-258 
(94-133) 
Anti-Xa 
activity 
(iu/mL) 
- 0.13 
0.01-0.3 
(0.09-0.18) 
- 0.11 
0.0-0.29 
(0.07-0.19) 
Data shown are the median and range (inter-quartile range). * indicates significantly different results 
between post-CPB samples in those bleeding did not did not require haemostatic treatment (p<0.05). 
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Table 3.9 Concentrations of clotting factors, inhibitors and platelet count before and after CPB 
in those who did and did not undergo re-operation due to bleeding. 
End point No Re-op Pre No Re-op Post Re-op Pre Re-op Post- 
APTT 
(sec) 
29 
25-38 
(28-32) 
 
31 
22-46 
(30-35) 
30 
23-31 
(28-31) 
34 
30-46 
(30-40) 
PT  
(sec) 
11 
10-16 
(10-12) 
15 
12-20 
(14-17) 
11 
11-14 
(11-12) 
17 
14-22 
(15-18) 
Fibrinogen  
(g/L) 
3.1 
1.7-7.9 
(2.6-4.0) 
1.6 
1.1-3.8 
(1.4-1.9) 
3.5 
2.3-4.5 
(2.6-4) 
1.4 
1.2-2.2 
(1.3-1.7) 
Factor II 
(iu/dL) 
95 
44-152 
 (84-108) 
53 
33-83 
(48-61) 
94 
60-101 
(85-98) 
47 
37-57 
(39-52) 
Factor V  
(iu/dL) 
92 
51-135  
(79-109) 
50 
24-93 
(41-58) 
90 
60-111 
(76-101) 
30 
17-59 
(26-56) 
Factor VII  
(iu/dL) 
104 
48-192  
(79-120) 
70 
25-146 
 (60-81) 
99 
48-110 
 (80-107) 
57 
37-73 
 (47-67) 
Factor VIII  
(iu/dL) 
127 
75-262 
(104-156) 
93 
49-216 
(75-118) 
174 
114-252 
(118-208) 
82 
52-135 
 (73-113) 
Factor IX 
(iu/dL) 
133 
59-224 
(115-151) 
105 
65-157 
(95-124) 
129 
98-173 
(127-144) 
84 
79-105 
 (81-104) 
Factor X 
(iu/dL)  
90 
27-148 
(77-104) 
46 
20-77 
(38-55) 
97 
52-106 
(81-103) 
39 
29-48 
(30-47) 
Factor XI 
(iu/dL) 
95 
42-183  
(82-108) 
60 
35-137 
(51-72) 
98 
63-161 
(85-127) 
49 
37-65 
(42-60) 
Full length TFPI  
(ng/mL) 
20 
7-39 
(16-24) 
15 
4-35 
(11-22) 
22 
10-31 
(20-26) 
17 
8-33 
(10-22) 
Total TFPI  
(ng/mL) 
56 
32-99 
(48-67) 
114 
60-165 
 (94-127) 
52 
42-79 
(44-61) 
107 
65-153  
(87-129) 
VWF  
(iu/dL) 
145 
62-322 
(111-184) 
172 
85-367 
 (137-204) 
165 
113-268 
(126-260) 
193 
84-290 
(87-277) 
Anti-Thrombin 
(%) 
92 
11-144 
(83-101) 
51 
30-77 
(45-58) 
92 
87-100 
 (88-96) 
46 
34-57 
(35-56) 
Protein S  
(%) 
84 
43-125 
(72-96) 
47 
30-85 
(40-56) 
83 
63-104 
(74-100) 
40 
32-50 
(35-44) 
Protein C  
(%) 
106 
64-204  
(92-121) 
62 
39-93 
(54-70) 
103 
76-112  
(95-112) 
50 
45-62 
(46-59) 
Factor XIII  
(%) 
104 
59-213  
(89-117) 
58 
21-107 
(45-67) 
95 
30-131  
(90-114) 
49 
25-64 
(40-55) 
TAFI 
(%) 
99 
42-182 
 (83-123) 
71 
31-120 
(60-80) 
127 
64-175 
 (104-159) 
69 
46-117  
(61-103) 
Platelet Count 
(x109/L) 
224 
124-670 
(188-258) 
116 
42-258 
(98-138) 
232 
207-448 
(214-349) 
108 
62-173 
(94-129) 
Anti-Xa activity 
(iu/mL) 
- 0.12 
0.0-.03 
(0.08-0.19) 
- 0.1 
0.01-0.2 
(0.05-0.13) 
Data shown are the median and range (inter-quartile range). * indicates significantly different results 
between post-CPB samples in those bleeding did not did not require re-operation (p<0.05). 
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3.2.3 Relationship between intraoperative fluids and coagulation factor 
concentrations 
Colloids and crystalloids had different effects on the concentration of coagulation factors and 
anticoagulants. The volume of intraoperative colloid received in mL per kilogram body weight 
of the patient, showed a weak inverse correlation with full length TFPI, antithrombin, protein C 
and free protein S (Figure 3.1).  A similar relationship was seen for FII, FV, FX, FXIII and 
fibrinogen (Figures 3.2 and 3.3).  
 
The volume of intravenous crystalloid was inversely correlated with free TFPI and fibrinogen. 
The effect of colloid is likely to be due to dilution in view of the mild inverse correlation with 
post-CPB haemoglobin concentration (Figure 3.4A). Less crystalloid appears to have remained 
in the intravascular space compared to colloid as the volume of crystalloid did not correlate 
with post-CPB haemoglobin (Figure 3.4B). 
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Figure 3.1 Correlation plots between intravenous fluids received intra-operatively and full-
length TFPI (A,B), antithrombin (C,D), free protein S (E, F) and protein C (G,H). Spearman’s 
correlation coefficients (ρ) are shown with p- values. 
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Figure 3.2 Correlation plots between intravenous fluids received intra-operatively and FII (A, 
B), FV (C, D), FX (E, F) and FXIII (G, H). Spearman’s correlation coefficients (ρ) are shown with p- 
values. 
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Figure 3.3 Correlation plots between intravenous fluids received intra-operatively and 
fibrinogen (A, B), PT (C, D) and APTT (E, F). Spearman’s correlation coefficients (ρ) are shown 
with p- values. 
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Figure 3.4 Correlation plots between the volume of intraoperative fluids infused and the 
haemoglobin concentration. Spearman’s correlation coefficients (ρ) are shown with p- values. 
 
3.2.4 Thrombin Generation Assays 
There was a progressive concentration dependent increase in the ETP, peak thrombin, Velocity 
Index and concentration dependent shortening of the lag time as the concentration of tissue 
factor increased in both pre and post-CPB samples when collected into CTI with citrate (ETP 
summarised in Figure 3.5, peak thrombin Figure 3.6, lag time Figure 3.7 and Velocity Index 
Figure 3.8). In contrast in pre-CPB samples when using citrate alone these parameters were 
similar when using triggers using 0.5-5 pmol/L (pM) tissue factor, with a significant increase 
between 5 and 10 pM. Post-cardiopulmonary bypass there was a tissue factor concentration 
dependent increase mirroring that seen in CTI. At tissue factor concentrations below 5 pM, 
thrombin generation parameters were lower in samples anticoagulated with CTI compared to 
citrate. 
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Figure 3.5 Changes for in Endogenous Thrombin Potential (ETP) between pre and post-
cardiopulmonary bypass samples using triggers of varying tissue factor concentrations taken 
into CTI (upper panel)and citrate (lower panel). Data shown are median values (horizontal 
black bar), interquartile range (box), values with 1.5 times interquartile range (whiskers) and 
values between 1.5-3 times interquartile range (asterisks and circles). 
 
The ETP was lower post-CPB regardless of anticoagulant used. Samples collected into CTI 
demonstrated an increase in ETP as the concentration of tissue factor in the trigger solution 
increased. In contrast, samples taken into citrate showed little difference in the ETP pre-CPB 
using trigger solutions containing 0.5 to 3 pM tissue factor, with a concentration dependent 
increase only being observed using tissue factor concentrations of 5 pM and higher. Post-CPB 
there was an increase in ETP as the concentration of tissue factor in the trigger solution 
increased as seen with CTI.  The median peak thrombin concentration and velocity index, 
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obtained when using triggers with tissue factor concentrations between 0.5 and 5 pM, was 
paradoxically no different or slightly higher in post-CPB in samples collected into CTI compared 
to pre-CPB samples. This may be due to the reduced full-length TFPI concentrations allowing 
greater activation of the initiation phase of coagulation at low tissue factor concentrations 
compared to the preoperative samples. 
 
 
Figure 3.6 Changes for in peak thrombin between pre and post-cardiopulmonary bypass 
samples using triggers of varying tissue factor concentrations taken into CTI (upper panel) and 
citrate (lower panel). Data shown are median values (horizontal black bar), interquartile range 
(box), values with 1.5 times interquartile range (whiskers) and values between 1.5-3 times 
interquartile range (asterisks and circles). 
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Figure 3.7 Changes for in lag time between pre and post-cardiopulmonary bypass samples 
using triggers of varying tissue factor concentrations taken into CTI (upper panel) and citrate 
(lower panel). Data shown are median values (horizontal black bar), interquartile range (box), 
values with 1.5 times interquartile range (whiskers) and values between 1.5-3 times 
interquartile range (asterisks and circles). 
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Figure 3.8 Changes for in velocity index between pre and post-cardiopulmonary bypass 
samples using triggers of varying tissue factor concentrations taken into CTI (upper panel) and 
citrate (lower panel). Data shown are median values (horizontal black bar), interquartile range 
(box), values with 1.5 times interquartile range (whiskers) and values between 1.5-3 times 
interquartile range (asterisks and circles). 
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3.2.5 Commercial thrombin generation reagents 
Commercial thrombin generation trigger solutions consisted of Stago PPP Low and Stago PPP 
which according to the manufacturer have a tissue factor activity equivalent to 1 pM and 5 pM 
respectively. Using these reagents there was a significant reduction in the ETP and peak 
thrombin concentration post-CPB (Figures 3.9A and 3.9B). The lag time was significantly 
increased using the Stago PPP low reagent, but was only increased using the Stago PPP reagent 
when thrombin generation was measured in samples collected into CTI (Figure 3.9C). There 
was no difference in the velocity index using either of the reagents when thrombin generation 
was measured in samples collected into CTI, but was significantly reduced when measured in 
samples collected into citrate alone (Figure 3.9D). 
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Figure 3.9 Peak thrombin (A), ETP (B), lag time (C) and velocity index (D) measured pre (shaded 
boxes) and post-CPB in samples taken into citrate containing CTI or citrate alone, using Stago 
PPP Low or PPP trigger solutions. Data shown are median values (horizontal black bar), 
interquartile range (box), values with 1.5 times interquartile range (whiskers) and values 
between 1.5-3 times interquartile range (asterisks and circles). 
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3.2.6 Near-patient testing 
In order to reduce the delay in availability of laboratory results to clinical areas, near patient 
testing has been shown to be of value. In order to investigate the feasibility of performing 
calibrated automated thrombography close to the operating theatre, two members of staff 
were trained in how to perform the assay. A Fluoroscan Reader and desk-top computer with 
associated Thrombinoscope software were provided on loan by Diagnostica-Stago. A room was 
identified close to the main operating theatres. The equipment, along with a centrifuge was 
installed. Ten patients were included in this study. As is shown by Figure 3.10, whilst the ETP 
using the PPP Low reagent did show a moderate positive correlation, there was no correlation 
using the PPP reagent and no correlation with either reagent for peak thrombin.  The poor 
correlation demonstrates that calibrated automated thrombography is too complex a 
technique to use in this setting. 
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Figure 3.10 Scatter plots comparing thrombin generation parameters obtained from near 
patient testing with those obatined in the laboratory. Spearman’s correlation coefficients (ρ) 
are shown with p- values. 
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3.2.7 Association of thrombin generation assays and bleeding end points 
The lag time measured in samples taken into CTI in post-CPB samples was shorter in those who 
lost more than 1 L at 24 hours when using triggers containing 0.5 pM, 1 pM, 5 pM, 10 pM of 
tissue factor or the Stago PPP solution (Figure 3.11). This suggests the bleeding in these 
patients may be the result of a persistent low level activation of the coagulation cascade which 
over time may lead to consumption of coagulation factors leading to bleeding. A ROC analysis 
was undertaken for the post-CPB lag time. This indicated that there was no clinical utility in 
identifying patients who bled in excess of 1 L at 24 hours (Table 3.10). 
 
Regardless of anticoagulant or trigger solution used, there was no significant difference in ETP, 
peak thrombin or velocity index comparing patient who did or did not bleed for any of the 
bleeding endpoints used in the study. This applied to both pre and post-CPB samples. The 
results are summarised in tables 3.11 3.15 for ETP, tables 3.16-3.20 for peak thrombin and 
tables 3.21-3.25 for the velocity index. 
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Figure 3.11 Lag time post-CPB in samples collected into CTI in those with a drain blood loss 
more or less than 1 litre at 24 hours. The lag time was shorter in those who bled more than 1 L 
(A, B D-G), although no different when a trigger containing 3 pM TF was used (C). Data shown 
are median values (horizontal black bar), interquartile range (box), values with 1.5 times 
interquartile range (whiskers) and values between 1.5-3 times interquartile range (asterisks 
and circles). 
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Table 3.10 ROC curve values for the post-CPB lag time using different trigger solutions in 
discriminating those who bled > 1L at 24 hours post-CPB. 
Trigger Solution ROC area post-CPB (95% CI) 
0.5 pM 0.33 
(0.14-0.52) 
1 pM 0.24 
(0.09-0.40) 
3 pM 0.49 
(0.29-0.68) 
5 pM 0.33 
(0.14-0.53) 
10 pM 0.35 
(0.17-0.53) 
PPP Low 0.35 
(0.19-0.52) 
PPP 0.41 
(0.24-0.58) 
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Table 3.11 ETP using different trigger solutions before and after cardiopulmonary bypass 
comparing those who bled less or more than 1L.  
End Point <1L Pre-CPB <1L Post-CPB >1L Pre-CPB >1L Post-CPB 
0.5 pM TF CTI 74 
0-250 
(18-127) 
6 
0-354 
(0-64) 
32 
0-245 
(3-109) 
5 
0-429 
(0-95) 
0.5 pM TF Citrate 716 
207-1415 
(563-853) 
209 
0-681 
(104-388) 
672 
429-884 
(570-754) 
197 
0-539 
(147-291) 
1  pM TF CTI 141 
0-419 
(71-221) 
101 
0-492 
(0-266) 
127 
0-570 
(58-226) 
50 
0-554 
(0-291) 
1  pM TF Citrate 642 
160-1160 
(496-728) 
231 
0-758 
(140-424) 
583 
380-905 
(434-693) 
214 
0-288 
(151-424) 
3  pM TF CTI 396 
50-1110 
(250-524) 
409 
0-936 
(258-538) 
359 
129-730 
(219-620) 
471 
54-620 
(338-523) 
3  pM TF Citrate 701 
224-1402 
(578-844) 
454 
0-1017 
(321-578) 
616 
402-904 
(486-748) 
469 
38-755 
(287-563) 
5  pM TF CTI 612 
151-1298 
(423-721) 
530 
0-1080 
(429-628) 
578 
341-826 
(525-714) 
550 
247-706 
(445-587) 
5  pM TF Citrate 755 
220-1478 
(625-891) 
543 
0-1108 
(431-682) 
723 
439-915 
(634-763) 
539 
174-765 
(437-608) 
10  pM TF CTI 746 
211-1773 
(670-912) 
618 
271-1160 
(548-748) 
733 
461-930 
(662-819) 
592 
342-764 
(522-656) 
10  pM TF Citrate 801 
232-1843 
(677-938) 
652 
348-1195 
(565-763) 
784 
485-936 
(429-829) 
614 
347-781 
(503-651) 
PPP Low CTI 637 
10-835 
(248-503) 
162 
0-985 
(45-383) 
264 
126-867 
(201-628) 
221 
0-863 
(67-390) 
PPP Low Citrate 858 
184-1508 
(716-1056) 
346 
0-1112 
(129-459) 
834 
426-1217 
(578-1011) 
347 
46-866 
(175-415) 
PPP CTI 988 
276-1751 
(806-1194) 
799 
248-1148 
(685-1003) 
892 
523-1406 
(689-1204) 
718 
410-1120 
(626-801) 
PPP Citrate 1088 
265-2154 
(912-1290) 
814 
177-1517 
(663-976) 
1026 
591-1615 
(802-1216) 
725 
429-1087 
(608-943) 
PPP+TM CTI 528 
157-1282 
(392-747) 
598 
47-1077 
(477-796) 
593 
168-1158 
(242-885) 
605 
271-1025 
(492-706) 
PPP+TM Citrate 534 
0-1648 
(434-749) 
549 
53-942 
(408-688) 
591 
157-1185 
(304-881) 
537 
256-946 
(403-651) 
Data shown are the median and range (inter-quartile range). Units for ETP are nM/min. 
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Table 3.12 ETP using different trigger solutions before and after cardiopulmonary bypass 
comparing those who bled at a rate of more or less than 200 mL/hr. 
End point <200mL/hr Pre-CPB <200mL/hr Post-CPB >200mL/hr Pre-CPB >200mL/hr Post-CPB 
0.5 pM TF CTI 74 
0-250 
(18-127) 
6 
0-429 
(0-76) 
18 
0-133 
(0-105) 
2 
0-198 
(0-95) 
0.5 pM TF Citrate 709 
207-1415 
(568-840) 
202 
0-681 
(91-388) 
725 
429-879 
(666-758) 
192 
140-464 
(156-284) 
1  pM TF CTI 142 
0-570 
(78-225) 
101 
0-554 
(3-281) 
67 
0-304 
(5-183) 
22 
0-467 
(0-196) 
1  pM TF Citrate 631 
160-1160 
(480-721) 
231 
0-758 
(131-433) 
641 
384-781 
(478-722) 
214 
151-473 
(180-414) 
3  pM TF CTI 384 
50-1110 
(249-512) 
431 
0-936 
(258-522) 
514 
129-720 
(207-625) 
472 
54-620 
(430-573) 
3  pM TF Citrate 692 
224-1402 
(573-830) 
452 
0-1017 
(319-578) 
684 
429-857 
(456-798) 
473 
113-755 
(446-563) 
5  pM TF CTI 605 
151-1298 
(445-716) 
540 
0-1080 
(429-616) 
672 
341-792 
(525-714) 
546 
351-706 
(450-587) 
5  pM TF Citrate 744 
220-1478 
(625-883) 
543 
0-1108 
(429-659) 
746 
439-871 
(691-813) 
539 
361-765 
(468-608) 
10  pM TF CTI 746 
211-1773 
(665-909) 
614 
271-1160 
(548-729) 
734 
461-860 
(701-819) 
588 
397-764 
(522-663) 
10  pM TF Citrate 801 
232-1843 
(677-930) 
639 
347-1195 
(560-747) 
777 
485-865 
(735-825) 
608 
394-781 
(503-673) 
PPP Low CTI 383 
10-835 
(241-513) 
223 
0-985 
(54-388) 
252 
159-867 
(201-476) 
217 
0-489 
(10-307) 
PPP Low Citrate 864 
184-1508 
(685-1048) 
346 
0-1112 
(132-459) 
823 
556-1217 
(632-941) 
336 
70-546 
(242-415) 
PPP CTI 1002 
276-1751 
(784-1204) 
788 
248-1448 
(670-1003) 
867 
625-1406 
(689-1026) 
718 
538-996 
(656-801) 
PPP Citrate 1088 
265-2154 
(905-1290) 
814 
177-1517 
(655-976) 
961 
679-1468 
(802-1130) 
725 
498-1062 
(655-912) 
PPP+TM CTI 530 
157-1282 
(386-764) 
599 
47-1077 
(477-796) 
490 
168-1158 
(242-869) 
584 
278-760 
(497-706) 
PPP+TM Citrate 535 
0-1648 
(408-686) 
549 
53-946 
(655-976) 
547 
243-1185 
(802-1130) 
519 
281-903 
(655-912) 
Data shown are the median and range (inter-quartile range). Units for ETP are nM/min. 
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Table 3.13 ETP using different trigger solutions before and after cardiopulmonary bypass in 
those who bled more or less than 2 mL/kg/hr for 2 consecutive hours. 
End point <2mL/kg/hr for 2 
hours Pre-CPB 
<2mL/kg/hr for 2 
hours Post-CPB 
>2mL/kg/hr for 2 
hours Pre-CPB 
>2mL/kg/hr for 2 
hours Post-CPB 
0.5 pM TF 
CTI 
69 
0-250 
(17-116) 
6 
0-429 
(0-67) 
32 
0-245 
(4-124) 
5 
0-248 
(0-90) 
0.5 pM TF 
Citrate 
706 
207-1415 
(559-851) 
213 
0-680 
(115-395) 
720 
429-884 
(660-775) 
185 
7-464 
(143-272) 
1  pM TF CTI 138 
0-419 
(71-217) 
99 
0-554 
(0-278) 
154 
0-570 
(54-283) 
53 
0-467 
(4-277) 
1  pM TF 
Citrate 
628 
160-1160 
(481-724) 
236 
0-758 
(148-453) 
642 
384-905 
(468-710) 
199 
5-473 
(154-338) 
3  pM TF CTI 387 
50-1110 
(235-508) 
420 
0-936 
(262-523) 
728 
129-730 
(264-622) 
468 
54-625 
(339-548) 
3  pM TF 
Citrate 
692 
224-1402 
(270-843) 
466 
0-1017 
(322-585) 
692 
429-904 
(579-793) 
467 
38-755 
(219-535) 
5  pM TF CTI 607 
151-1298 
(414-719) 
543 
0-1080 
(431-623) 
657 
341-826 
(527-694) 
530 
247-706 
(448-581) 
5  pM TF 
Citrate 
745 
220-1478 
(619-890) 
554 
0-1108 
(431-623) 
728 
439-915 
(683-821) 
519 
174-765 
(448-581) 
10  pM TF 
CTI 
745 
211-1773 
(658-911) 
611 
271-1160 
(544-748) 
748 
461-930 
(704-859) 
595 
342-764 
(541-672) 
10  pM TF 
Citrate 
797 
232-1843 
(671-931) 
635 
348-1195 
(561-750) 
811 
485-936 
(754-844) 
608 
347-781 
(524-675) 
PPP Low CTI 366 
10-835 
(235-510) 
225 
0-985 
(59-387) 
267 
159-867 
(217-554) 
215 
0-624 
(25-349) 
PPP Low 
Citrate 
861 
184-1508 
(660-1053) 
350 
0-1112 
(147-469) 
832 
556-1217 
(696-97) 
313 
0-805 
(153-410) 
PPP CTI 995 
276-1751 
(777-1204) 
789 
248-1448 
(685-1005) 
517 
168-1158 
(765-1113) 
717 
410-1066 
(640-891) 
PPP Citrate 1098 
265-2154 
(899-1293) 
818 
177-1517 
(660-1013) 
996 
678-1468 
(849-1167) 
696 
429-1062 
(622-906) 
PPP+TM CTI 529 
157-1282 
(381-762) 
606 
47-1077 
(492-805) 
517 
168-1158 
(320-877) 
577 
271-865 
(407-840) 
PPP+TM 
Citrate 
535 
0-1648 
(426-758) 
554 
53-946 
(413-687) 
582 
243-1185 
(407-840) 
503 
198-903 
(345-628) 
Data shown are the median and range (inter-quartile range). Units for ETP are nM/min. 
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Table 3.14 ETP using different trigger solutions before and after cardiopulmonary bypass in 
those who did and did not require haemostatic treatment. 
End point No Haemostatic 
Treatment Pre-CPB 
No Haemostatic 
Treatment Post-CPB 
Haemostatic 
Treatment Pre-CPB 
Haemostatic 
Treatment Post-CPB 
0.5 pM TF 
CTI 
74 
0-250 
(19-116) 
6 
0-429 
(0-53) 
64 
0-245 
(6-118) 
5 
0-286 
(0-96) 
0.5 pM TF 
Citrate 
703 
354-1415 
(552-870) 
195 
0-676 
(119-418) 
715 
207-1097 
(614-784) 
200 
0-681 
(110-319) 
1  pM TF CTI 141 
0-417 
(94-213) 
126 
0-554 
(0-250) 
128 
0-570 
(61-234) 
91 
0-467 
(0-296) 
1  pM TF 
Citrate 
647 
252-1160 
(479-745) 
241 
0-758 
(168-454) 
632 
160-1129 
(489-700) 
213 
0-575 
(107-405) 
3  pM TF CTI 389 
50-1066 
(228-483) 
409 
0-936 
(205-510) 
394 
116-1110 
(274-599) 
455 
17-704 
(343-548) 
3  pM TF 
Citrate 
691 
308-1402 
(574-858) 
448 
0-924 
(296-571) 
693 
224-1222 
(567-789) 
473 
38-1017 
(329-576) 
5  pM TF CTI 607 
186-1207 
(456-696) 
562 
0-1080 
(426-651) 
590 
151-1298 
(467-717) 
523 
173-786 
(444-584) 
5  pM TF 
Citrate 
745 
322-1478 
(619-913) 
589 
0-1108 
(443-697) 
737 
220-1302 
(644-841) 
511 
174-1097 
(431-599) 
10  pM TF 
CTI 
781 
384-1773 
(654-911) 
602 
271-1160 
(552-749) 
737 
211-1298 
(681-875) 
615 
342-1121 
(530-679) 
10  pM TF 
Citrate 
791 
407-1843 
(671-930) 
609 
353-1195 
(558-747) 
800 
232-1339 
(728-892) 
639 
347-1091 
(557-691) 
PPP Low CTI 637 
21-835 
(248-495) 
192 
0-985 
(59-390) 
352 
10-867 
(223-516) 
221 
0-624 
(45-380) 
PPP Low 
Citrate 
864 
275-1508 
(722-1030) 
346 
0-1112 
(133-469) 
845 
184-1334 
(637-1048) 
374 
0-805 
(150-432) 
PPP CTI 988 
610-1751 
(768-1208) 
817 
248-1148 
(685-1005) 
927 
276-1673 
(796-1183) 
758 
410-1237 
(658-930) 
PPP Citrate 1159 
720-2154 
(899-1323) 
824 
177-1517 
(657-1014) 
1071 
265-1729 
(849-1206) 
762 
215-1190 
(651-932) 
PPP+TM CTI 530 
157-1282 
(401-762) 
599 
47-1077 
(513-853) 
515 
168-1158 
(356-781) 
585 
271-916 
(461-711) 
PPP+TM 
Citrate 
537 
0-1648 
(462-817) 
574 
53-946 
(413-710) 
532 
157-1185 
(366-749) 
514 
198-903 
(391-653) 
Data shown are the median and range (inter-quartile range). Units for ETP are nM/min. 
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Table 3.15 ETP using different trigger solutions before and after cardiopulmonary bypass in 
those who did and did not undergo re-operation due to bleeding. 
End point No Re-op 
Pre-CPB 
No Re-op 
Post-CPB 
Re-op Pre-CPB Re-op Post-CPB 
0.5 pM TF CTI 75 
0-250 
(15-120) 
6 
0-429 
(0-67) 
22 
0-245 
(2-50) 
5 
0-198 
(2-136) 
0.5 pM TF Citrate 701 
207-1415 
(566-819) 
195 
0-681 
(115-380) 
796 
429-884 
(715-855) 
242 
15-464 
(169-326) 
1  pM TF CTI 142 
0-419 
(71-226) 
99 
0-554 
(0-278) 
72 
0-570 
(31-137) 
18 
0-467 
(4-252) 
1  pM TF Citrate 616 
160-1160 
(478-717) 
231 
0-758 
(148-429) 
711 
384-905 
(647-751) 
228 
5-473 
(168-389) 
3  pM TF CTI 393 
50-1110 
(242-531) 
436 
0-936 
(262-523) 
274 
129-730 
(232-672) 
475 
54-620 
(277-557) 
3  pM TF Citrate 691 
224-1402 
(573-798) 
461 
0-1017 
(321-571) 
778 
452-904 
(516-855) 
475 
38-755 
(280-570) 
5  pM TF CTI 611 
151-1298 
(456-714) 
541 
0-1080 
(431-623) 
547 
341-826 
(469-722) 
524 
323-706 
(448-574) 
5  pM TF Citrate 742 
220-1478 
(621-872) 
544 
0-1108 
(429-656) 
828 
439-915 
(701-861) 
523 
174-765 
(453-591) 
10  pM TF CTI 746 
211-1773 
(662-905) 
604 
271-1160 
(544-721) 
708 
467-930 
(686-839) 
656 
467-764 
(567-686) 
10  pM TF Citrate 797 
232-1843 
(673-924) 
619 
347-1195 
(544-741) 
800 
498-936 
(751-860) 
660 
503-858 
(624-729) 
PPP Low CTI 366 
10-867 
(235-516) 
221 
0-985 
(49-379) 
267 
159-628 
(189-449) 
215 
0-491 
(50-440) 
PPP Low Citrate 856 
184-1508 
(660-1053) 
344 
0-1112 
(133-449) 
836 
561-1090 
(732-976) 
404 
46-486 
(300-437) 
PPP CTI 987 
276-1751 
(777-1208) 
789 
248-1448 
(659-1001) 
916 
626-1064 
(779-1031) 
700 
507-996 
(658-739) 
PPP Citrate 1087 
265-2154 
(898-1294) 
818 
177-1517 
(657-1007) 
1076 
782-1205 
(874-1113) 
721 
498-1032 
(632-827) 
PPP+TM CTI 523 
157-1282 
(381-767) 
598 
47-1077 
(492-788) 
607 
201-885 
(380-811) 
655 
278-760 
(401-711) 
PPP+TM Citrate 533 
0-1648 
(426-758) 
543 
53-946 
(409-685) 
665 
243-883 
(469-811) 
520 
281-775 
(345-670) 
Data shown are the median and range (inter-quartile range). Units for ETP are nM/min. 
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Table 3.16 Peak thrombin concentration using different trigger solutions before and after 
cardiopulmonary bypass comparing those who bled less or more than 1L.  
End point <1L Pre-CPB <1L Post-CPB >1L Pre-CPB >1L Post-CPB 
0.5 pM TF CTI 5 
0-19 
(1-10) 
 0.5 
0-39 
(0-9) 
2 
0-33 
(0-10) 
0.5 
0-49 
(0-8) 
0.5 pM TF Citrate 161 
62-273 
(121-198) 
35 
0-159 
(11-70) 
152 
96-260 
(139-188) 
30 
1-104 
(20-50) 
1  pM TF CTI 12 
0-57 
(6-22) 
12 
0-100 
(0-36) 
12 
0-90 
(4-22) 
4 
0-96 
(0-51) 
1  pM TF Citrate 138 
45-259 
(96-185) 
 36 
0-151 
(18-75) 
128 
57-286 
(94-147) 
39 
0-106 
(20-74) 
3  pM TF CTI 46 
9-186 
26-84) 
81 
0-189 
(30-118) 
42 
12-161 
(23-87) 
97 
4-132 
(71-117) 
3  pM TF Citrate 142 
46-243 
(114-174) 
97 
1-178 
(50-130) 
118 
60-257 
(90-174) 
101 
3-186 
(67-118) 
5  pM TF CTI 95 
21-240 
(50-136) 
121 
0-244 
(92-152) 
102 
50-213 
(71-141) 
136 
41-168 
(93-156) 
5  pM TF Citrate 163 
50-261 
(128-214) 
130 
0-238 
(89-156) 
153 
101-248 
(131-186) 
136 
22-191 
(99-157) 
10  pM TF CTI 217 
59-327 
(170-244) 
161 
33-286 
(143-182) 
190 
126-299 
(159-221) 
150 
107-200 
(142-171) 
10  pM TF Citrate 224 
74-370 
(197-251) 
174 
82-291 
(143-193) 
210 
143-318 
(185-233) 
152 
106-213 
(144-176) 
PPP Low CTI 36 
1-115 
(25-51) 
20 
0-196 
(3-55) 
30 
13-104 
(20-82) 
23 
0-110 
(4-41) 
PPP Low Citrate 161 
34-294 
(117-202) 
52 
0-206 
(15-72) 
142 
10-295 
(111-189) 
51 
3-133 
(23-60) 
PPP CTI 212 
76-369 
(170-266) 
189 
41-303 
(161-212) 
192 
120-330 
(145-276) 
168 
94-249 
(151-207) 
PPP Citrate 246 
80-424 
(214-294) 
195 
30-307 
(158-214) 
253 
142-344 
(195-293) 
169 
97-255 
(138-216) 
PPP+TM CTI 140 
47-333 
(107-193) 
146 
12-243 
(116-178) 
151 
51-300 
(73-253) 
143 
67-213 
(119-153) 
PPP+TM Citrate 149 
47-348 
(114-198) 
127 
11-220 
(82-163) 
155 
56-299 
(100-230) 
118 
69-195 
(84-143) 
Data shown are the median and range (inter-quartile range). Units for peak thrombin concentration are 
nM. 
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Table 3.17 Peak thrombin concentration using different trigger solutions before and after 
cardiopulmonary bypass comparing those who bled at a rate of more or less than 200 mL/hr. 
End point <200mL/hr Pre-CPB <200mL/hr Post-CPB >200mL/hr Pre >200mL/hr Post 
0.5 pM TF CTI 5 
0-28 
(1-10) 
0.5 
0-49 
(0-9) 
1 
0-33 
(0-10) 
0 
0-12 
(0-8) 
0.5 pM TF Citrate 156 
62-273 
(121-198) 
32 
0-159 
(10-70) 
156 
109-196 
(150-188) 
29 
20-79 
(23-50) 
1  pM TF CTI 13 
0-90 
(6-22) 
12 
0-100 
(0-37) 
4 
0-39 
(4-16) 
1 
0-62 
(0-30) 
1  pM TF Citrate 136 
45-286 
(93-180) 
36 
0-151 
(17-79) 
132 
84-177 
(108-153) 
39 
20-92 
(21-73) 
3  pM TF CTI 43 
9-186 
(26-79) 
83 
0-189 
(30-118) 
72 
12-140 
(23-91) 
97 
4-131 
(71-117) 
3  pM TF Citrate 137 
46-257 
(99-173) 
96 
1-178 
(50-129) 
142 
64-209 
(110-174) 
106 
16-186 
(71-118) 
5  pM TF CTI 94 
21-240 
(55-136) 
123 
0-244 
(92-155) 
121 
50-197 
(71-154) 
135 
76-168 
(93-146) 
5  pM TF Citrate 162 
50-261 
(125-208) 
130 
0-238 
(89-157) 
173 
104-223 
(144-194) 
136 
80-191 
(99-147) 
10  pM TF CTI 216 
59-327 
(166-240) 
160 
33-256 
(144-180) 
190 
126-269 
(153-211) 
144 
111-200 
(125-172) 
10  pM TF Citrate 221 
74-370 
(194-249) 
172 
82-291 
(143-191) 
210 
143-263 
(186-228) 
151 
117-213 
(130-176) 
PPP Low CTI 38 
1-115 
(25-55) 
21 
0-196 
(4-60) 
26 
14-104 
(19-59) 
16 
0-57 
(1-39) 
PPP Low Citrate 160 
34-295 
(114-201) 
52 
0-206 
(16-72) 
164 
10-217 
(134-189) 
47 
7-76 
(23-56) 
PPP CTI 212 
76-369 
(169-269) 
188 
41-303 
(159-212) 
188 
120-310 
(145-246) 
166 
137-225 
(151-174) 
PPP Citrate 249 
80-424 
(212-294) 
194 
30-307 
(158-215) 
232 
162-329 
(211-272) 
164 
131-235 
(138-206) 
PPP+TM CTI 144 
47-333 
(107-196) 
146 
12-243 
(116-176) 
137 
51-287 
(70-199) 
132 
67-157 
(119-150) 
PPP+TM Citrate 149 
47-348 
(111-211) 
127 
11-220 
(82-162) 
155 
74-299 
(106-218) 
115 
69-195 
(84-136) 
Data shown are the median and range (inter-quartile range). Units for peak thrombin concentration are 
nM. 
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Table 3.18 Peak thrombin concentration using different trigger solutions before and after 
cardiopulmonary bypass in those who bled more or less than 2 mL/kg/hr for 2 consecutive 
hours. 
End point <2mL/kg/hr for 2 
hours Pre-CPB 
<2mL/kg/hr for 2 
hours Post-CPB 
>2mL/kg/hr for 2 
hours Pre-CPB 
>2mL/kg/hr for 2 
hours Post-CPB 
0.5 pM TF 
CTI 
5 
0-19 
(1-9) 
0.5 
0-49 
(0-7) 
7 
0-33 
(0.3-11) 
1 
0-24 
(0-9) 
0.5 pM TF 
Citrate 
154 
62-273 
(121-198) 
39 
0-159 
(13-70) 
159 
96-260 
(147-185) 
28 
0-79 
(20-46) 
1  pM TF CTI 12 
0-57 
(6-21) 
10 
0-100 
(0-37) 
13 
0-90 
(4-23) 
3 
0-62 
(0.3-35) 
1  pM TF 
Citrate 
135 
45-259 
(95-180) 
38 
0-151 
(19-80) 
134 
66-286 
(106-159) 
39 
1-92 
(20-53) 
3  pM TF CTI 45 
9-186 
(25-74) 
84 
0-189 
(33-118) 
57 
12-160 
(29-89) 
96 
4-149 
(52-112) 
3  pM TF 
Citrate 
133 
46-243 
(99-173) 
98 
1-178 
(113-169) 
142 
67-257 
(56-129) 
98 
3-186 
(40-112) 
5  pM TF CTI 95 
21-240 
(53-136) 
123 
0-244 
(102-155) 
116 
50-213 
(40-112) 
132 
41-168 
(78-146) 
5  pM TF 
Citrate 
163 
50-261 
(125-208) 
131 
0-238 
(97-157) 
161 
101-248 
(141-184) 
129 
22-191 
(83-145) 
10  pM TF 
CTI 
215 
59-327 
(164-238) 
162 
33-286 
(145-180) 
190 
126-299 
(167-238) 
145 
107-200 
(134-168) 
10  pM TF 
Citrate 
218 
74-370 
(194-246) 
174 
82-291 
(144-191) 
219 
143-318 
(194-255) 
151 
206-213 
(137-168) 
PPP Low CTI 36 
1-115 
(25-52) 
21 
0-196 
(5-55) 
33 
14-104 
(20-71) 
11 
0-88 
(2-40) 
PPP Low 
Citrate 
160 
34-294 
(114-201) 
53 
0-206 
(18-72) 
144 
10-295 
(133-188) 
45 
1-153 
13-58) 
PPP CTI 206 
76-369 
(169-266) 
189 
41-303 
(164-212) 
195 
120-330 
(164-282) 
159 
94-225 
(139-173) 
PPP Citrate 246 
80-424 
(212-293) 
196 
30-307 
(161-215) 
258 
162-344 
(214-292) 
159 
80-235 
(134-191) 
PPP+TM CTI 139 
47-333 
(107-193) 
147 
12-243 
(118-176) 
158 
51-300 
(99-224) 
128 
45-202 
(86-151) 
PPP+TM 
Citrate 
148 
47-348 
(111-198) 
128 
11-220 
(91-162) 
157 
74-299 
(126-243) 
114 
21-195 
(77-141) 
Data shown are the median and range (inter-quartile range). Units for peak thrombin concentration are 
nM. 
 
 
  
107 
 
Table 3.19 Peak thrombin concentration using different trigger solutions before and after 
cardiopulmonary bypass in those who did and did not require haemostatic treatment. 
End point No Haemostatic 
Treatment Pre-CPB 
No Haemostatic 
Treatment Post-CPB 
Haemostatic 
Treatment Pre-CPB 
Haemostatic 
Treatment Post-
CPB 
0.5 pM TF 
CTI 
5 
0-18 
(1-10) 
0.4 
0-49 
(0-3) 
4 
0-33 
(0.4-10) 
0.6 
0-35 
(0-10) 
0.5 pM TF 
Citrate 
156 
65-273 
(116-199) 
30 
0-159 
(14-70) 
156 
62-260 
(131-193) 
32 
0-151 
(15-50) 
1  pM TF 
CTI 
14 
0-40 
(9-21) 
12 
0-100 
(0-33) 
11 
0-90 
(4-24) 
9 
0-77 
(0-40) 
1  pM TF 
Citrate 
138 
51-259 
(90-195) 
39 
0-151 
(24-79) 
131 
45-286 
(98-153) 
35 
0-114 
(12-74) 
3  pM TF 
CTI 
46 
9-186 
(25-67) 
75 
0-189 
(19-116) 
45 
12-160 
(26-92) 
97 
1-153 
(53-118) 
3  pM TF 
Citrate 
132 
46-243 
(114-171) 
94 
1-178 
(47-122) 
144 
64-257 
(105-175) 
107 
3-186 
(64-135) 
5  pM TF 
CTI 
98 
21-240 
(52-135) 
126 
0-244 
(87-151) 
96 
25-225 
(60-147) 
123 
41-218 
(94-157) 
5  pM TF 
Citrate 
166 
50-261 
(123-216) 
133 
0-238 
(105-157) 
160 
65-256 
(132-185) 
127 
22-228 
(85-152) 
10  pM TF 
CTI 
216 
93-327 
(171-238) 
161 
33-286 
(138-180) 
200 
59-300 
(160-240) 
159 
107-233 
(142-180) 
10  pM TF 
Citrate 
228 
117-370 
(195-247) 
169 
82-291 
(141-191) 
217 
74-318 
(189-249) 
164 
106-244 
(147-190) 
PPP Low 
CTI 
36 
9-107 
(26-53) 
20 
0-196 
(5-56) 
34 
0.6-115 
(20-57) 
23 
0-95 
(3-48) 
PPP Low 
Citrate 
159 
34-294 
(124-200) 
53 
0-206 
(13-70) 
164 
10-295 
(113-201) 
50 
0.6-176 
(17-66) 
PPP CTI 212 
101-369 
(171-267) 
193 
41-303 
(159-212) 
198 
76-330 
(164-268) 
180 
94-276 
(157-212) 
PPP Citrate 245 
110-424 
(211-294) 
194 
41-307 
(148-213) 
254 
80-347 
(213-290) 
189 
30-281 
(159-216) 
PPP+TM 
CTI 
140 
47-333 
(109-200) 
146 
12-243 
(117-181) 
147 
51-300 
(99-193) 
144 
45-239 
(117-162) 
PPP+TM 
Citrate 
149 
47-348 
(116-225) 
127 
11-220 
(85-163) 
155 
56-299 
(107-197) 
122 
21-195 
(81-146) 
Data shown are the median and range (inter-quartile range). Units for peak thrombin concentration are 
nM. 
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Table 3.20 Peak thrombin concentration using different trigger solutions before and after 
cardiopulmonary bypass in those who did and did not undergo re-operation due to bleeding. 
End point No Re-op 
Pre-CPB 
No Re-op 
Post-CPB 
Re-op Pre-CPB Re-op Post-CPB 
0.5 pM TF CTI 5 
0-19 
(1-10) 
0.5 
0-49 
(0-8) 
1 
0-33 
(0-16) 
0.6 
0-24 
(0-10) 
0.5 pM TF Citrate 154 
62-273 
(121-193) 
31 
0-159 
(13-69) 
193 
109-260 
(171-197) 
39 
1-79 
(21-46) 
1  pM TF CTI 13 
0-57 
(6-22) 
10 
0-100 
(0-37) 
5 
0-90 
(4-10) 
1 
0-62 
(0-39) 
1  pM TF Citrate 133 
45-259 
(93-175) 
38 
0-151 
(19-79) 
137 
105-286 
(133-161) 
39 
1-74 
(22-67) 
3  pM TF CTI 46 
9-186 
(26-81) 
87 
0-189 
(36-119) 
36 
12-160 
(18-101) 
94 
4-117 
(40-110) 
3  pM TF Citrate 133 
46-243 
(106-169) 
98 
1-178 
(56-129) 
164 
64-257 
(113-192) 
98 
3-186 
(43-112) 
5  pM TF CTI 96 
21-240 
(58-136) 
128 
0-244 
(98-155) 
98 
44-213 
(60-152) 
114 
41-168 
(78-130) 
5  pM TF Citrate 162 
50-261 
(127-198) 
131 
0-238 
(97-157) 
174 
104-248 
(128-203) 
110 
22-191 
(83-138) 
10  pM TF CTI 215 
59-327 
(170-238) 
160 
33-286 
(144-179) 
200 
126-299 
(132-231) 
142 
121-200 
(127-172) 
10  pM TF Citrate 218 
74-370 
(194-248) 
174 
82-291 
(144-191) 
220 
143-318 
(198-243) 
151 
21-213 
(132-157) 
PPP Low CTI 36 
0.6-115 
(25-55) 
21 
0-196 
(4-53) 
20 
14-98 
(17-49) 
11 
0-91 
(4-39) 
PPP Low Citrate 159 
34-294 
(118-198) 
51 
0-206 
(17-69) 
189 
10-295 
(127-237) 
50 
3-95 
(25-56) 
PPP CTI 206 
76-369 
(169-269) 
187 
41-303 
(161-212) 
195 
120-330 
(160-239) 
156 
94-225 
(147-165) 
PPP Citrate 246 
80-424 
(212-293) 
194 
30-307 
(158-215) 
242 
162-344 
(215-285) 
159 
97-235 
(138-171) 
PPP+TM CTI 139 
47-333 
(107-196) 
146 
12-243 
(118-175) 
158 
56-300 
(107-195) 
145 
67-157 
(86-152) 
PPP+TM Citrate 148 
47-348 
(111-198) 
126 
11-220 
(88-162) 
203 
74-299 
(131-223) 
115 
69-148 
(77-141) 
Data shown are the median and range (inter-quartile range). Units for peak thrombin concentration are 
nM. 
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Table 3.21 Velocity index using different trigger solutions before and after CPB comparing 
those who bled less or more than 1L.  
End point <1L Pre-CPB <1L Post-CPB >1L Pre-CPB >1L Post-CPB 
0.5 pM TF CTI 1 
0-5 
(0.3-2) 
0.3 
0-12 
(0-2) 
0.5 
0-8 
(0.2-1.5) 
0 
0-12 
(0-1.3) 
0.5 pM TF Citrate 71 
22-139 
(50-88) 
9 
0-75 
(3-23) 
76 
32-142 
(56-81) 
11 
0-43 
(6-16) 
1  pM TF CTI 2.3 
0-15 
(1-5) 
2.4 
0-43 
(0-10) 
2.7 
0-33 
(0.5-4) 
0.7 
0-38 
(0-19) 
1  pM TF Citrate 56 
15-113 
(34-76) 
13 
0-65 
(5-31) 
54 
16-187 
(36-63) 
14 
0-48 
(5-28) 
3  pM TF CTI 12 
2-67 
(7-25) 
31 
0-93 
(9-65) 
15 
3-68 
(7-27) 
46 
1-78 
(21-58) 
3  pM TF Citrate 56 
16-120 
(38-72) 
46 
2-106 
(17-67) 
50 
16-127 
(30-72) 
46 
1-93 
(28-56) 
5  pM TF CTI 32 
5-119 
(16-50) 
64 
0-161 
(43-80) 
42 
15-106 
(22-61) 
80 
11-96 
(56-91) 
5  pM TF Citrate 64 
15-122 
(47-90) 
62 
0-154 
(34-85) 
66 
31-124 
(49-79) 
71 
6-104 
(56-89) 
10  pM TF CTI 116 
23-180 
(78-134) 
94 
9-182 
(82-113) 
95 
44-179 
(73-133) 
95 
54-130 
(85-104) 
10  pM TF Citrate 121 
36-201 
(99-143) 
102 
27-191 
(84-121) 
108 
64-223 
(90-134) 
103 
52-132 
(88-124) 
PPP Low CTI 7 
2-56 
(6-14) 
5 
0-43 
(1-17) 
10 
3-84 
(5-19) 
7 
0-32 
(1-13) 
PPP Low Citrate 52 
8-140 
(37-81) 
16 
0-91 
(4-22) 
53 
7-146 
(37-68) 
16 
0-46 
(8-18) 
PPP CTI 91 
32-188 
(64-125) 
106 
14-166 
(89-127) 
91 
42-200 
(71-127) 
99 
35-140 
(80-115) 
PPP Citrate 113 
33-213 
(90-140) 
100 
17-175 
(84-126) 
120 
45-242 
(88-144) 
100 
41-145 
(78-116) 
PPP+TM CTI 69 
22-169 
(53-100) 
81 
3-138 
(56-100) 
76 
24-209 
(58-123) 
71 
29-121 
(54-92) 
PPP+TM Citrate 92 
33-189 
(67-125) 
63 
4-117 
(39-91) 
118 
26-242 
(57-125) 
64 
33-117 
(40-73) 
Data shown are the median and range (inter-quartile range). Units for velocity index are nM/min. 
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Table 3.22 Velocity index using different trigger solutions before and after CPB comparing 
those who bled at a rate of more or less than 200 mL/hr. 
End point <200mL/hr Pre <200mL/hr Post >200mL/hr Pre >200mL/hr Post 
0.5 pM TF CTI 1 
0-8 
(0.3-2) 
0.3 
0-12 
(0-2) 
0.2 
0-2.3 
(0-1) 
0 
0-3 
(0-1.3) 
0.5 pM TF Citrate 70 
22-142 
(50-88) 
10 
0-75 
(3-23) 
77 
52-87 
(62-81) 
10 
5-29 
(9-14) 
1  pM TF CTI 3 
0-33 
(1-5) 
2 
0-43 
(0-10) 
1 
0-11 
(0.4-3) 
0.1 
0-20 
(0-10) 
1  pM TF Citrate 55 
15-187 
(33-72) 
12 
0-65 
(4-32) 
55 
29-80 
(48-70) 
15 
5-48 
(6-25) 
3  pM TF CTI 12 
2-68 
(7-23) 
37 
0-93 
(9-65) 
22 
3-53 
(7-34) 
44 
1-78 
(21-58) 
3  pM TF Citrate 56 
16-127 
(35-72) 
44 
1-106 
(17-66) 
62 
20-89 
(41-72) 
48 
4-93 
(28-56) 
5  pM TF CTI 32 
5-119 
(16-50) 
66 
0-161 
(43-87) 
45 
17-99 
(22-67) 
73 
25-94 
(56-82) 
5  pM TF Citrate 61 
15-124 
(46-88) 
64 
0-154 
(34-87) 
72 
44-101 
(60-94) 
69 
30-103 
(56-86) 
10  pM TF CTI 117 
23-180 
(78-134) 
95 
9-182 
(82-113) 
93 
44-162 
(73-120) 
86 
54-130 
(73-99) 
10  pM TF Citrate 120 
36-223 
(94-143) 
104 
27-191 
(85-121) 
106 
72-195 
(90-132) 
90 
52-132 
(84-126) 
PPP Low CTI 9 
2-56 
(6-14) 
5 
0-43 
(1-17) 
8 
4-84 
(4-22) 
6 
0-18 
(0-13) 
PPP Low Citrate 52 
8-146 
(35-78) 
16 
0-91 
(4-22) 
57 
7-104 
(41-69) 
15 
1-26 
(12-18) 
PPP CTI 92 
32-200 
(65-127) 
107 
14-166 
(87-127) 
86 
42-157 
(71-127) 
92 
65-118 
(80-108) 
PPP Citrate 115 
33-242 
(90-140) 
100 
17-175 
(84-126) 
109 
45-159 
(88-155) 
99 
57-138 
(78-105) 
PPP+TM CTI 74 
22-209 
(54-105) 
78 
3-138 
(56-100) 
66 
34-139 
(56-101) 
74 
29-103 
(54-87) 
PPP+TM Citrate 92 
33-242 
(67-125) 
64 
4-117 
(40-91) 
88 
26-159 
(53-155) 
62 
35-97 
(39-73) 
Data shown are the median and range (inter-quartile range). Units for velocity index are nM/min. 
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Table 3.23 Velocity index using different trigger solutions before and after CPB in those who 
bled more or less than 2 mL/kg/hr for 2 consecutive hours. 
End point <2mL/kg/hr for 2 
hours Pre-CPB 
<2mL/kg/hr for 2 
hours Post-CPB 
>2mL/kg/hr for 2 
hours Pre-CPB 
>2mL/kg/hr for 2 
hours Post-CPB 
0.5 pM TF 
CTI 
0.9 
0-4.8 
(0.3-2) 
0.3 
0-12 
(0-1.5) 
0.8 
0-8 
(0-2) 
0 
0-6 
(0-1.3) 
0.5 pM TF 
Citrate 
69 
22-139 
(50-88) 
10 
0-76 
(3-23) 
77 
34-142 
(62-84) 
9 
0-29 
(5-14) 
1  pM TF 
CTI 
2.3 
0-15 
(1-5) 
2.1 
0-43 
(0-10) 
3.2 
0-33 
(0.5-6) 
0.5 
0-20 
(0-10) 
1  pM TF 
Citrate 
55 
15-113 
(34-72) 
13 
0-65 
(5-33) 
55 
19-187 
(40-70) 
11 
0-48 
(5-19) 
3  pM TF 
CTI 
12 
2-67 
(6-21) 
38 
0-93 
(11-65) 
21 
3-68 
(7-34) 
39 
1-84 
(14-58) 
3  pM TF 
Citrate 
56 
16-120 
(35-72) 
47 
2-106 
(17-66) 
53 
20-127 
(41-72) 
41 
1-93 
(6-56) 
5  pM TF 
CTI 
32 
5-119 
(16-50) 
67 
0-161 
(46-87) 
45 
16-106 
(22-67) 
68 
11-101 
(31-82) 
5  pM TF 
Citrate 
64 
15-122 
(46-88) 
64 
0-154 
(40-87) 
68 
31-124 
(53-94) 
63 
6-106 
(30-86) 
10  pM TF 
CTI 
117 
23-180 
(78-133) 
95 
9-182 
(83-113) 
101 
44-179 
(73-143) 
86 
54-137 
(73-99) 
10  pM TF 
Citrate 
120 
36-201 
(94-142) 
105 
24-191 
(86-121) 
111 
64-223 
(90-150) 
90 
52-134 
(79-126) 
PPP Low 
CTI 
9 
2-56 
(6-14) 
5 
0-43 
(1-17) 
11 
4-84 
(5-22) 
3 
0-29 
(0-13) 
PPP Low 
Citrate 
53 
8-140 
(34-78) 
16 
0-91 
(4-22) 
51 
7-146 
(41-69) 
13 
0-63 
(4-18) 
PPP CTI 86 
32-188 
(64-121) 
109 
14-166 
(91-127) 
95 
42-200 
(71-136) 
84 
35-135 
(71-108) 
PPP Citrate 115 
33-213 
(88-140) 
100 
21-175 
(86-126) 
122 
45-242 
(90-157) 
90 
17-138 
(69-105) 
PPP+TM 
CTI 
69 
22-169 
(53-100) 
83 
3-138 
(58-100) 
74 
24-209 
(58-113) 
69 
12-121 
(45-87) 
PPP+TM 
Citrate 
91 
33-189 
(63-123) 
64 
4-117 
(41-91) 
115 
26-242 
(72-155) 
55 
5-101 
(36-76) 
Data shown are the median and range (inter-quartile range). Units for velocity index are nM/min. 
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Table 3.24 Velocity index using different trigger solutions before and after CPB in those who 
did and did not require haemostatic treatment. 
End point No Haemostatic 
Treatment Pre-CPB 
No Haemostatic 
Treatment Post-CPB 
Haemostatic 
Treatment Pre-CPB 
Haemostatic 
Treatment Post-
CPB 
0.5 pM TF 
CTI 
0.9 
0-4.5 
(0.2-2) 
0.3 
0-12 
(0-1) 
0.8 
0-8 
(0.2-2) 
0.2 
0-12 
(0-2) 
0.5 pM TF 
Citrate 
70 
22-139 
(48-83) 
9 
0-68 
(3-23) 
74 
27-142 
(57-87) 
11 
0-75 
(2-18) 
1  pM TF 
CTI 
2.6 
0-9 
(1-5) 
2.6 
0-43 
(0-10) 
1.9 
0-33 
(1-6) 
1.2 
0-30 
(0-10) 
1  pM TF 
Citrate 
60 
16-113 
(34-82) 
13 
0-65 
(7-31) 
54 
15-187 
(36-68) 
12 
0-49 
(4-28) 
3  pM TF 
CTI 
12 
2.5-67 
(7-21) 
29 
0-93 
(6-61) 
14 
3-68 
(7-33) 
42 
0-89 
(16-64) 
3  pM TF 
Citrate 
55 
16-120 
(36-70) 
44 
2-106 
(17-63) 
56 
19-127 
(40-75) 
48 
1-93 
(17-69) 
5  pM TF 
CTI 
37 
6-119 
(17-48) 
64 
0-124 
(46-84) 
32 
5-106 
(21-61) 
70 
11-161 
(41-85) 
5  pM TF 
Citrate 
69 
15-117 
(43-91) 
61 
0-117 
(43-86) 
61 
27-124 
(50-85) 
67 
6-154 
(33-87) 
10  pM TF 
CTI 
116 
33-169 
(80-133) 
93 
9-182 
(81-114) 
112 
23-180 
(74-133) 
97 
54-146 
(85-107) 
10  pM TF 
Citrate 
122 
43-201 
(84-144) 
100 
27-191 
(83-122) 
114 
36-223 
(96-140) 
105 
52-169 
(88-122) 
PPP Low 
CTI 
9 
2-35 
(6-14) 
5 
0-43 
(1-18) 
8 
2-84 
(5-17) 
6 
0-41 
(1-13) 
PPP Low 
Citrate 
55 
9-140 
(37-79) 
16 
0-85 
(4-22) 
52 
7-146 
(37-70) 
16 
0-91 
(5-22) 
PPP CTI 92 
32-188 
(64-127) 
105 
14-160 
(87-126) 
92 
39-200 
(68-127) 
105 
35-166 
(83-122) 
PPP Citrate 115 
33-213 
(91-140) 
99 
21-175 
(79-125) 
113 
45-242 
(88-143) 
101 
17-164 
(86-128) 
PPP+TM 
CTI 
73 
22-169 
(57-103) 
78 
3-135 
(56-100) 
69 
22-209 
(54-105) 
73 
12-138 
(54-95) 
PPP+TM 
Citrate 
92 
33-189 
(62-120) 
62 
4-117 
(39-88) 
95 
26-242 
(70-128) 
66 
5-107 
(40-89) 
Data shown are the median and range (inter-quartile range). Units for velocity index are nM/min. 
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Table 3.25 Velocity index using different trigger solutions before and after CPB in those who 
did and did not undergo re-operation due to bleeding. 
End point No Re-op 
Pre-CPB 
No Re-op 
Post-CPB 
Re-op Pre-CPB Re-op Post-CPB 
0.5 pM TF CTI 1 
0-5 
(0.3-2) 
0.2 
0-12 
(0-1) 
0.2 
0-8 
(0-0.3) 
0 
0-7 
(0-1.7) 
0.5 pM TF Citrate 68 
22-13 
(50-83) 
9 
0-75 
(3-23) 
84 
52-142 
(77-93) 
14 
0-29 
(6-14) 
1  pM TF CTI 3 
0-15 
(1-6) 
2 
0-43 
(0-10) 
1 
0-33 
(0.4-2) 
1 
0-19 
(0-13) 
1  pM TF Citrate 55 
15-113 
34-70) 
13 
0-65 
(5-33) 
56 
48-187 
(50-66) 
14 
0-28 
(6-25) 
3  pM TF CTI 13 
5-67 
(7-25) 
39 
0-93 
(12-65) 
11 
3-68 
(3-31) 
35 
1-67 
(11-56) 
3  pM TF Citrate 56 
16-120 
(36-71) 
47 
2-106 
(17-66) 
67 
20-127 
(48-82) 
35 
1-93 
(14-64) 
5  pM TF CTI 32 
5-119 
(17-51) 
67 
0-161 
(46-90) 
37 
11-106 
(19-64) 
69 
11-82 
(28-77) 
5  pM TF Citrate 62 
15-122 
(46-89) 
65 
0-154 
(39-87) 
73 
44-124 
(64-90) 
59 
6-102 
(33-83) 
10  pM TF CTI 114 
23-180 
(81-133) 
95 
9-182 
(82-112) 
107 
44-179 
(57-131) 
85 
54-130 
(75-97) 
10  pM TF Citrate 118 
36-201 
(92-143) 
104 
27-191 
(87-124) 
122 
72-223 
(90-141) 
84 
52-128 
(80-99) 
PPP Low CTI 9 
2-84 
(6-15) 
5 
0-43 
(1-15) 
5 
4-31 
(4-12) 
5 
0-39 
(2-15) 
PPP Low Citrate 52 
7-140 
(35-74) 
16 
0-91 
(4-22) 
69 
37-146 
(52-108) 
16 
0-44 
(13-18) 
PPP CTI 92 
32-188 
(65-127) 
107 
14-166 
(87-127) 
71 
42-200 
(59-113) 
83 
35-118 
(68-96) 
PPP Citrate 115 
33-213 
(90-140) 
101 
17-175 
(86-126) 
138 
61-242 
(89-157) 
84 
41-116 
(63-103) 
PPP+TM CTI 71 
22-169 
(55-105) 
77 
3-138 
(56-102) 
69 
24-209 
(45-90) 
71 
29-95 
(44-90) 
PPP+TM Citrate 92 
26-189 
(64-125) 
64 
4-117 
(40-93) 
97 
40-242 
(66-157) 
55 
33-89 
(37-75) 
Data shown are the median and range (inter-quartile range). Units for velocity index are nM/min. 
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The reduction in protein C (55%  versus 62%, p=0.023) and free protein S (42% versus 47%, 
p=0.046) may explain why the reduced clotting factors measured post-cardiopulmonary bypass 
in those who bled in excess of 2mL/kg/hr for 2 consecutive hours did not translate into 
reduced thrombin generation. Addition of thrombomodulin to these samples resulted in very 
similar thrombin generation results in both groups pre and post-CPB as shown in Figure 3.12. 
 
 
Figure 3.12 Velocity Index (A), Peak thrombin (B) and ETP (C) measured pre and post 
cardiopulmonary bypass in samples taken into anticoagulant consisting of citrate and CTI or 
citrate alone. The trigger used was Stago PPP containing thrombomodulin. Data shown are 
median values (horizontal black bar), interquartile range (box), values with 1.5 times 
interquartile range (whiskers) and values between 1.5-3 times interquartile range (asterisks 
and circles). 
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3.3 Discussion 
The aim of this section was to investigate whether any haemostatic tests were useful for 
predicting progression to post-operative bleeding. Blood loss in excess of 1L at 24 hours or at a 
rate exceeding 2mL/kg/hr for two consecutive hours in the first six post-operative hours was 
associated with a significantly lower FXIII and fibrinogen concentration and a lower platelet 
count. FXIII was also lower in those who bled at a rate exceeding 200mL/hr for 2 consecutive 
hours in the first 24 hours. A longer time on cardiopulmonary bypass was associated with 
blood loss in excess of 1L at 24 hours and the need for haemostatic treatment. A longer time 
on bypass is likely to indicate greater complexity of the operation being performed, something 
which in itself is also a risk factor for bleeding (181). The observations regarding FXIII falling 
post-bypass are consistent with other studies (103, 182), although reports of its association 
with bleeding have been conflicting (108, 110).  A lower fibrinogen has also been associated 
with bleeding (105, 183) although the critical concentration at which replacement is 
appropriate has not yet been determined (109). Thrombocytopenia has also been previously 
described as a risk factor for bleeding (11, 184) .   
 
Thrombin generation assays were generally unable to identify patients at risk of excess 
bleeding regardless of tissue factor concentration or anticoagulant used. The significant 
reduction of factors II, V and X seen in those who bled in excess of 2mL/kg/hr for two 
consecutive hours in the first six post-operative hours which would have been expected to 
reduce thrombin generation and hence increase bleeding, was balanced by a reduction in 
protein C and S. Activation of Protein C by addition of thrombomodulin to the trigger resulted 
in near identical thrombin generation, supporting this conclusion. 
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Previous studies have reported that reduced thrombin generation was associated with an 
increased risk of bleeding (11, 169). The reasons why the results reported here differ from 
previous studies may in part be the result of having recruited a patient group undergoing more 
complex operations where bleeding is more frequent. Previous studies included patients 
undergoing CABG as the sole procedure, an operation that is associated with a lower incidence 
of post-CPB bleeding (11, 169). In addition in this study the pattern of abnormalities in clotting 
factors in those bleeding in excess of 2mL/kg/hr and 1L at twenty four hours indicates that 
initial clot formation will have been reduced through reduction in fibrinogen and platelet 
count. The quality of the clot would have been further compromised by the reduction in FXIII 
resulting in reduced fibrin cross-linkage. Also the longevity of this clot would have been 
shortened by the reduction in activity of TAFI which was reduced compared to pre-CPB 
samples and would have comparatively had a greater impact in those where clot stability had 
already been impaired. This would then result in excess bleeding. As FXIII and TAFI have no 
influence on thrombin generation, and this study used PPP rather than PRP, thus removing any 
influence of platelets, it is unsurprising that thrombin generation parameters were unable to 
detect those at risk of bleeding. Furthermore, the data suggests that correction of these 
factors in isolation may not be the most effective strategy, which may partly explain the 
negative result from a recent clinical trial using recombinant FXIII (185).  
 
Tests of platelet function were not performed in this study. It is already well described that 
following exposure to cardiopulmonary bypass, platelets exhibit reduced aggregation in 
response to ADP (115, 118). Furthermore, thrombin generation assays performed in platelet 
rich plasma (PRP) may have been sensitive to any alteration in platelet membrane 
phospholipid composition, which may be another factor explaining some of the differences in 
conclusion between this study and that of Bosch et al (169).  
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A paradoxical increase was observed in median peak thrombin and velocity index observed 
post-CPB compared to pre-CPB samples taken into CTI when trigger solutions containing lower 
concentrations of TF were used. This may be due to the reduction in full length TFPI having a 
greater effect on the TF-FVIIa interaction. Full-length TFPI has previously been shown to 
significantly influence calibrated automated thrombography (186). Addition of CTI increases 
the sensitivity of the assay to the initiation phase of coagulation. In the post-CPB samples the 
lower full-length TFPI concentration may have resulted in a greater amount of FVIIa being 
generated compared to pre-operative samples. At higher TF concentrations, the FVII 
concentration becomes rate limiting, therefore post-CPB the reduction in FVII would reduce 
thrombin generation, thus resulting in the expected pattern of reduced thrombin generation 
post-cardiopulmonary bypass compared to pre. 
 
In summary, the post-CPB fibrinogen concentration had modest clinical utility in identifying 
patients who went on to lose more than 1L of blood at 24 hours or at a rate greater than 2 
mL/kg/hr for two consecutive hours in the first 6 hours post-surgery. Other coagulation 
factors, whilst having some clinical utility, in practice would not be available in a timely manner 
to guide clinical management. Calibrated automated thrombography performed in PPP was 
unable to predict bleeding regardless of the definition used. 
118 
 
Chapter 4 The effect of CPB on platelet phospholipids 
 
4.1 Introduction 
Under resting conditions, the external platelet membrane is composed predominantly of 
the inert phospholipid phosphatidylcholine (PC). On activation of the platelet, the 
negatively charged phospholipids phosphatidylethanolamine (PE) (77, 79) and 
phosphatidylserine (PS) (80) move to the external membrane to support coagulation. 
Phospholipid exposure on cell membranes is considered to be mediated by three types of 
transporter: flippase, floppase and scramblase, as discussed in Chapter 1. 
 
Following CPB, platelet aggregation is reduced in response to ADP (115-118). P-selectin, a 
marker of platelet activation, has generally been reported to be either unchanged (119) or 
increased (120, 121). The ability of platelets to express P-selectin in response to thrombin 
receptor stimulation appears unchanged post-CPB where thrombin has been used as the 
agonist (119), but where thrombin receptor activating peptide-6 (TRAP-6) has been used 
the response post-CPB has been reported to be reduced (187).  Whilst this difference is 
likely to be related to thrombin being able to activate more types of receptor, such as PAR3 
and PAR4, it nevertheless suggests that the ability of platelets to respond to thrombin 
receptor activation may be different post-CPB.  
 
These observations suggest there may also be changes in the phospholipids expressed on 
the external membrane of the platelets. Evidence to support this comes from studies which 
have reported changes in annexin V binding post-CPB. Annexin V binds to negatively 
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charged phospholipids and therefore has been used as indicator of presence of these lipids. 
However, the studies have been contradictory, with some reporting an increase in annexin 
V binding (120) and others reporting a decrease (122). 
 
Recently a novel family of oxidised phospholipids has been described that are rapidly 
generated by 12-lipoxygenase in platelets activated by thrombin or collagen (99). The 
phospholipids have a hydroxyl group added to the 12th carbon of arachidonic acid in the 
Sn2 position of phosphatidylethanolamine (PE) and phosphatidylcholine (PC). These 
oxidised fatty acids are termed hydroxyeicosatetraenoic acids (HETE) and hence activated 
platelets generate 12-HETE-PE and 12-HETE-PC. These HETE-phospholipids have been 
shown to increase thrombin generation (99). The effect of CPB on these novel lipids is 
currently unknown. The structures of the platelet phospholipids measured in this Chapter 
are shown in Figure 4.1 for PE and PS species, Figure 4.2 for 12-HETE-PE species and Figure 
4.3 for PC and 12-HETE-PC species. 
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Figure 4.1 Structures of phosphatidylethanolamine (PE) species and phosphatidylserine (PS) 
species measured in this Chapter. 
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Figure 4.2 Structures of the 12-HETE-PE phospholipids measured in this Chapter. They differ 
from the parent PE phospholipids shown Figure 4.1 by the addition of a hydroxyl group to 
the 12th carbon atom of arachidonic acid. 
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Figure 4.3 Structures of the PC and 12-HETE-PC phospholipids measured in this Chapter. 
The 12-HETE-PC species differ from the parent PC phospholipids by the addition of a 
hydroxyl group to the 12th carbon atom of arachidonic acid. 
 
The purpose of the experiments described in this Chapter was firstly to investigate whether 
the externalisation of negatively charged phospholipids and the generation of oxidised 
phospholipids was altered by CPB. The second objective was to investigate their effect on 
thrombin generation and whether their inclusion in trigger solutions would alter the ability 
of calibrated automated thrombography to identify those at risk of bleeding. 
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4.2 Results 
4.2.1 Flowcytometry 
Platelets were identified by initially gating on forward and side scatter, with CD61 being 
used as a platelet marker to identify platelets co-expressing Annexin V.  Annexin V 
expression was increased in washed platelets compared to whole blood (p=0.012) as 
shown in Figure 4.4. There was no significant difference in the percentage of platelets 
positive for Annexin V post-CPB compared to pre-CPB (p=0.484 for washed platelets; 
p=0.169 for platelets in whole blood). The percentage of Annexin V positive platelets did 
not correlate with the amount of individual species of externalised PE and PS, nor did it 
correlated with the total amount of externalised PE and PS (Figure 4.5).  
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Figure 4.4 The gating strategy is summarised using plots from a representative sample. The 
region where platelets were expected to be present was initially identified using forward 
and side scatter (A, whole blood and C, washed platelets). This population was then gated 
upon comparing CD61 positive events (PE-Cy7 fluorochrome) with Annexin V positive 
events (FITC fluorochrome) in both whole blood (B) and washed platelets (D). A positive 
control using fixed washed platelets stained only for Annexin V is included for comparison 
(E).  The percentage of Annexin V positive platelets was lower in whole blood (F) than in 
washed platelets (G). 
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Figure 4.5 Correlation plots comparing total amounts of externalised PS and PE with the 
percentage of Annexin V positive platelets from washed platelets (A, C) and whole blood 
(B,D) pre and post-CPB. Spearmen’s correlation coefficient (ρ) and p-value are shown. 
There was no correlation in any of the four conditions. 
 
4.2.2 Effect of CPB on externalisation of PE and PS 
As expected, thrombin and collagen both induced the externalisation of PE (Figure 4.6) and 
PS (Figure 4.7). Post-CPB the amount of PE and PS externalised in response to stimulation 
was reduced compared to pre-CPB. This reduction in externalisation suggests that 
scramblase function within the platelet membrane is partially inhibited. The total amount 
of PE and PS did not change comparing pre and post CPB.  
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Figure 4.6 Median concentrations of PE species on the external platelet membrane 
increased in response to collagen and thrombin. Post-CPB the levels were lower (A,C,E, G, 
I). Total concentrations remained similar pre and post-CPB (B, D, F, H, J) Data shown are 
median values (horizontal black bar), interquartile range (box), values with 1.5 times 
interquartile range (whiskers) and values between 1.5-3 times interquartile range (asterisks 
and circles) (n=11). 
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Figure 4.7 PS was externalised in response to thrombin and collagen. Post-CPB, 
externalisation was reduced (A, C, E). Total concentrations remained similar (B, D, F). Data 
shown are median (horizontal black bar), interquartile range (box), values with 1.5 times 
interquartile range (whiskers) and values between 1.5-3 times interquartile range (asterisks 
and circles) (n=11). 
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Figure 4.8 Concentrations of 12-HETE-PE species increased in response to thrombin and 
collagen; post-CPB they were reduced (A, C, E, G).  Total levels post-CPB were lower than 
pre-CPB, although there was still evidence to of a response to stimulation with thrombin (B, 
D, F, H). Data shown are median (horizontal black bar), interquartile range (box), values 
with 1.5 times interquartile range (whiskers) and values between 1.5-3 times interquartile 
range (asterisks and circles) (n=11). 
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Figure 4.9 12-HETE-PC increased in response to stimulation with thrombin and collagen, 
with a reduction post-CPB (A,C). Amounts of parent species of PC were unchanged pre and 
post-CPB (B,D). Data shown are median (horizontal black bar), interquartile range (box), 
values with 1.5 times interquartile range (whiskers) and values between 1.5-3 times 
interquartile range (asterisks and circles) (n=11). 
 
4.2.3 Effect of CPB on 12-HETE-PE and 12-HETE-PC 
Following CPB less 12-HETE-PE was externalised and less was synthesised in response to 
stimulation with thrombin or collagen (Figure 4.8). In addition, post-CPB less 12-HETE-PC 
was synthesised in response to thrombin and collagen, although the difference was not 
statistically significant (Figure 4.9). These results suggest that 12-LOX, the lipoxygenase 
present in platelets responsible for oxygenation of arachidonic acid to HETE, has reduced 
function post-CPB.  
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Figure 4.10 summaries the effect of CPB on the synthesis of the overall amounts of 12-
HETE-PC and 12-HETE-PE (Figure 4.10A and Figure 4.10B) and the externalisation of the 
overall amounts of 12-HETE-PE (Figure 4.10C), PE (Figure 4.10D) and PS (Figure 4.10E). 
 
 
Figure 4.10 Total amounts of 12-HETE-PC (A) and 12-HETE-PC (B) were lower post-CPB.  
Total externalised 12-HETE-PE (C), PE (D) and PS (E) were lower post CPB. Data shown are 
median (horizontal black bar), interquartile range (box), values with 1.5 times interquartile 
range (whiskers) and values between 1.5-3 times interquartile range (asterisks and circles) 
(n=11). 
 
4.2.4 Effect of 12-HETE-PE and PC on thrombin generation 
In order to investigate the effect of the 12-HETE-PE and 12-HETE-PC on thrombin 
generation it was necessary to generate liposomes that would only reflect the lipids added. 
1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC), 1,2-dioleoyl-sn-glycero-3-
phosphatidylserine (DOPS) and 1,2-dioleoyl-sn-glycero-3-phosphatidylethanolamine 
(DOPE), as used in standard thrombin generation tests, are lipids that have not been 
131 
 
reported in human platelets.  For these experiments, they were substituted for 
phospholipid species previously identified in platelets: 1-stearoyl-2-arachidonoyl-sn-
glycero-3-phosphocholine (SAPC), 1-stearoyl-2-arachidonoyl-sn-glycero-3-phospho-L-serine 
(SAPS) and 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamines (SAPE), at 
proportions better reflecting those previously reported in the literature (188). 
 
Innovin as a source of TF has the disadvantage of already containing phospholipids which 
may interfere with experiments investigating the effects of changing the phospholipid 
composition of liposomes. Using human full length recombinant TF avoids this potential 
problem. However, incorporating this into the liposomes required a different method as 
when using the method described in Chapter 2.9.2, very little thrombin generation was 
observed. In order for a complete thrombin generation curve to be obtained the trigger 
solution required 20 pM of TF (final in-well concentration). A freeze-thawing step was 
introduced prior to passing the lipid and TF mixture through the extruder device, which 
resulted in liposomes which supported more thrombin generation (Figure 4.11 A). In five 
patients a comparison was made of the effect of freeze-thawing on the preparation of 
liposomes using Innovin as the source of tissue factor. These also showed enhanced 
thrombin generation when a freeze-thawing step was used (Figure 4.11 B-E).  
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Figure 4.11 A freeze-thaw step was necessary to demonstrate any tissue factor induced 
thrombin generation (A). Concentrations of tissue factor refer to the final in-well 
concentration when running the thrombin generation assay. Making liposomes using rTF 
(10 pM final in-well concentration) without freeze-thawing resulted in an increase in lag 
time (B) and a reduction in measured ETP (C), Peak thrombin (D) and Velocity Index (E). 
Using Innovin (10 pM final in-well concentration) as the source of tissue factor and making 
the liposomes without a freeze-thaw step resulted in a similar pattern. Data shown in B-E 
are mean (columns) and standard deviation (error bars), n=5. 
 
133 
 
In addition it was necessary to use a version of buffer A with either a lower pH of 7.05 or 
lower sodium chloride concentration of 100 mmol/L, when making the initial liposome 
preparation (Figure 4.12) prior to freeze-thawing. After this step, all liposomes were diluted 
in standard buffer A (see Chapter 2) to obtain the final working concentration. This 
suggests that the lower pH or lower sodium chloride concentration enhanced the 
incorporation of the recombinant tissue factor into the liposome rather than having any 
effect on coagulation factor interaction with tissue factor or the phospholipid membrane.  
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Figure 4.12 Effect of sodium chloride concentration and pH on thrombin generation results.  
Reducing the pH or the sodium chloride concentration of the buffer used to make the 
liposomes improved the thrombin generation (A). The mean values (columns) and standard 
deviation (error bars) of thrombin generation parameters measured in three separate 
experiments are shown in panels B-E (n=3).  
 
Whilst interesting, these observations would only be of clinical interest if the effect of 12-
HETE-PE or 12-HETE-PC could be shown to influence thrombin generation. Therefore 
liposomes were constructed where 10% of the total lipids were replaced by 12-HETE-PE or 
12-HETE-PC, with the proportion of SAPE and SAPC being reduced accordingly. Addition of  
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12-HETE-PE or 12-HETE-PC to liposomes resulted in an increase in thrombin generation 
compared with un- oxidised phospholipids in both pre and post-CPB samples as shown in 
Figure 4.13. 
 
  
Figure 4.13 The lag time (A) was shorter and ETP (B), peak thrombin (C) and velocity index 
(D) were increased when measured using liposomes containing either 12-HETE-PE or 12-
HETE-PC, and also in all samples post-CPB compared to pre-CPB (n=87). In five patients who 
had previously shown a decrease in thrombin generation parameters post-CPB, the effect 
of the change in method of producing the liposomes was investigated. Data shown are 
median (horizontal black bar), interquartile range (box), values with 1.5 times interquartile 
range (whiskers) and values between 1.5-3 times interquartile range (asterisks and circles). 
 
The fold-increase in thrombin generation in response to the presence of 12-HETE-PE or 12-
HETE-PC was less in those patients who went on to require haemostatic treatment post-
CPB (Figure 4.14). This suggests that the interaction of the coagulation factors and the 
lipids in these individuals was different to those who did not bleed. 
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Figure 4.14 Fold change in ETP (A), Peak Thrombin (B) and Velocity Index (C), measured in 
pre-operative samples using triggers with and without 12-HETE-PC (pale grey boxes) and 
12-HETE-PE (unshaded boxes) was significantly less in those who went on the receive 
haemostatic treatment following the end of cardiopulmonary bypass (n=87). 
 
A ROC analysis was preformed to assess the clinical use of these tests in predicting 
bleeding. The results are shown in Table 4.1. Only the fold change in thrombin generation 
in response to 12-HETE-PC measured pre-CPB had any predictive value, but this was only 
modest and in clinical practice would be of limited clinical utility. 
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Table 4.1 ROC curve values for the fold change in discriminating those who needed 
haemostatic treatment post-CPB. 
Fold change in thrombin 
generation parameter 
ROC area pre-CPB  
(95% confidence interval) 
ROC area post-CPB  
(95% confidence interval) 
ETP with 12-HETE-PC 0.63  
(0.51-0.76) 
0.53  
(0.40-0.66) 
ETP with 12-HETE-PE 0.62  
(0.5-0.75) 
0.54  
(0.41-0.66) 
Peak Thrombin with 12-
HETE-PC 
0.64  
(0.52-0.76) 
0.55  
(0.42-0.68) 
Peak Thrombin with 12-
HETE-PE 
0.60  
(0.42-0.72) 
0.54  
(0.41-0.66) 
Velocity Index with 12-HETE-
PC 
0.65  
(0.53-0.77) 
0.55  
(0.42-0.68) 
Velocity Index with 12-HETE-
PE 
0.59  
(0.47-0.72) 
0.54  
(0.42-0.67) 
ROC curve area values for fold-change in thrombin generation are shown pre and post-CPB with 95% 
confidence intervals. 
 
4.3 Discussion 
As might have been anticipated from previous reports of reduced platelet responses to 
thrombin and collagen post-CPB, the ability of platelets to externalise PE, PS and 12-HETE-
PE in response to thrombin was reduced.  This implies either a reduction in flippase activity 
or a reduction in scramblase activity, or both.  The ability to synthesise 12-HETE-PE was also 
diminished and there was a trend towards a reduction in synthesis of 12-HETE-PC. This 
finding suggests the activity of 12-LOX is reduced post-CPB. There were insufficient 
numbers of patients to make any conclusions about the risk of bleeding associated with 
these changes, although from the experience with patients with Scott’s Syndrome, it can be 
implied that these changes would lead to a reduction in thrombin generation and 
consequently an increased risk of bleeding. The observed changes in phospholipids may 
explain why Bosch et al found significantly lower thrombin generation measured in platelet 
rich plasma (PRP) pre and post-CPB in patients who bled excessively, but only in post-CPB 
samples when measuring thrombin generation in platelet poor plasma (PPP) (169).  
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The ability of 12-HETE-PE and 12-HETE-PC to enhance thrombin generation supports 
previous findings (99). The lower fold-change in thrombin generation in those who went on 
to need haemostatic therapy for bleeding post-CPB suggests there may be differences in 
either the direct interaction of the coagulation factors of these individuals with the 12-
HETE phospholipids, or that the 12-HETE phospholipids are influencing the way the 
coagulation factors interact with the other phospholipids. As the gla-domain containing 
clotting factors II,VII, IX and X require the presence of negatively charged phospholipids to 
interact with cell membranes (74) and thereby allow stable catalytic reactions to take 
place, changes in these lipids would affect this process and could in turn lead to changes in 
thrombin generation.  FVIII and FV also have phospholipid binding sites located in their C-
domains, and mutations induced affecting these sites have been shown to impair their pro-
coagulant activity (189-191). Families with FIX mutations have also been described where 
the FIX activity has been widely different between different APTT reagents, where the only 
differences identified have been the phospholipid content of those reagents (192). 
However, the ROC analysis showed that only the fold-change in thrombin generation in 
response to 12-HETE-PC had any predictive value. However, this was only modest which is 
likely to be because almost half of the patients received some form of haemostatic 
treatment. Therefore the overall clinical value of this observation is limited and would need 
further investigation in an independent cohort of patients. 
 
Other types of lipid, not measured in these experiments, have been reported to influence 
coagulation such as sphingolipids (193). The degree of saturation of the fatty acid chains of 
phospholipids has also been shown to influence thrombin generation, with Kung et al 
reporting that thrombin generation was around twenty times lower when measured using 
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liposomes composed of PS and PC species that were fully saturated compared to those that 
were unsaturated (194). Others have reported similar findings (195). Therefore there may 
be changes in other lipids present in the platelet membrane that influence coagulation and 
hence bleeding that have not been accounted for in these experiments. 
 
The technical aspects of the thrombin generation assays reported in this chapter suggest 
that firstly freeze-thawing improves incorporation of tissue factor into liposomes. 
Incorporation of tissue factor into liposomes using freeze-thawing has previously been 
reported to result in its random distribution between the external and internal membrane 
(196), although no studies have reported on the effects on thrombin generation. Freeze-
thawing has also been shown to result in a more uniform diameter of liposomes, which 
may be another contributing factor by providing a larger surface area with a more even 
distribution of lipids upon which thrombin generation can take place (197). Secondly, lower 
pH or sodium chloride concentration also enhanced thrombin generation. Whether this 
relates to incorporation of tissue factor into the membrane or not is uncertain. It has 
previously been reported that lower sodium chloride concentrations in thromboplastin 
reagents reduce their sensitivity to lower levels of prothrombin and FV, but had no effect 
on their sensitivity to FVII or FX (86). It also been reported that increasing sodium chloride 
concentrations also increase liposome diameter (197) which may result in the size of 
liposome becoming less favourable to the assembly of the prothrombinase complex due its 
components binding further apart from each other. Another consideration is that thrombin 
has a sodium ion binding site. However, this is less likely to explain the experimental 
findings because binding of sodium ions results in enhanced substrate binding and catalytic 
activity, leading to enhanced procoagulant activity (198). This would be expected to 
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increase thrombin generation rather than cause the apparent impairment that was 
observed. 
 
Overall these experiments indicate the need for further investigation to provide a clearer 
indication of the normal range for the phospholipids described herein and also to identify 
the effect of CPB on other platelet membrane lipids. Further investigation is also warranted 
into polymorphisms in phospholipid binding domains of coagulation and anticoagulant 
factors. 
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Chapter 5 The effect on thrombin generation of adding FFP, fVIIa, 
PCC and inhibiting TFPI in vitro 
5.1 Introduction 
For patients who bleed due to impairment of thrombin generation, the currently 
available haemostatic options consist of fresh frozen plasma (FFP) and the off-label use 
of recombinant FVIIa and Prothrombin Complex Concentrate (PCC). FFP is the most 
commonly used and readily available way to replace coagulation factors. However, the 
volume of FFP needed to produce a clinically relevant increase in clotting factors has 
been reported to be as much as 30 mL/kg (124). In the context of surgery involving 
CPB, this constitutes a considerable volume load in a group of patients who may 
already have compromised cardiac function. In addition the transfusion of plasma can 
be complicated by transfusion related acute lung injury, and transfusion of larger the 
volumes FFP have been associated with an increased risk of stroke in some studies 
(199). 
 
rFVIIa has been used off label and in clinical trials in the setting of massive 
haemorrhage but evidence to demonstrate efficacy and safety has been limited (200-
202). Two recent meta-analyses were unable to demonstrate a reduction in mortality 
but did find an increased incidence of thrombotic events (128, 129) . Furthermore the 
optimal dose is unknown, and lower doses than those used to treat haemophilia-
relating bleeding may be preferable to minimise any risk of thrombosis. Successful off 
label use of PCCs to manage excess bleeding following cardiac has been reported in a 
number of studies (131-133).  However, the optimal dose is unknown and 
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disseminated intravascular coagulation has been reported when using high 
concentrations in a porcine trauma model (203), although this may relate to the type 
of PCC used.  
 
Tissue Factor Pathway Inhibitor (TFPI) is an important regulator of the initiation phase 
of coagulation. Heparin, the principal anticoagulant used during CPB,  induces the 
release of TFPI from the endothelial surface (64). In vitro studies have shown that in 
the presence of TFPI the rate of thrombin generation is reduced in a concentration 
dependent manner (165). Recently a number of studies have reported using TFPI-
inhibition to prevent bleeding in patients with severe haemophilia A and FVIII 
inhibitors (204, 205). This raises the possibility that inhibition of TFPI may be a 
therapeutic target in treating bleeding in other circumstances, including cardiac 
surgery. The experiments described in this chapter sought to identify the most 
effective haemostatic agents to correct thrombin generation. 
 
5.2 Results 
Samples from the same patients recruited in Chapter 3 were used for these 
experiments. Ten patients were excluded from analysis because they had heparin anti-
Xa levels greater than 0.3 anti-Xa units/mL in the post-CPB samples. This left 92 
patients in the analysis.  
 
CAT results are summarised for peak thrombin in Figure 5.1, ETP in Figure 5.2, lag time 
in Figure 5.3 and velocity index in Figure 5.4. There was a fall in peak thrombin, ETP 
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and velocity index in the post-CPB samples compared to pre-CPB, whilst lag time 
increased.  
 
The addition of FFP resulted in a progressive, concentration dependent increase in 
peak thrombin, ETP and velocity index and shortening of the lag time. The largest 
effect was seen with a concentration equivalent to 30mL/kg. FFP at 15 mL/kg resulted 
in an increased peak thrombin to a level significantly greater than both pre and post-
operative levels. Exceeding this volume resulted in a further dose-dependent increase. 
For rFVIIa, 45 µg/kg was sufficient to increase peak thrombin to preoperative levels, 
but not above preoperative levels, and exceeding this dose produced no further 
improvement. PCC at 25 units/kg resulted in peak thrombin greater than that seen 
pre-operatively. There was no increase in peak thrombin between 25 units/kg and 35 
units/kg, but there was a small but statistically significant difference comparing doses 
of 25 units/kg and 50 units/kg. Inhibition of TFPI resulted in a peak thrombin 
concentration that was much higher than the pre-operative level. Results for ETP were 
similar to peak thrombin.  
 
FFP at a dose of 15 mL/kg was sufficient to correct the velocity index to pre-operative 
levels. Exceeding this dose resulted in increases statistically significantly greater than 
pre-operative levels.  For rFVIIa and PCC, 45µg/kg and 25 units/kg respectively were 
sufficient to return the velocity index to preoperative levels. Exceeding these doses 
produced no further increase. Inhibition of TFPI produced a dramatic increase in 
velocity index well exceeding the pre-operative level. Similar results were obtained for 
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the lag time with the exception that it required 30 mL/kg of FFP before the lag time 
corrected to pre-operative levels. 
 
Full length TFPI measured post-CPB was inversely correlated with ETP, peak thrombin 
and velocity index in the absence and presence of all concentrations of FFP, rFVIIa and 
PCC, the weakest correlation being seen with FFP. Thrombin generation in the 
presence of the anti-TFPI antibody did not correlate the full length TFPI concentration.  
Figure 5.5 summarises these findings for ETP. Results for peak thrombin and velocity 
index were similar. 
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p<0.0001
 
Figure 5.1 Effect on peak thrombin of adding increasing concentrations of FFP (A), rFVIIa (B), 
PCC (C) and in the presence or absence of an anti-TFPI antibody. Data shown are median 
(horizontal black bar), interquartile range (box), values with 1.5 times interquartile range 
(whiskers) and values between 1.5-3 times interquartile range (asterisks and circles). P values 
shown are for the Wilcoxon ranks test for comparison between pre and post samples, and 
Friedman’s test for comparison between samples at the same time point (i.e. post samples).  
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Figure 5.2 Effect on ETP of adding increasing concentrations of FFP (A), rFVIIa (B), PCC (C) and 
in the presence or absence of an anti-TFPI antibody. Data shown are median (horizontal black 
bar), interquartile range (box), values with 1.5 times interquartile range (whiskers) and values 
between 1.5-3 times interquartile range (asterisks and circles). P values shown are for the 
Wilcoxon ranks test for comparison between pre and post samples, and Friedman’s test for 
comparison between samples at the same time point (i.e. post samples). 
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Figure 5.3 Effect on lag time of adding increasing concentrations of FFP (A), rFVIIa (B), PCC (C) 
and in the presence or absence of an anti-TFPI antibody. Data shown are median (horizontal 
black bar), interquartile range (box), values with 1.5 times interquartile range (whiskers) and 
values between 1.5-3 times interquartile range (asterisks and circles). P values shown are for 
the Wilcoxon ranks test for comparison between pre and post samples, and Friedman’s test for 
comparison between samples at the same time point (i.e. post samples). 
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Figure 5.4 Velocity Index in response to increasing concentrations of FFP (A), rFVIIa (B), PCC (C), 
and inhibition of TFPI (D). Data shown are median (horizontal black bar), interquartile range 
(box), values with 1.5 times interquartile range (whiskers) and values between 1.5-3 times 
interquartile range (asterisks and circles). P values shown are for the Wilcoxon ranks test for 
comparison between pre and post samples, and Friedman’s test for comparison between 
samples at the same time point (i.e. post samples). 
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Figure 5.5 Scatter plots comparing full-length TFPI concentration post-CPB  with ETP post-CPB 
in patient plasma alone (A), or with the addition of FFP(B), PCC (C), rFVIIa (D) and an anti-TFPI 
antibody (E). Spearman’s correlation coefficients (ρ) are shown with p- values. 
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5.3 Discussion 
The results show that 15 mL/kg of FFP was sufficient to correct ETP, peak thrombin and 
velocity index to pre-CPB levels, but 30 mL/kg was required to correct the lag time. 
Larger volumes of FFP improved thrombin generation above baseline. rFVIIa at a dose 
of 45 µg/kg was sufficient to correct all measured thrombin generation parameters to 
pre-CPB levels but there was no further improvement by exceeding this dose. Similarly, 
25 units/kg of PCC was required for the same effect and 50 units/kg enhanced 
thrombin generation further. Inhibition of TFPI markedly increased the ETP, peak 
thrombin, and velocity index beyond pre-operative levels and shortened the lag time.  
 
FFP remains the main treatment available to most clinicians for correcting any 
coagulopathy. The optimum dose of FFP to return the majority of thrombin generation 
parameters to pre-CPB levels was 15 mL/kg. Some studies have reported a correlation 
with lag time and bleeding (206) and 30 mL/kg was required to achieve this. The full-
length TFPI concentration correlated with all thrombin generation parameters post-
CPB and in the presence of FFP, rFVIIa and PCC. This supports the view that TFPI is an 
important determinant of thrombin generation. FFP had weaker correlation with 
thrombin generation parameters than rFVIIa and PCC. This may be because FFP 
contains both pro-coagulant factors and inhibitors and would tend to normalise both 
where rFVIIa and PCC only affected the pro-coagulant pathways. There was no 
correlation between full length TFPI and thrombin generation in the presence of an 
anti-TFPI inhibitor further supporting the importance of this inhibitor in thrombin 
generation assays activated with low concentrations of TF.  
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The enhancing effect of FFP observed on thrombin generation may be overestimated 
by the in vitro nature of the assay. Patient plasma was contacted inactivated with CTI 
and so after addition of rFVIIa, PCC and TFPI antibody thrombin generation was 
activated through TF. In contrast, the added FFP was not CTI inhibited and would 
therefore have been prone to contact activation in addition to TF activation. Contact 
activation has previously been shown to result in higher ETP and peak thrombin and 
shorter lag time when using lower concentrations of TF as used in these experiments 
(156, 207).   
 
rFVIIa made no significant difference to thrombin generation parameters beyond 
doses of 45µg/kg, indicating that lower doses are as effective as higher doses in 
enhancing thrombin generation in vitro. This would be predicted given the global 
reduction in clotting factors observed in this patient cohort. A similar result was 
observed by Altman and colleagues (208) using a model of dilutional coagulopathy. 
This suggests that rFVIIa may be inappropriate to use in isolation to treat bleeding. 
Whilst there are a number of studies which have reported safety using rFVIIa in 
paediatric patients undergoing CPB (209),  some studies have reported an increase in 
thrombotic events in adult patients (168). Studies looking at adult patients from a 
broader population have also shown an increase in arterial events (210), something 
that would be particularly deleterious in the typical adult patient population 
undergoing cardiac surgery. Therefore, based on these in vitro assays, if rFVIIa is used, 
lower doses may offer the best balance of achieving a beneficial effect whilst possibly 
reducing the chance of an adverse event. 
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PCC corrected thrombin generation parameters to pre-operative levels at a 
concentration of 25 units/kg. There was some further statistically significant 
improvement at concentrations of 50 units/kg although this was so small it is unlikely 
to be clinically significant. This finding is consistent with other in vitro studies where 
PCC has been shown to enhance thrombin generation (211). In vivo PCC has been 
shown to be effective in reducing blood loss in human studies (132, 212). As well as 
different numbers of clotting factors, different PCCs contain different amounts of 
heparin, with some containing more heparin than the PCC used in this study, which in 
turn has been shown to affect thrombin generation (130). While a four factor PCC was 
used in this study, others have shown similar effects on thrombin generation using a 3 
factor PCC (211). PCC has the advantage of additional safety over FFP for transmission 
of infection and smaller volumes in patients with cardiac compromise. However, large 
doses have been associated with disseminated intravascular coagulation in some 
studies (203).  
 
Inhibition of TFPI had a marked effect on enhancing thrombin generation. TFPI in vivo 
is increased by administration of heparin (64), the anticoagulant routinely used in CPB  
and therefore may be a good target in this group of patients. TFPI inhibition has been 
reported to enhance thrombin generation in plasma from people with haemophilia 
(204).  However, a number of studies have reported higher ETP and peak thrombin 
concentration in patients with pro-thrombotic tendencies (213-215). This suggests 
caution may be required if TFPI inhibition was to be used as a therapeutic target 
especially in cardiac patients where arterial thrombosis is often already a significant 
risk. 
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A weakness of studies investigating thrombin generation in plasma is that it takes no 
account of other important factors that require correction in controlling bleeding 
following cardiac surgery: fibrinogen concentration, platelet count and function and 
fibrinolysis. A low fibrinogen has been associated with excessive post-operative 
bleeding in a number of studies (105, 183). Thrombocytopenia has also been described 
as a risk factor for bleeding following CPB (11, 184).  Clot formation and durability 
requires sufficient thrombin to cleave fibrinogen to fibrin, FXIII to cross-link fibrin 
monomers, platelets and reduced fibrinolysis. Therefore correction of thrombin 
generation forms only one component in the management of bleeding. 
 
In summary these results suggest that comparatively low doses of FFP, rFVIIa and PCC 
may be sufficient to correct thrombin generation in patients who have undergone 
surgery requiring CPB. Inhibition of TFPI may offer a future therapeutic strategy for 
managing bleeding in this group of patients. However, these in vitro results will need 
to be validated in vivo.  
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Chapter 6 Modelling the effect of changes in lipids and 
coagulation factors on in vitro thrombin generation 
 
6.1 Introduction 
The results presented thus far demonstrate that whilst coagulation and anticoagulant factor 
concentrations change between pre and post-CPB, there are also changes in the phospholipids 
that platelets generate and externalise. This raises the question whether if these measured 
changes were accounted for in the thrombin generation assay, this would lead to significant 
differences in the thrombin generation parameters between groups of patients who bled 
excessively.  
 
The inability of platelets to externalise phospholipids reduces thrombin generation as 
demonstrated in patients with Scott’s Syndrome, where thrombin generation is reduced 
compared to normal controls (216). An expectation that there may be differences in thrombin 
generation between pre and post-CPB liposomes is inferred by the findings of Bosch et al 
(169). They reported that when thrombin generation was measured in PRP there was a 
statistically significant difference between those who bled and those who did not, in samples 
taken both pre and post-CPB. This finding, coupled with the results presented in Chapter 4, 
suggests that differences in thrombin generation might be observed due to changes in platelet 
phospholipids. 
 
Another factor that may influence thrombin generation is the source of tissue factor. Current 
concepts of coagulation are based upon the initiation phase of coagulation taking place on a 
tissue factor expressing surface, before the reaction then moves to the surface of an activated 
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platelet. Under normal circumstances in vivo, the cells expressing tissue factor would be in the 
sub-endothelial matrix, such as smooth muscle cells, fibroblasts and macrophages. Monocytes 
are also able to express tissue factor and this can be measured through sampling of the 
peripheral blood. Following CPB, TF expression on leucocytes has been reported to increase 
(217, 218). The monocyte count has also been reported to increase (219). It has also been 
shown that in a model of cardiopulmonary bypass, monocyte activation markers and tissue 
factor expression increases (220). Monocytes can also support thrombin generation on their 
cell membrane through exposure of negatively charged phospholipids on activation (221, 222). 
However, it is generally considered that monocytes and other tissue factor expressing cells 
provide the surface for the initiation of coagulation after which the propagation phase moves 
to the platelet membrane (223, 224). Therefore inclusion of monocytes in the thrombin 
generation assay might increase the information provided by better reflecting these different 
stages. 
 
Monocytes can be induced to express tissue factor using lipopolysaccharide (LPS) (225, 226). 
Monroe et al have previously reported on a model for thrombin generation using LPS 
stimulated monocytes as a source of tissue factor (227). In this model, washed platelets, 
purified factors II, V, VIIa, VIII, IX and X, along with TFPI and antithrombin were added to wells 
of a cell culture plate containing monocytes. Thrombin generation was then measured by 
repeatedly sampling the supernatant and using a chromogenic assay. Such a model is laborious 
and due to the constant loss of substrate may result in a misrepresentation of true thrombin 
generation. If it were adaptable to continuous measurement of thrombin generation using a 
method such as that of Hemker et al (154), such a model might offer opportunities to further 
explore the interaction of coagulation factors and phospholipids under conditions more 
relevant to the in vivo situation. 
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The objectives of the experiments described in this chapter were firstly to identify whether 
there were any differences in thrombin generation using liposomes reflecting pre and post-
CPB phospholipid proportions. The second objective was to investigate the feasibility of 
developing a model of thrombin generation using purified coagulation factors and monocytes 
as a source of tissue factor, similar to that described by Monroe et al (227). Platelets were 
replaced by liposomes composed of phospholipids reflecting changes observed pre and post-
CPB. Protein S was included because of its activity as a cofactor for TFPI (228, 229). 
 
6.2 Results 
The total amounts of the different species of PE, PS, PC, 12-HETE-PE and 12-HETE-PC measured 
in thrombin stimulated platelets pre and post-CPB in Chapter 4 were converted into moles and 
then summed to give a figure for the total number of moles of phospholipid measured. The 
proportions of this number contributed to by the total moles of PE, PS, PC and the respective 
12-HETE phospholipids were then expressed as a percentage and liposomes reflecting this 
were constructed with 60 pM rTF to achieve a final in-well concentration of 4 µM 
phospholipids and 10 pM rTF. The proportions of the phospholipids are shown in Table 6.1. 
There was a reduction in the proportion of PC post-CPB, which may reflect a loss of membrane 
during CPB. 
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Table 6.1 Proportions of phospholipids measured pre and post-CPB and used to construct 
liposomes. 
Phospholipid Pre-CPB (%) Post-CPB (%) 
PE 50.85 52.93 
PS 2.99 2.99 
PC 46 44 
12-HETE-PE 0.06 0.02 
12-HETE-PC 0.1 0.06 
(PE= phosphatidylethanolamine; PS= phosphatidylserine; PC= phosphatidylcholine; 12-HETE-PE= 12-
hydroxyeicosatetraenoic-PE; 12-HETE-PC= 12- hydroxyeicosatetraenoic-PC). 
 
Thrombin generation assays were then performed in pooled normal (4 donors) PPP collected 
into citrate and CTI. Thrombin generation curves showed subtle differences between pre and 
post-CPB liposomes (Figure 6.1 A). Peak Thrombin and velocity index were lower using the 
post-CPB liposome, although these differences were not statistically significant (Figure 6.1 B-
E). Lag time was slightly shorter using the post-CPB liposome (mean 7.94 minutes, range 6.11 
to 10.11 minutes pre; mean 7.69 minutes, range 6.56 to 9.22 minutes post) whilst the ETP was 
slightly higher, but again these differences were not statistically significant. 
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Figure 6.1The effect on thrombin generation of using liposomes reflecting measured 
phospholipid concentrations pre and post-CPB. Panel A shows a representative thrombin 
generation curve from a single patient. Panels B-E show the mean values for the thrombin 
generation parameters. Error bars represent the standard deviation (n=5). 
 
However, these differences when coupled with observed changes in coagulation factor and 
anticoagulant concentrations might result in clearer differences in thrombin generation 
parameters between those who did and did not bleed excessively.  
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6.2.1 Monocyte based thrombin generation model 
A tissue factor expressing surface, provided in vivo by activated monocytes and other cells in 
the sub-endothelium, is considered to be the initiator of coagulation. Therefore to try to 
replicate this, a model was designed where monocytes were used to coat the wells of a 96-well 
plate as described in Chapter 2 (Materials and Methods). After incubation for 18 hours in RPMI 
media with or without LPS, the media was removed, and liposomes were added followed by 
pooled normal PPP. Thrombin generation was then measured using calibrated automated 
thrombography (with all conditions measured in quadruplicate). The first series of experiments 
aimed to establish the optimal cell concentration to use for coating the wells and the 
concentration of LPS to use for stimulation of the monocytes to induce tissue factor 
expression. Increasing concentrations of cells in the original cell suspension resulted in an 
improvement in the coefficient of variation (CV) for all thrombin generation parameters 
(Figure 6.2 A-D). The 1x107/mL cell concentration produced the lowest CV, therefore this 
concentration was selected for the next series of experiments. Thrombin generation was then 
measured after stimulating the cells with varying concentration of LPS. In absence of LPS there 
was considerable variation between wells (in excess of 20 %) in all thrombin generation 
parameters apart from lag time, where the CV was less than 10%. In the presence of all 
concentrations of LPS, the CV was below 10%, with overall 0.5 µg/mL showing the least 
variation (Figure 6.2 E-H).  
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Figure 6.2 Intra-assay coefficients of variation in thrombin generation parameters using 
different concentrations of cells (A-D), and different concentrations of LPS (E-H). Panels A-D 
and E-H represent separate experiments (n=1 in each case, each condition performed in 
quadruplicate). 
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Adhesion to the culture plate was used to select monocytes in this model. Whilst this is a 
widely used method to select monocytes, the concentration of cells in the original cell 
suspension did not necessarily indicate the number that had adhered to the plate and were 
present for the thrombin generation measurement. In an attempt to obtain a measure of how 
evenly cells were distributed between wells, the cells were fixed, nuclear material was stained 
using crystal violet and the cells where then lysed. Light absorbance at 590 nm was measured. 
Absorbance was higher (indicating a greater number of cells present) in wells where the cells 
had been incubated with media without LPS, but the standard deviation was lower than in the 
wells not exposed to LPS (Figure 6.3).  
  
 
Figure 6.3 Light absorbance at a wave length of 590 nm measured from cell lysates after 
staining with crystal violet. Absorbance was lower in wells exposed to LPS, suggesting fewer 
cells were present, although the standard deviation was lower indicating less variation 
between wells. Columns represent the mean readings, error bars the standard deviation (n=3). 
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The next series of experiments used plates coated with cells from a cell suspension with a 
concentration of 1x107 cells per mL and exposed to 0.5 µg/mL LPS. Thrombin generation 
increased in response to LPS compared to wells containing monocytes that were not exposed 
to LPS (Figure 6.4 A).  However, even in the absence of liposomes there was still considerable 
thrombin generation with LPS stimulated monocytes (Figure 6.4 B). Whilst there was a trend 
toward the ETP and peak thrombin concentration being lower using the post-CPB liposome, 
there was no statistically significant difference between pre and post-CPB liposomes (Figure 
6.4 B-E).  
 
163 
 
 
Figure 6.4 Thrombin generation parameters measured using monocytes stimulated with 0.5 
µg/mL LPS, liposomes reflecting phospholipids measured pre and post-CPB, and pooled normal 
PPP collected into CTI/citrate. Panel A shows a representative thrombin generation curve; 
even in the absence of LPS stimulation, there was detectable thrombin generation. Panel B 
shows a representative thrombin generation curve comparing monocytes stimulated with LPS 
in the presence and absence of liposomes. Panels C-F summarise the thrombin generation 
parameters measured. There was no significant difference between pre and post-CPB 
liposomes. Columns represent mean and error bars the standard deviation (n=3). 
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6.2.2 Thrombin generation model using purified coagulation factors and 
anticoagulants 
The monocyte model appeared unlikely to be sensitive enough to detect subtle differences in 
thrombin generation. Therefore this model was abandoned in favour of one where median 
concentrations of FII, FV, FVII, FVIII, FIX, FX, protein S, antithrombin and full length TFPI were 
added to wells of a 96 well plate to replicate the levels measured pre and post CPB in the 
following:  those who did or did not bleed >1 L; those who did or did not bleed >2 mL/kg/hr; 
those who did or did not need haemostatic treatment. These endpoints were chosen based on 
those endpoints where there had either been a significant difference in coagulation or 
anticoagulant factors or thrombin generation parameters.  
 
The ETP, peak thrombin concentration and velocity index were lower in the post-CPB setting 
for all end points, whilst the lag time increased (Figure 6.5). However, there was no significant 
difference between conditions reflecting those who did and did not bleed.  
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Figure 6.5 Thrombin generation parameters measured in a system containing liposomes 
reflecting measured phospholipids pre and post CPB, containing 10 pM rTF (final in-well 
concentration), and  median concentrations of  II, V, VII, VIII, IX, X, AT, PS and full length TFPI. 
There was no significant difference between any parameter for any of the bleeding end points 
listed (n=3). 
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6.3 Discussion 
The absence of any demonstrable difference in these experiments in thrombin generation 
parameters between bleeding end points may have a number of explanations. The monocyte 
model had a number of weaknesses, including uncertainty of how pure the original cell 
suspension was, and also the inability to directly quantify the number of cells adherent to the 
wells of the 96 well plate at the point of measuring thrombin generation. Whilst some of these 
problems could  potentially be overcome by using flow cytometry to assess the purity of the 
cell suspension, it would still not be possible to be certain of the number of cells that remained 
adherent to the 96-well plate at the point of measuring thrombin generation. It may also be 
that with as much as 50% of the measured thrombin generation being contributed by the 
tissue factor expressing monocytes alone (Figure 6.4B), the limits of sensitivity of the thrombin 
generation assay had been reached and the chance of any small differences conferred by the 
addition of liposomes being measurable was low. 
 
The absence of a significant difference in thrombin generation using the purified model 
reflects the absence of a difference observed using the standard liposomes described in 
Chapter 3. In addition this model excluded the contribution of variations in individual 
coagulation factors and also excluded other plasma proteases, such as protein Z, which may 
influence thrombin generation (230). 
 
Finally, the liposomes used in both models were unable to fully replicate the function of 
platelets because of the lack of any ability to change membrane conformation or composition 
in response to activation.  As shown in Chapter 4, it appears there are differences between 
individuals in how their coagulation factors and anticoagulant factors interact with oxidised 
phospholipids. There is published evidence demonstrating that variations in the C2 domains of 
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FVIII and FV alter their binding to phospholipids (231, 232), and there have also been reports 
of mutations in FIX influencing the results of the APTT depending on the phospholipid used 
(192). Ultimately measuring thrombin generation in PRP would be a superior method of taking 
into account changes in platelet phospholipids and variations in coagulation factors. However, 
this would make the clinical application of calibrated automated thrombography more difficult 
given the technical skills and staff time required to prepare and process PRP. 
 
In conclusion, the experiments described in this chapter demonstrate the feasibility of 
modifying the calibrated automated thrombin generation assay to investigate thrombin 
generation in the setting of cell based tissue factor presentation. This model provides a basis 
to further investigate the influence of different TF expressing cells on thrombin generation. 
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Chapter 7 General Discussion 
 
The primary objective of this thesis was to test the hypothesis that thrombin generation assays 
were useful in identifying patients at risk of increased bleeding post-CPB. A variety of 
definitions of bleeding were used: these were based on total blood loss at 24 hours, rate of 
blood loss, need for re-exploration or the need for haemostatic treatment. The basis of this 
hypothesis was two previous studies which found that calibrated automated thrombography 
in PPP measured post-CPB predicted bleeding (11, 169). In one of those studies, pre-CPB 
thrombin generation was also predictive of bleeding and it was this finding that provided the 
catalyst for this thesis (11). In contrast, the results presented in Chapter 3 show that thrombin 
generation measured in PPP using calibrated automated thrombography was unable to 
identify those at risk of bleeding, irrespective of the definition of bleeding, the concentration 
of tissue factor in the trigger solution and whether or not CTI was used to prevent contact 
activation.  
 
The reason of the absence of a difference in this study may relate to the patient population. 
The patients in the previous studies either exclusively or predominantly underwent coronary 
artery bypass grafting as the sole surgical procedure, whereas the patients recruited in this 
thesis all underwent surgery to repair or replace heart valves or part of the ascending aorta. 
This type of surgery is more complex and is associated with a higher incidence of post-CPB 
bleeding compared to operations where CABG is the sole procedure (233, 234). Therefore it 
may be that in the lower risk setting of CABG, excessive bleeding post-CPB may be more 
influenced by impaired thrombin generation than in higher risk surgery where surgical 
bleeding is more frequent and bypass times are longer, which in itself is a risk factor for 
bleeding (181). Furthermore thrombin generation in PPP takes no account of other important 
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factors that have been associated with bleeding, depending on the definition used, both in this 
thesis and in other studies:  the fibrinogen concentration (105, 183) and thrombocytopenia 
(11, 184).  A further but minor aim was to investigate whether thrombin generation assays 
could be performed as a near patient test. As shown in Chapter 3, the assay is too complex and 
even with training there was a poor correlation between the results obtained from the central 
laboratory. 
 
The use of thrombin generation to assess the effect of available haemostatic agents in 
correcting thrombin generation post-CPB was investigated in Chapter 4. The results show that 
15 mL/kg of FFP was sufficient to correct the majority of thrombin generation parameters to 
pre-CPB levels, but 30 mL/kg was required to correct all. rFVIIa at a dose of 45 µg/kg was 
sufficient to correct all measured thrombin generation parameters to pre-CPB levels. 
Experiments using PCC showed that 25 units/kg was required for the same effect. Inhibition of 
TFPI not only corrected thrombin generation but enhanced it beyond the levels measured pre-
CPB.  TFPI inhibition is a theoretically attractive therapeutic strategy because it would be 
potentially quicker to administer and represent a smaller fluid load compared to FFP. However, 
increased thrombin generation has been reported in patients with pro-thrombotic phenotypes 
(213-215), so the risk of inducing thrombosis would need to be balanced against any potential 
benefit. This is especially so in cardiac patients where arterial thrombosis is often already a 
significant risk. Whilst these in vitro results need to be validated in vivo before they could be 
applied directly to patient management, they do provide a basis on which to select doses for 
use in such studies. 
 
Traditional tests of platelet function such as light transmission aggregometry were not 
performed in this thesis. Reduced platelet aggregation in response to ADP following CPB has 
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previously been described in a number of studies (115, 118). Instead, a novel approach was 
taken to investigate the effect of CPB on platelet phospholipids. The data presented in Chapter 
5 demonstrates that post-CPB platelets are less able to externalise PS and PE. As discussed in 
Chapter 1, proteins with flippase, floppase and scramblase activity are believed to control this 
process, therefore targeting these proteins may lead to new therapeutic strategies in 
managing bleeding and thrombosis. 
 
The experiments in Chapter 5 also found that post-CPB the ability of platelets to externalise 
12-HETE-PE and to synthesise 12-HETE-PC and 12-HETE-PE was decreased. This is likely to 
further impair haemostasis because  they were shown to enhance thrombin generation, a 
finding consistent with previous studies (99).  The finding that the effect of 12-HETE-PE and 12-
HETE-PC in increasing thrombin generation was less in those who went on to need 
haemostatic therapy for bleeding post-CPB, suggests that either the direct interaction of the 
coagulation factors of these individuals with the 12-HETE phospholipids may be different, or 
that the in the presence of 12-HETE phospholipids the interaction of their coagulation factors 
with PE and PS was impaired. This explanation is supported by the finding that mutations in 
the phospholipid binding sites located in the C-domain of FVIII and FV impair their pro-
coagulant activity (189-191) and that mutations in FIX  which result in discrepant activity  when 
measured using APTT reagents containing different phospholipids (192).  
 
However, the differences observed were small and given that nearly half of patients needed 
haemostatic treatment, the value of this observation can be questioned. Equally it may be that 
the decision to give haemostatic treatment was based on the clinical team caring for the 
patient correctly responding to haemostatic failure. Giving FFP, which was received by all these 
patients, would correct any haemostatic defect due to the patient’s own coagulation factors 
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interacting less effectively with phospholipids on the platelet surface and thus improve 
haemostasis. Whether this is a plausible argument rests not only on whether the observation 
can be repeated in an independent cohort of patients, but what the true prevalence of such 
mutations in coagulation factors are and what the normal range of phospholipid expression in 
platelets is in the wider population. 
 
The effects of 12-HETE-PE and 12-HETE-PC in enhancing thrombin generation also indicate the 
importance of carefully considering the composition of phospholipids used in any haemostatic 
assay.  When this is coupled with the other findings reported in Chapter 5 of the effects of 
source of tissue factor, the use of freeze-thawing in liposome production and the effects of pH 
and sodium chloride concentration on thrombin generation, the importance of carefully 
considering how the choice of experimental conditions determine the results obtained can be 
clearly seen. 
 
The experiments reported in Chapter 6 attempted to address whether using liposomes 
reflecting the proportions of the phospholipids measured in Chapter 5 would influence the 
ability of calibrated automated thrombography to identify patients at risk of bleeding post-
CPB. As there were insufficient volumes of patient plasma remaining this necessitated using 
purified human coagulation factors and anticoagulants to model a “typical patient.” Based on 
the likelihood that in vivo variations in the interaction of these proteins with phospholipids 
influence thrombin generation it is unsurprising that the experiments were unable to 
demonstrate any differences. However, the experiments where monocytes were used to 
provide tissue factor represent a novel adaptation of calibrated automated thrombography 
that allows the real-time measurement of thrombin generation initiated by tissue factor 
expressing cells. This model provides the possibility to investigate whether differences exist in 
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the amount of thrombin generated between different cells types. Theoretically this could allow 
an individualised thrombin generation assay utilising plasma, platelets and tissue factor 
producing cells from the same patient, although this would be highly labour intensive. 
 
This thesis has raised a number of questions which require further work. Firstly a larger study 
investigating the effect of CPB on phospholipid externalisation and oxidised phospholipid 
synthesis is required to validate these findings in an independent patient cohort and provide a 
population wide overview. This also needs to be combined with genomic studies looking for 
polymorphisms in coagulation factor and anticoagulant genes in regions that encode for their 
phospholipid binding domains. The question also arises that as the phospholipids investigated 
in this thesis are important in enhancing thrombin generation, could a reduction in their 
externalisation or synthesis explain some cases of hitherto unclassified bleeding disorders? 
Conversely, could an increase in externalisation or synthesis contribute to cases of venous or 
arterial thrombosis where no other cause can be identified, or could they influence the risk of 
ischaemic stroke or the phenotype in anti-phospholipid syndrome? Furthermore to what 
extent do differences in other membrane lipids, such as cholesterol or sphingolipids, influence 
thrombin generation and hence bleeding or thrombosis? Cholesterol has been reported to 
enhance the effect of phospholipids in activating protein C (235), which would in turn affect 
thrombin generation in vivo. Sphingolipids have been reported to reduce thrombin generation 
(193). Increasing saturation of the fatty acid chains of phospholipids has also been shown to 
reduce thrombin generation (194, 195). These observations suggest that changes in other 
lipids present in the platelet membrane, beyond those investigated in this thesis, warrant 
further investigation. 
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Finally, the cell-based model of thrombin generation lends itself to exploring the contribution 
of different tissue factor bearing cell types to thrombin generation. Tissue factor can be 
expressed on a variety of cell types including monocytes, eosinophils and endothelial cells 
(236). At present little is known about the composition of the cell membrane upon which they 
express tissue factor. The techniques used in Chapter 4 to investigate phospholipids in 
platelets could also be applied to these cells types to answer this question.  
 
In summary, the original hypothesis that thrombin generation assays are useful for identifying 
patients at increased risk of excess bleeding following CPB and can be used in clinical practice 
to inform blood product usage, can be rejected on the basis of this thesis, at least for patients 
who are undergoing valve replacement or surgery on the aorta.  The experiments in this thesis 
also demonstrate that CPB alters the externalisation of PE, PS and 12-HETE-PE suggesting that 
either scramblase or flippase activity, or both, are impaired. CPB also reduces the synthesis of 
12-HETE-PE and 12-HETE-PC indicating a reduction in 12-LOX activity. 12-HETE-PE and 12-
HETE-PC enhance thrombin generation and there is the suggestion that the magnitude of this 
effect differs between patients. For the management of bleeding, 30 mL/kg FFP, 45mcg/kg 
rFVIIa and 25 units/kg PCC may be sufficient to correct thrombin generation, but this would 
need to be confirmed in in vivo studies. Finally, this thesis provides insight into how the choice 
of phospholipids can influence thrombin generation and raises a number of questions for 
further study. 
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Appendix 1 Data collection proforma 
Patient Trial Number:     
Age: 
Weight: 
Nature of operation:                                                                    Date of operation 
Anti platelet agents: Yes            Specify:                                    Date stopped:             
                                  No  
Anticoagulants:       Yes              Specify:                                    Date Stopped:                            
                                No 
Intra-operative data: 
Tranexamic acid -Dose : Pre CPB----gms    On CPB----gms    Post CPB ---- gms                      
Heparin Dose:--------Units   Time Given :                                                   
Bypass:                    Time on:                             Time off: 
Aortic cross clamp:  Time on :                            Time off: 
Skin closure time: 
Time of heparin reversal:   Protamine dose: ----mg 
Haemoglobin (g/dL): pre op:                                          post (on admission to CITU) 
Platelet count (10x10/L): pre                                           post (on admission to CITU) 
ACT pre:                                                        ACT post reversal of heparin: 
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Fluids infused (including salvaged red cells and blood products) 
Type of Fluid Volume Time 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
 
Patient Trial Number: 
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Post-operative data: 
Volume of Blood loss from drains for first 24 hours or until removal:  
Time post operation Volume of blood lost (or record if drain removed) 
1 hr  
2 hrs  
3 hrs  
4 hrs  
5 hrs  
6 hrs  
7 hrs  
8 hrs  
9 hrs  
10 hrs  
11 hrs  
12 hrs  
13 hrs  
14 hrs  
15 hrs  
16 hrs  
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17 hrs  
18 hrs  
19 hrs  
20 hrs  
21 hrs  
22 hrs  
23 hrs  
24 hrs  
 
Total volume of Blood loss:                     HCT of the lost blood: 
Fluids infused (including blood products) in CITU 
Type of Fluid Volume Time 
   
   
   
   
 
Patient Trial Number: 
Length of time ventilated (days): 
Duration of Level 2/3 Care (days): 
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Duration from operation to discharge (days): 
Major complications of cardiac surgery:                                                                                    
 myocardial infarction (defined as an elevated cardiac troponin) 
 significant haemodynamic instability (defined as use of two or more inotropic drugs or 
intra-aortic balloon pump) 
 occurrence of atrial fibrillation lasting for more than 24 hours 
 reoperation for bleeding or any cause 
 prolonged ventilation (requirement for positive pressure ventilation(including NIV) for 
>48 hours ) 
 
 sepsis 
 renal impairment requiring renal replacement therapy  
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Appendix 2 Titration of anti-TFPI antibody (AF2974) to inhibit 
TFPI 
 
 
 
This graph plots the effect on ETP (y-axis) of spiking plasma with different concentrations of 
full length TFPI (x-axis). The blue line indicates no anti-TFPI antibody, red line 50 nmol/L anti-
TFPI antibody and orange line 100 nmol/L anti-TFPI antibody. Courtesy of Mr Erwin Panholzer, 
Baxter Biosciences, Vienna, Austria.
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Appendix 3 Tissue factor concentrations in trigger solutions 
 
TF activity in thrombin generation trigger solutions was measured using an IMUBIND ® ELISA 
kit purchased from Sekisui Diagnostics, Stamford, CT, USA. The lyophilised TF standards (50, 
100,200,500 and pg/mL) were reconstituted by adding 1 mL of distilled water to each vial and 
agitating gently for 3 minutes.  A vial of lyophilised biotinylated anti-human tissue factor 
antibody was reconstituted by adding 5.5 mL of distilled water and agitating gently for 3 
minutes.  The lyophilised contents of the vial of enzyme conjugate diluent provided in the kit 
was reconstituted by adding 20 mL distilled water and agitation gently. The packet of wash 
buffer (PBS, 0.1% Triton X-100, pH 7.4) was dissolved in 1 L of distilled water. A sample dilution 
buffer was prepared by making a solution of 1% (w/v) BSA dissolved in an appropriate volume 
of the wash buffer. Aliquots of the trigger solutions were diluted 1 in 4 and 1 in 8 using the 
sample dilution buffer described. All samples were run in triplicate. The results are shown in 
the table below (measured concentration is mean value). 
 
Supposed Trigger TF 
concentration 
Measured Concentration (pM) Standard Deviation 
3 pM  4.3 1.2 
6 pM  11.9 7.9 
18 pM  20.6 1.3 
30 pM 36 3.6 
60 pM 78.2 8.4 
60 pM rTF  72.2 11.1 
